



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : A61K 31/40, 31/44, 31/70, 38/02, 38/07, 38/08, 38/10, 38/14	A1	(11) International Publication Number: WO 97/14416 (43) International Publication Date: 24 April 1997 (24.04.97)
(21) International Application Number: PCT/US96/16490 (22) International Filing Date: 15 October 1996 (15.10.96) (30) Priority Data: 60/005,664 18 October 1995 (18.10.95) US 9602903.8 13 February 1996 (13.02.96) GB (71) Applicant (for all designated States except US): MERCK & CO., INC. [US/US]; 126 East Lincoln Avenue, Rahway, NJ 07065 (US). (72) Inventors; and (73) Inventors/Applicants (for US only): DeFEO-JONES, Deborah [US/US]; 126 East Lincoln Avenue, Rahway, NJ 07065 (US). JONES, Raymond, E. [US/US]; 126 East Lincoln Avenue, Rahway, NJ 07065 (US). OLIFF, Allen, I. [US/US]; 126 East Lincoln Avenue, Rahway, NJ 07065 (US). SCOLNICK, Edward, M. [US/US]; 126 East Lincoln Avenue, Rahway, NJ 07065 (US). GARSKY, Victor, M. [US/US]; 126 East Lincoln Avenue, Rahway, NJ 07065 (US). (74) Common Representative: MERCK & CO., INC.; 126 East Lincoln Avenue, Rahway, NJ 07065 (US).		(81) Designated States: AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CU, CZ, EE, GE, HU, IL, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TJ, TM, TR, TT, UA, US, UZ, VN, ARIPO patent (KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i>
(54) Title: CONJUGATES USEFUL IN THE TREATMENT OF BENIGN PROSTATIC HYPERPLASIA (57) Abstract <p>Novel pharmaceutical compositions useful for the treatment of benign prostatic hyperplasia which comprises novel oligopeptides, which are selectively cleaved by enzymatically active PSA, in conjugation with a cytotoxic agent are described. Methods of treating benign prostate hypertrophy are also disclosed.</p>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AM	Armenia	GB	United Kingdom	MW	Malawi
AT	Austria	GE	Georgia	MX	Mexico
AU	Australia	GN	Guinea	NE	Niger
BB	Barbados	GR	Greece	NL	Netherlands
BE	Belgium	HU	Hungary	NO	Norway
BF	Burkina Faso	IE	Ireland	NZ	New Zealand
BG	Bulgaria	IT	Italy	PL	Poland
BJ	Benin	JP	Japan	PT	Portugal
BR	Brazil	KE	Kenya	RO	Romania
BY	Belarus	KG	Kyrgyzstan	RU	Russian Federation
CA	Canada	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	KZ	Kazakhstan	SG	Singapore
CH	Switzerland	LI	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovakia
CM	Cameroon	LR	Liberia	SN	Senegal
CN	China	LT	Lithuania	SZ	Swaziland
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	LV	Latvia	TG	Togo
DE	Germany	MC	Monaco	TJ	Tajikistan
DK	Denmark	MD	Republic of Moldova	TT	Trinidad and Tobago
EE	Estonia	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	UG	Uganda
FI	Finland	MN	Mongolia	US	United States of America
FR	France	MR	Mauritania	UZ	Uzbekistan
GA	Gabon			VN	Viet Nam

- 1 -

TITLE OF THE INVENTION**CONJUGATES USEFUL IN THE TREATMENT OF BENIGN
PROSTATIC HYPERPLASIA****5 BACKGROUND OF THE INVENTION**

Benign prostate hyperplasia (or "prostatism") can be seen in almost 100 percent of all men over the age of 80, and changes in the prostate can be discovered in about 50 percent of men by the time they reach the age of 60. Many men with benign prostate hyperplasia (BPH) remain without symptoms, others show slow progression, while others remain stable. However, some 400,000 men a year have symptoms severe enough to require surgery. The most common surgery, transurethral resection, is effective in relieving the symptoms of BPH, although side-effects, including morbidity from the operation itself, mild to severe urinary incontinence and some degree of erectile or ejaculatory dysfunction, have been reported in a limited number of patients.

Normally the prostate remains stable until after the age of 45, when the tissue begins to change, growing and causing the size of the prostate to increase. The enlarging prostate squeezes the urethra, producing the symptoms that characterize BPH. These include difficulty in starting urination (hesitancy), a weak urinary stream, dribbling after urination, and increased frequency or urgency to urinate during the sleep period. Sometimes urination may be painful. The symptoms of obstruction of the urethra can often become more severe if a urinary infection develops. one of the common complications of BPH.

Prostate specific Antigen (PSA) is a single chain 33 kDa glycoprotein that is produced almost exclusively by the human prostate epithelium and occurs at levels of 0.5 to 2.0 mg/ml in human seminal fluid (Nadji, M., Taber, S.Z., Castro, A., et al. (1981) Cancer 48:1229; Papsidero, L., Kuriyama, M., Wang, M., et al. (1981). JNCI 66:37; Qui, S.D., Young, C.Y.F., Bihartz, D.L., et al. (1990), J. Urol. 144:1550; Wang, M.C., Valenzuela, L.A., Murphy, G.P., et al. (1979). Invest. Urol. 17:159). The single carbohydrate unit is attached at asparagine residue number 45 and accounts for 2 to 3 kDa of the total

- 2 -

molecular mass. PSA is a protease with chymotrypsin-like specificity (Christensson, A., Laurell, C.B., Lilja, H. (1990). *Eur. J. Biochem.* 194:755-763). It has been shown that PSA is mainly responsible for dissolution of the gel structure formed at ejaculation by proteolysis of the major proteins in the sperm entrapping gel, Semenogelin I and Semenogelin II, and fibronectin (Lilja, H. (1985). *J. Clin. Invest.* 76:1899; Lilja, H., Oldbring, J., Rannevik, G., et al. (1987). *J. Clin. Invest.* 80:281; McGee, R.S., Herr, J.C. (1988). *Biol. Reprod.* 39:499). The PSA mediated proteolysis of the gel-forming proteins generates several soluble Semenogelin I and Semenogelin II fragments and soluble fibronectin fragments with liquefaction of the ejaculate and release of progressively motile spermatozoa (Lilja, H., Laurell, C.B. (1984). *Scand. J. Clin. Lab. Invest.* 44:447; McGee, R.S., Herr, J.C. (1987). *Biol. Reprod.* 37:431). Furthermore, PSA may proteolytically degrade IGFBP-3 (insulin-like growth factor binding protein 3) allowing IGF to stimulate specifically the growth of PSA secreting cells (Cohen et al., (1992) *J. Clin. Endo. & Meta.* 75:1046-1053).

PSA complexed to alpha 1 - antichymotrypsin is the predominant molecular form of serum PSA and may account for up to 95% of the detected serum PSA (Christensson, A., Björk, T., Nilsson, O., et al. (1993). *J. Urol.* 150:100-105; Lilja, H., Christensson, A., Dahlén, U. (1991). *Clin. Chem.* 37:1618-1625; Stenman, U.H., Leinoven, J., Alfthan, H., et al. (1991). *Cancer Res.* 51:222-226). The prostatic tissue (normal, benign hyperplastic, or malignant tissue) is implicated to predominantly release the mature, enzymatically active form of PSA, as this form is required for complex formation with alpha 1 - antichymotrypsin (Mast, A.E., Enghild, J.J., Pizzo, S.V., et al. (1991). *Biochemistry* 30:1723-1730; Perlmutter, D.H., Glover, G.I., Rivetna, M., et al. (1990). *Proc. Natl. Acad. Sci. USA* 87:3753-3757). Therefore, in the microenvironment of prostatic PSA secreting cells, the PSA is believed to be processed and secreted in its mature enzymatically active form not complexed to any inhibitory molecule. PSA also forms stable complexes with alpha 2 - macroglobulin, but as this results in encapsulation of PSA and complete loss of the PSA epitopes, the in vivo

- 3 -

significance of this complex formation is unclear. A free, noncomplexed form of PSA constitutes a minor fraction of the serum PSA (Christensson, A., Björk, T., Nilsson, O., et al. (1993). J. Urol. 150:100-105; Lilja, H., Christensson, A., Dahlén, U. (1991). Clin. Chem. 37:1618-1625). The size of this form of serum PSA is similar to that of PSA in seminal fluid (Lilja, H., Christensson, A., Dahlén, U. (1991). Clin. Chem. 37:1618-1625) but it is yet unknown as to whether the free form of serum PSA may be a zymogen; an internally cleaved, inactive form of mature PSA; or PSA manifesting enzyme activity. However, it seems unlikely that the free form of serum PSA manifests enzyme activity, since there is considerable (100 to 1000 fold) molar excess of both unreacted alpha 1 - antichymotrypsin and alpha 2 - macroglobulin in serum as compared with the detected serum levels of the free 33 kDa form of PSA (Christensson, A., Björk, T., Nilsson, O., et al. (1993). J. Urol. 150:100-105; Lilja, H., Christensson, A., Dahlén, U. (1991). Clin. Chem. 37:1618-1625).

Serum measurements of PSA are useful for monitoring the treatment of adenocarcinoma of the prostate (Duffy, M.S. (1989). Ann. Clin. Biochem. 26:379-387; Brawer, M.K. and Lange, P.H. (1989). Urol. Suppl. 5:11-16; Hara, M. and Kimura, H. (1989). J. Lab. Clin. Med. 113:541-548). Above normal serum concentrations of PSA have also been reported in benign prostatic hyperplasia and subsequent to surgical trauma of the prostate (Lilja, H., Christensson, A., Dahlén, U. (1991). Clin. Chem. 37:1618-1625). Therefore, a cytotoxic compound that could be activated by the proteolytic activity of PSA should be prostate cell specific as well as specific for PSA secreting prostate metastases. Such a specific agent may be effective against BPH without causing the side-effects associated with other therapies.

Accordingly, it is the object of this invention to provide a novel pharmaceutical composition useful for the treatment of benign prostatic hyperplasia which comprises novel oligopeptides, which are selectively cleaved by enzymatically active PSA, in conjugation with a cytotoxic agent.

- 4 -

Another object of this invention is to provide a method of treating benign prostatic hyperplasia which comprises administration of the novel pharmaceutical composition.

5 SUMMARY OF THE INVENTION

Novel pharmaceutical compositions useful for the treatment of adverse conditions of the prostate, in particular benign prostatic hyperplasia, which comprise novel oligopeptides, which are selectively cleaved by enzymatically active PSA, in conjugation with a
10 pharmaceutical agent are described. Methods of treating such conditions of the prostate are also disclosed.

BRIEF DESCRIPTION OF THE FIGURES

15 **FIGURES 1 and 1A: *Primary Amino Acid Sequence of Semenogelin I:***
The primary amino acid sequence of Semenogelin I is shown.
(SEQ.ID.NO.: 1) The PSA proteolytic cleavage sites ("CS") are shown
(numbered in order of the relative affinity of a site towards PSA
hydrolysis) and the protein fragments are numbered sequentially starting
20 at the amino terminus.

FIGURE 2: *Cleavage Affinity of Synthetic Oligopeptides:*

A nested set of synthetic oligopeptides was prepared and the oligopeptides were digested with enzymatically active free PSA for
25 various times. The results are shown in Table 2. All of the oligopeptides were tested as trifluoroacetate salts.

FIGURES 3, 3A and 3B: *Cleavage Affinity of Synthetic Oligopeptides:*

Synthetic oligopeptides were prepared and the oligopeptides were
30 digested with enzymatically active free PSA for four (4) hours. The percentage of the oligopeptide that is cleaved in this period of time is listed. The results are shown in Table 4. Table 4a shows the amount of time (in minutes) required for 50% cleavage of the noted oligopeptides with enzymatically active free PSA. If no salt is indicated for an
35 oligopeptide, the free base was tested.

- 5 -

FIGURE 4: Cytotoxicity Data of Non-cleavable Oligopeptide-Doxorubicin Conjugates:

5 The data of the figure shows comparative cytotoxicity of doxorubicin and a conjugate of doxorubicin covalently bound to an oligopeptide (Compound 12d) that does not contain the free PSA proteolytic cleavage site. The EC₅₀ for doxorubicin is 0.3 μ M, while the acetylated oligopeptide modified doxorubicin has an EC₅₀ that has been reduced by greater than 300 fold. This conjugate had no HPLC detectable
10 contamination with unmodified doxorubicin. The oligopeptide alone had no detectable cell killing activity.

FIGURES 5 and 5A: Cleavage Affinity of Oligopeptides in Conjugation with Doxorubicin by Free PSA In Vitro:

15 Oligopeptides-doxorubicin conjugates were prepared and the conjugates were digested with enzymatically active free PSA for four (4) hours. The percentage conjugate that is enzymatically cleaved in the oligopeptide in this period of time is listed. The results are shown in Table 5. Table 5a shows the amount of time (in minutes) required for 50% cleavage of the
20 noted oligopeptide-cytotoxic agent conjugates with enzymatically active free PSA. If no salt is indicated for the conjugate, the free conjugate was tested.

FIGURE 6: Cleavage Affinity of Oligopeptides in Conjugation with Doxorubicin in Cell Conditioned Media:

25 Oligopeptides-doxorubicin conjugates were reacted for four (4) hours with cell culture media that had been conditioned by exposure to LNCaP cells (which are known to secrete free PSA) or DuPRO cell (which do not secrete free PSA). The percentage conjugate that is enzymatically
30 cleaved in the oligopeptide in this period of time is listed. The results are shown in Table 6.

FIGURE 7: Cytotoxicity Data of Cleavable Oligopeptide-Doxorubicin Conjugates:

- 6 -

The data in Table 7 shows cytotoxicity (as EC50) of conjugates of doxorubicin covalently bound to an oligopeptide that contain a free PSA proteolytic cleavage site against a cancer cell line that is known to secrete free PSA. Also shown for selected conjugates is the cytotoxicity of the conjugate against a cell line (DuPRO) which does not secrete free PSA. If no salt is indicated for the conjugate, the free conjugate was tested.

DETAILED DESCRIPTION OF THE INVENTION

The present invention relates to pharmaceutical compositions that comprise conjugates that contain oligopeptides, which are specifically recognized by the free prostate specific antigen (PSA) and are capable of being proteolytically cleaved by the enzymatic activity of the free prostate specific antigen, and pharmaceutical agents covalently linked to such oligopeptides directly or through a linker unit, or pharmaceutically acceptable salts thereof. In particular, this invention is directed to such conjugates wherein the pharmaceutical agent is a cytotoxic agent. The present invention also relates to a novel method of treating adverse conditions of the prostate, in particular benign prostatic hyperplasia, which utilizes these compositions.

Such oligopeptides include oligomers that comprise an amino acid sequence selected from:

- a) AsnLysIleSerTyrGlnSer (SEQ.ID.NO.: 13),
- 25 b) LysIleSerTyrGlnSer (SEQ.ID.NO.: 14),
- c) GlyGluAsnGlyValGlnLysAspValSerGlnXaaSerIleTyrIleSerGlnThrGlu (SEQ.ID.NO.: 15),
- 30 d) GlyLysGlyIleSerSerGlnTyrIleSerAsnThrGluGluArgLeu (SEQ.ID.NO.: 2),
- e) AsnLysIleSerTyrTyrIleSer (SEQ.ID.NO.: 127),

- 7 -

f) AsnLysAlaSerTyrGlnSer (SEQ.ID.NO.: 128),

g) SerTyrGlnSerSer (SEQ.ID.NO.: 129);

5 h) LysTyrGlnSerSer (SEQ.ID.NO.: 140);

i) hArgTyrGlnSerSer (SEQ.ID.NO.: 141);

10 j) hArgChaGlnSerSer (SEQ.ID.NO.: 185); and

k) TyrGlnSerSer (SEQ.ID.NO.: 186);

wherein hArg is homoarginine, Cha is cyclohexylalanine and Xaa is any natural amino acid.

15

In an embodiment of the instant invention, the oligopeptides include oligomers that comprise an amino acid sequence that is selected from:

20 a) AsnLysIleSerTyrGlnSerSer (SEQ.ID.NO.: 16),

b) AsnLysIleSerTyrGlnSerAla (SEQ.ID.NO.: 130),

25 c) AsnLysIleSerTyrGlnSerSerSer (SEQ.ID.NO.: 17),

d) AlaAsnLysIleSerTyrGlnSerSerSer (SEQ.ID.NO.: 18),

e) LysIleSerTyrGlnSerSerSerThrGlu (SEQ.ID.NO.: 19),

30 f) GlyGluAsnGlyValGlnLysAspValSerGlnArgSerIleTyrIleSerGlnThrGlu (SEQ.ID.NO.: 4),

g) GlyGluAsnGlyValGlnLysAspValSerGlnSerSerIleTyrIleSerGlnThrGlu (SEQ.ID.NO.: 5),

- 8 -

- h) AlaAsnLysIleSerTyrTyrIleSer (SEQ.ID.NO.: 131),
i) AlaAsnLysAlaSerTyrGlnIleSer (SEQ.ID.NO.: 132),
5 j) SerTyrGlnIleSerSerThr (SEQ.ID.NO.: 133),
k) SerTyrGlnIleSerSerSer (SEQ.ID.NO.: 134),
10 l) LysTyrGlnIleSerSerSer (SEQ.ID.NO.: 142),
m) hArgTyrGlnIleSerSerSer (SEQ.ID.NO.: 143), and
n) SerTyrGlnIleSerSerLeu (SEQ.ID.NO.: 135);
15 or the pharmaceutically acceptable salt thereof.

In a more preferred embodiment of the instant invention, the oligopeptides include oligomers that comprise an amino acid sequence that is selected from:

20

- a) AsnLysIleSerTyrGlnIleSerSerSerThr (SEQ.ID.NO.: 10),
b) AlaAsnLysIleSerTyrGlnIleSerAla (SEQ.ID.NO.: 136),
25 c) AsnLysIleSerTyrGlnIleSerSerSerThrGlu (SEQ.ID.NO.: 3),
d) AlaAsnLysIleSerTyrGlnIleSerSerSerThrGlu (SEQ.ID.NO.: 11),
30 e) GlyGluAsnGlyValGlnLysAspValSerGlnArgSerIleTyrIleSerGlnThrGlu (SEQ.ID.NO.: 4),
f) AlaAsnLysIleSerTyrTyrIleSerSer (SEQ.ID.NO.: 137),

- 9 -

g) AlaAsnLysIleSerTyrTyrIleSerAla (SEQ.ID.NO.: 138),

h) AlaAsnLysAlaSerTyrGlnIleSerAla (SEQ.ID.NO.: 139),

5 i) AlaSerTyrGlnIleSerSerLeu (SEQ.ID.NO.: 94);

or the pharmaceutically acceptable salt thereof.

10 In a further embodiment of the instant invention, the oligopeptides include oligomers that comprise an amino acid sequence that is selected from:

a) GlyArgLysAlaAsnLysIleSerTyrGlnIleSerSerSerThrGluGluArgArg
LeuHisTyr GlyGluAsnGly (SEQ.ID.NO.: 6).

15

The phrase "oligomers that comprise an amino acid sequence" as used hereinabove, and elsewhere in the Detailed Description of the Invention, describes oligomers of from about 6 to about 100 amino acids residues which include in their amino acid
20 sequence the specific amino acid sequence described and which are therefore proteolytically cleaved within the amino acid sequence described by free PSA. Thus, for example, the following oligomer: GlnLeuAspAsnLysIleSerTyrGlnIleSerSerSerThrHisGlnSerSer (SEQ.ID.NO.: 20) comprises the amino acid sequence:
25 AsnLysIleSerTyrGlnIleSerSerSerThr (SEQ.ID.NO.:10) and would therefore come within the instant invention. It is understood that such oligomers do not include semenogelin I and semenogelin II.

It is also understood that the instant invention includes oligomers wherein the N-terminus amino acid or the C-terminus amino
30 acid, or both terminus amino acids are modified. Such modifications include, but are not limited to, acylation of the amine group at the N-terminus and formation of an amide to replace the carboxylic acid at the C-terminus. Addition of such moieties may be performed during solid-phase synthesis of the oligomer; thus, attachment of the C-terminus

- 10 -

amino acid to a solid phase resin may be through an amine which results in an amide moiety upon acidic cleavage of the oligomer from the resin. Thus the following compounds are considered "oligomers that comprise an amino acid sequence" as used hereinabove and are meant to be illustrative and are not limiting:

- AlaAsnLysIleSerTyrGlnSerSerSerThrGlu-amide (SEQ.ID.NO.: 11)
 Ac-AlaAsnLysIleSerTyrGlnSerSerSerThrLeu (SEQ.ID.NO.: 70)
- 10 Ac-AlaAsnLysIleSerTyrGlnSerSerSerThrGlu-amide (SEQ.ID.NO.: 11)
 Ac-AlaAsnLysIleSerTyrGlnSerSerSerThrLeu-amide (SEQ.ID.NO.: 70)
 Ac-AlaAsnLysIleSerTyrGlnSerAlaSerThrGlu-amide (SEQ.ID.NO.: 73)
 Ac-AlaAsnLysIleSerTyrGlnSerSerLysThrGlu-amide (SEQ.ID.NO.: 74)
 Ac-AlaAsnLysIleSerTyrGlnSerSerThrGlu-amide (SEQ.ID.NO.: 75)
- 15 Ac-AlaAsnLysIleSerTyrGlnSerSerGlnThrGlu-amide (SEQ.ID.NO.: 78)
 Ac-AlaAsnLysIleSerTyrGlnSerAlaLysThrGlu-amide (SEQ.ID.NO.: 79)
 Ac-AlaAsnLysIleSerTyrGlnSerThrGlu-amide (SEQ.ID.NO.: 81)
 Ac-AlaAsnLysSerTyrGlnSerSerThrGlu-amide (SEQ.ID.NO.: 82)
 Ac-AlaAsnLysAlaSerTyrGlnSerAlaSerThrGlu-amide (SEQ.ID.NO.: 84)
- 20 Ac-AlaAsnGluIleSerTyrGlnSerAlaSerThrGlu-amide (SEQ.ID.NO.: 85)
 Ac-AsnLysIleSerTyrGlnSerSer-amide (SEQ.ID.NO.: 16)
 Ac-LysIleSerTyrGlnSerSer-amide (SEQ.ID.NO.: 86)
 Ac-SerTyrGlnSerSerThrGlu-amide (SEQ.ID.NO.: 87)
- 25 Ac-AlaSerTyrGlnSerSerThrGlu-amide (SEQ.ID.NO.: 89)
 Ac-AlaAsnLysIleSerTyrTyrSerSerSerThrGlu-amide (SEQ.ID.NO.: 92)
 Ac-AlaAsnLysIleSerTyrTyrSerAlaSerThrGlu-amide (SEQ.ID.NO.: 93)
 Ac-AlaSerTyrGlnSerSerLeu-amide (SEQ.ID.NO.: 94)
 Ac-AlaAsnSerTyrGlnSerSerSerThrGlu-amide (SEQ.ID.NO.: 95)
- 30 Ac-AlaSerTyrGlnSerSerSerThrGlu-amide (SEQ.ID.NO.: 96)
 Ac-SerTyrGlnSerSerSerThrGlu-amide (SEQ.ID.NO.: 97)
 Ac-AlaAsnLysAlaSerTyrGlnSerAlaSerCys-amide (SEQ.ID.NO.: 98)
 Ac-hArg(Cha)GlnSerNle-Acid (SEQ.ID.NO.: 147)
 Ac-hArgThrGlnSerSerNle-Acid (SEQ.ID.NO.: 148)

- 11 -

- Ac-hArg(Cha)GlnSerSerNle-Acid (SEQ.ID.NO.: 149)
- Ac-AlaAspLysAlaSerTyrGlnSerSer-Cha-NHNH₂ (SEQ.ID.NO.: 150)
- Ac-hArgTyrGlnSerSerPro-Acid (SEQ.ID.NO.: 151)
- Ac-hArgTyrGlnSerSerHis-Acid (SEQ.ID.NO.: 152)
- 5 Ac-hArgTyrGlnSerAsn-Acid (SEQ.ID.NO.: 153)
- Ac-hArgTyrGlnSerSerSerNle-Acid (SEQ.ID.NO.: 154)
- Ac-(Amf)TyrGlnSerSerSerNle-Acid (SEQ.ID.NO.: 155)
- H₂NCO-hArgTyrGlnSerSerSerLeu-Acid (SEQ.ID.NO.: 156)
- Ac-AlaAspLysAlaLysTyrGlnSerSer(Cha)-NHNH₂ (SEQ.ID.NO.: 157)
- 10 Ac-(DPL)TyrGlnSerSerSerNle-Acid (SEQ.ID.NO.: 158)
- Ac-(imidazole)LysTyrGlnSerSerLeu-Acid (SEQ.ID.NO.: 159)
- Ac-AlaAspLysAla(hArg)TyrGlnSerSerLeu-Acid (SEQ.ID.NO.: 160)
- Ac-(p-NH₂-Cha)TyrGlnSerSerSerNle-Acid (SEQ.ID.NO.: 161)
- Ac(imidazolyl)LysTyrGlnSerSerSerNle-Acid (SEQ.ID.NO.: 162)
- 15 Ac-hArg(Cha)GlnSerSerSerNle-Acid (SEQ.ID.NO.: 163)
- Ac-hArgTyrGlnSerSerSerhArg-Acid (SEQ.ID.NO.: 164)
- Ac-hArgTyrGlnSerSerSer(MeLeu) (SEQ.ID.NO.: 188)
- Ac-hArgTyrGlnSerSerSer(Ethylester-Leu) (SEQ.ID.NO.: 156)
- Ac-AlaAspLysAla(imidazoleLys)TyrGlnSerSerNle-Acid (SEQ.ID.NO.: 165)
- 20 Ac-hArg(3-Iodo-Tyr)GlnSerSerSerNle-Acid (SEQ.ID.NO.: 166)
- Ac-hArg(Me₂PO₃-Tyr)GlnSerSerSerNle-Acid (SEQ.ID.NO.: 167)
- Ac-hArgTyrGlnSerSerAsp-Acid (SEQ.ID.NO.: 168)
- Ac-hArg(O-Me-Tyr)GlnSerSerSerNle-Acid (SEQ.ID.NO.: 169)
- 25 Ac-AlaAspLysAlaLysTyrGlnSerSerNle-Acid (SEQ.ID.NO.: 170)
- Ac-hArg(Cha)GlnSerSerSer(ethylester-Leu) (SEQ.ID.NO.: 171)
- Ac-(imidazolyl)Lys(Cha)GlnSerSerSerNle-Acid (SEQ.ID.NO.: 172)
- Ac-hArg(Cha)GlnSerSerSer-Acid (SEQ.ID.NO.: 173)
- Ac-hArg(Cha)GlnSerSerNle-Acid (SEQ.ID.NO.: 174)
- 30 Ac-hArg(Cha)GlnSerProNle-Acid (SEQ.ID.NO.: 175) and
- Ac-hArg(m-fluoro-Tyr)GlnSerSerSerNle-Acid (SEQ.ID.NO.: 176),

or the pharmaceutically acceptable salt thereof.

- 12 -

A person of ordinary skill in the peptide chemistry art would readily appreciate that certain amino acids in a biologically active oligopeptide may be replaced by other homologous, isosteric and/or isoelectronic amino acids wherein the biological activity of the original oligopeptide has been conserved in the modified oligopeptide. Certain
 5 unnatural and modified natural amino acids may also be utilized to replace the corresponding natural amino acid in the oligopeptides of the instant invention. Thus, for example, tyrosine may be replaced by 3-iodotyrosine, 2-methyltyrosine, 3-fluorotyrosine, 3-methyltyrosine and
 10 the like. Further for example, lysine may be replaced with N'-(2-imidazolyl)lysine and the like. The following list of amino acid replacements is meant to be illustrative and is not limiting:

<u>Original Amino Acid</u>	<u>Replacement Amino Acid(s)</u>
Ala	Gly
Arg	Lys, Ornithine
Asn	Gln
Asp	Glu
Glu	Asp
Gln	Asn
Gly	Ala
Ile	Val, Leu, Met, Nle
Leu	Ile, Val, Met, Nle
Lys	Arg, Ornithine
Met	Leu, Ile, Nle, Val
Ornithine	Lys, Arg
Phe	Tyr, Trp
Ser	Thr
Thr	Ser
Trp	Phe, Tyr
Tyr	Phe, Trp
Val	Leu, Ile, Met, Nle

- 13 -

Thus, for example, the following oligopeptides may be synthesized by techniques well known to persons of ordinary skill in the art and would be expected to be proteolytically cleaved by free PSA:

- 5 AsnArgIleSerTyrGlnIser (SEQ.ID.NO.: 21)
- AsnLysValSerTyrGlnIser (SEQ.ID.NO.: 22)
- AsnLysMetSerTyrGlnIserSer (SEQ.ID.NO.: 23)
- AsnLysLeuSerTyrGlnIserSer (SEQ.ID.NO.: 24)
- AsnLysIleThrTyrGlnIserSerSer (SEQ.ID.NO.: 25)
- 10 AsnLysIleSerPheGlnIserSerSer (SEQ.ID.NO.: 26)
- AsnLysIleSerTrpGlnIserSerSerThr (SEQ.ID.NO.: 27)
- AsnLysIleSerTyrAsnIserSerSerThr (SEQ.ID.NO.: 28)
- AsnLysIleSerTyrGlnIthrSerSerThr (SEQ.ID.NO.: 29)
- AsnLysIleSerTyrGlnIser (SEQ.ID.NO.: 30)
- 15 GlnLysIleSerTyrGlnIserSer (SEQ.ID.NO.: 31)
- AsnArgIleThrTyrGlnIserSerSer (SEQ.ID.NO.: 32)
- AsnArgIleSerPheGlnIserSerSerThr (SEQ.ID.NO.: 33)
- AsnArgIleSerTrpGlnIserSerSerThr (SEQ.ID.NO.: 35)
- AsnArgIleSerTyrGlnIthrSerSerThr (SEQ.ID.NO.: 36)
- 20 AsnLysIleThrTyrGlnIthrSerSerThr (SEQ.ID.NO.: 37)
- AsnLysLeuSerTyrGlnIthrSerSerThr (SEQ.ID.NO.: 38)
- GlnLysLeuSerTyrGlnIserSerSerThr (SEQ.ID.NO.: 39)
- AsnArgLeuSerTyrGlnIthrSerSerThr (SEQ.ID.NO.: 40)
- AsnLysValSerPheGlnIserSerSerThr (SEQ.ID.NO.: 41)
- 25 AsnArgValSerTrpGlnIserSerSerThr (SEQ.ID.NO.: 42)
- GlnLysValSerTyrGlnIserSerSerThr (SEQ.ID.NO.: 43)
- GlnLysIleSerTyrGlnIthrSerSerThr (SEQ.ID.NO.: 34)
- AsnLysIleSerTyrGlnIserSerSerSerThr (SEQ.ID.NO.: 44);
- 30 or the pharmaceutically acceptable salt thereof.

Similarly, the following oligopeptides may be synthesized by techniques well known to persons of ordinary skill in the art and would be expected to be proteolytically cleaved by free PSA:

- 14 -

- GlyGluGlnGlyValGlnLysAspValSerGlnSerSerIleTyrI SerGlnThrGlu
(SEQ.ID.NO.: 45),
GlyGluAsnGlyLeuGlnLysAspValSerGlnSerSerIleTyrI SerGlnThrGlu
5 (SEQ.ID.NO.: 47),
GlyGluAsnGlyValAsnLysAspValSerGlnSerSerIleTyrI SerGlnThrGlu
(SEQ.ID.NO.: 48),
GlyGluAsnGlyValGlnArgAspValSerGlnArgSerIleTyrI SerGlnThrGlu
(SEQ.ID.NO.: 49),
10 GlyGluAsnGlyValGlnLysAspValSerGlnLysSerIleTyrI SerGlnThrGlu
(SEQ.ID.NO.: 50),
GlyGluAsnGlyValGlnLysAspLeuSerGlnThrSerIleTyrI SerGlnThrGlu
(SEQ.ID.NO.: 51),
GlyGluAsnGlyValGlnLysAspValSerGlnSerSerIlePheI SerGlnThrGlu
15 (SEQ.ID.NO.: 52),
GlyGluAsnGlyValGlnLysAspMetSerGlnSerSerIleTyrI ThrGlnThrGlu
(SEQ.ID.NO.: 53),
GlyGluAsnGlyValGlnLysAspValSerGlnArgSerIleTyrI ThrGlnThrGlu
(SEQ.ID.NO.: 54),
20 GlyGluAsnGlyValGlnLysAspValSerGlnSerSerIleTyrI SerGlnSerGlu
(SEQ.ID.NO.: 55),
GlyGluAsnGlyValGlnLysAspValSerGlnArgSerIleTyrI SerAsnThrGlu
(SEQ.ID.NO.: 56),
GlyLysAlaIleSerSerGlnTyrI SerAsnThrGluGluArgLeu (SEQ.ID.NO.:
25 57),
GlyArgGlyIleSerSerGlnTyrI SerAsnThrGluGluArgLeu (SEQ.ID.NO.:
59),
GlyLysGlyIleThrSerGlnTyrI SerAsnThrGluGluArgLeu (SEQ.ID.NO.:
60),
30 GlyLysGlyIleSerThrGlnTyrI SerAsnThrGluGluArgLeu (SEQ.ID.NO.:
61),
GlyLysGlyIleSerSerAsnTyrI SerAsnThrGluGluArgLeu (SEQ.ID.NO.:
62),

- 15 -

- AlaLysGlyIleSerSerGlnTyrI SerAsnThrGluGluArgLeu (SEQ.ID.NO.: 63),
 GlyLysGlyIleSerSerGlnPheI SerAsnThrGluGluArgLeu (SEQ.ID.NO.: 64),
 5 GlyLysGlyIleSerSerGlnTyrI ThrAsnThrGluGluArgLeu (SEQ.ID.NO.: 65),
 GlyLysGlyIleSerSerGlnTyrI SerAsnSerGluGluArgLeu (SEQ.ID.NO.: 58), and
 GlyLysGlyIleSerSerGlnTyrI SerAsnThrAspGluArgLeu (SEQ.ID.NO.: 46);
 10 and the like.

The inclusion of the symbol "I" within an amino acid sequence indicates the point within that sequence where the oligopeptide is proteolytically cleaved by free PSA.

- 15 The compounds of the present invention may have asymmetric centers and occur as racemates, racemic mixtures, and as individual diastereomers, with all possible isomers, including optical isomers, being included in the present invention. Unless otherwise specified, named amino acids are understood to have the natural "L" stereoconfiguration
 20

The following abbreviations are utilized in the specification and figures to denote the indicated amino acids and moieties:

25	hR or hArg:	homoarginine
	hY or hTyr:	homotyrosine
	Cha:	cyclohexylalanine
	Amf:	4-aminomethylphenylalanine
	DPL:	2-(4,6-dimethylpyrimidinyl)lysine
	(imidazolyl)K:	N'-(2-imidazolyl)lysine
30	Me ₂ PO ₃ -Y:	O-dimethylphosphotyrosine
	O-Me-Y:	O-methyltyrosine
	TIC:	tetrahydro-3-isoquinoline carboxylic acid
	MeL:	2-keto-3-amino-5-methylhexane
	DAP:	1,3-diaminopropane

- 16 -

TFA: trifluoroacetic acid
AA: acetic acid

The method of treatment of the instant invention utilizes
5 pharmaceutical compositions whose pharmaceutical activity is specific
for cells that secrete enzymatically active PSA. Such compositions
comprise the oligopeptides described herein above covalently bonded
directly, or through a linker unit, to a pharmaceutical agent. Such a
combination of an oligopeptide and pharmaceutical agent may be termed
10 a conjugate. The pharmaceutical agent component of the conjugate may
be selected from known compounds useful for treating conditions of the
prostate, whose site of biological activity or the desired target of the
biological activity is within the prostate or in close proximity to the
prostate. Such pharmaceutical agents include, but are not limited to
15 cytotoxic agents.

In a preferred embodiment, the method of treatment of the
instant invention utilizes cytotoxic compositions whose cytotoxicity is
specific for cells that secrete enzymatically active PSA. Such
20 compositions comprise the oligopeptides, described herein above,
covalently bonded directly, or through a linker unit, to a cytotoxic agent.
Ideally, the cytotoxic activity of the cytotoxic agent is greatly reduced or
absent when the oligopeptide containing the PSA proteolytic cleavage
site is bonded directly, or through a chemical linker, to the cytotoxic
25 agent and is intact. Also ideally, the cytotoxic activity of the cytotoxic
agent increases significantly or returns to the activity of the unmodified
cytotoxic agent upon proteolytic cleavage of the attached oligopeptide at
the cleavage site. While it is not necessary for practicing this aspect of
the invention, a preferred embodiment of this aspect of the invention is a
30 conjugate wherein the oligopeptide, and the linker unit if present, are
detached from the cytotoxic agent by the proteolytic activity of the free
PSA and any other native proteolytic enzymes present in the tissue
proximity, thereby releasing unmodified cytotoxic agent into the

- 17 -

physiological environment at the place of proteolytic cleavage.

Pharmaceutically acceptable salts of the conjugates are also included.

It is understood that the oligopeptide of the instant invention that is conjugated to the cytotoxic agent, whether through a direct
5 covalent bond or through a linker unit, does not need to be the oligopeptide that has the greatest recognition by free PSA and is most readily proteolytically cleaved by free PSA. Thus, the oligopeptide that is selected for incorporation in such an anti-BPH composition will be chosen both for its selective, proteolytic cleavage by free PSA and for the
10 cytotoxic activity of the cytotoxic agent-proteolytic residue conjugate (or, in what is felt to be an ideal situation, the unmodified cytotoxic agent) which results from such a cleavage.

Because the conjugates utilized in the instant invention can be used for modifying a given biological response, cytotoxic agent is not
15 to be construed as limited to classical chemical therapeutic agents. For example, the cytotoxic agent may be a protein or polypeptide possessing a desired biological activity. Such proteins may include, for example, a toxin such as abrin, ricin A, pseudomonas exotoxin, or diphtheria toxin; a protein such as tumor necrosis factor, α -interferon, β -interferon, nerve
20 growth factor, platelet derived growth factor, tissue plasminogen activator; or, biological response modifiers such as, for example, lymphokines, interleukin-1 ("IL-1"), interleukin-2 ("IL-2"), interleukin-6 ("IL-6"), granulocyte macrophage colony stimulating factor ("GM-CSF"), granulocyte colony stimulating factor ("G-CSF"), or other growth
25 factors.


The preferred cytotoxic agents include, in general, alkylating agents, antiproliferative agents, tubulin binding agents and the like. Preferred classes of cytotoxic agents include, for example, the
anthracycline family of drugs, the vinca drugs, the mitomycins, the
30 bleomycins, the cytotoxic nucleosides, the pteridine family of drugs, diynenes, the taxanes and the podophyllotoxins. Particularly useful members of those classes include, for example, doxorubicin, carminomycin, daunorubicin, aminopterin, methotrexate, methopterin, dichloro-methotrexate, mitomycin C, porfiromycin, 5-fluorouracil, 6-

- 18 -

mercaptapurine, cytosine arabinoside, podophyllotoxin, or podophyllotoxin derivatives such as etoposide or etoposide phosphate, melphalan, vinblastine, vincristine, leurosine, vindesine, leurosine, taxol and the like. Other useful cytotoxic agents include estramustine, cisplatin and cyclophosphamide. One skilled in the art may make chemical modifications to the desired cytotoxic agent in order to make reactions of that compound more convenient for purposes of preparing conjugates of the invention.

A highly preferred group of cytotoxic agents for the present invention include drugs of the following formulae:

THE METHOTREXATE GROUP OF FORMULA(1):



(1)


15

in which

- R¹² is amino or hydroxy;
 R⁷ is hydrogen or methyl;
 R⁸ is hydrogen, fluoro, chloro, bromo or iodo;
 R⁹ is hydroxy or a moiety which completes a salt of the carboxylic acid;

20

- 19 -


THE MITOMYCIN GROUP OF FORMULA (2):

(2)

in which

R¹⁰ is hydrogen or methyl;


5

THE BLEOMYCIN GROUP OF FORMULA (3)



(3)

10 in which R¹¹ is hydroxy, amino, C₁-C₃ alkylamino, di(C₁-C₃ alkyl)amino, C₄-C₆ polymethylene amino,

- 20 -


MELPHALAN OF FORMULA (4):

5

6-MERCAPTOPURINE OF FORMULA (5):

(5)


10

A CYTOSINE ARABINOSIDE OF FORMULA (6):

(6)

15

- 21 -


THE PODOPHYLLOTOXINS OF FORMULA(7):

5 in which

R¹³ is hydrogen or methyl;R¹⁴ is methyl or thienyl;

or a phosphate salt thereof;

- 22 -

THE VINCA ALKALOID GROUP OF DRUGS OF FORMULA (8):


(8)

5

in which

R¹⁵ is H, CH₃ or CHO; when R¹⁷ and R¹⁸ are taken singly;R¹⁸ is H, and one of R¹⁶ and R¹⁷ is ethyl and the other is H or OH; when R¹⁷ and R¹⁸ are taken together with the carbons to which they are attached, they form an oxirane ring in which case R¹⁶ is ethyl;

10


R¹⁹ is hydrogen, (C₁-C₃ alkyl)-CO, or chlorosubstituted (C₁-C₃ alkyl)-CO;15 DIFLUORONUCLEOSIDES OF FORMULA (9):

(9)

in which

R²¹ is a base of one of the formulae:

- 23 -




in which

R²² is hydrogen, methyl, bromo, fluoro, chloro or iodo;R²³ is -OH or -NH₂;

5 R²⁴ is hydrogen, bromo, chloro or iodo;
or,

THE ANTHRACYCLINES ANTIBIOTICS OF FORMULA (10):



(10)



10

wherein

R¹ is -CH₃, -CH₂OH, -CH₂OCO(CH₂)₃CH₃, or
-CH₂OCOCH(OC₂H₅)₂;

- 24 -

- R^3 is -OCH₃, -OH or -H;
 R^4 is -NH₂, -NHCOCF₃, 4-morpholinyl, 3-cyano-4-morpholinyl, 1-piperidinyl, 4-methoxy-1-piperidinyl, benzylamine, dibenzylamine, cyanomethylamine, or 1-cyano-2-methoxyethyl amine;
 R^5 is -OH -OTHP or -H; and
 R^6 is -OH or -H provided that R^6 is not -OH when R^5 is -OH or -OTHP.

10 ESTRAMUSTINE (11)15 CYCLOPHOSPHAMIDE (12)

12

The most highly preferred drugs are the anthracycline
 antibiotic agents of Formula (10), described previously. One skilled in
 the art understands that this structural formula includes compounds which
 are drugs, or are derivatives of drugs, which have acquired in the art
 different generic or trivial names. Table 1, which follows, represents a
 number of anthracycline drugs and their generic or trivial names and
 which are especially preferred for use in the present invention.

25

- 26 -

Of the compounds shown in Table 1, the most highly preferred cytotoxic agents are doxorubicin, vinblastine and desacetylvinblastine. Doxorubicin (also referred to herein as "DOX") is that anthracycline of Formula (10) in which R₁ is -CH₂OH, R₃ is -OCH₃, R₄ is -NH₂, R₅ is -OH, and R₆ is -H.

The oligopeptides, peptide subunits and peptide derivatives (also termed "peptides") incorporated in the conjugates utilized in the method of treatment of the present invention can be synthesized from their constituent amino acids by conventional peptide synthesis techniques, preferably by solid-phase technology. The peptides are then purified by reverse-phase high performance liquid chromatography (HPLC).

Standard methods of peptide synthesis are disclosed, for example, in the following works: Schroeder *et al.*, "The Peptides", Vol. I, Academic Press 1965; Bodansky *et al.*, "Peptide Synthesis", Interscience Publishers, 1966; McOmie (ed.) "Protective Groups in Organic Chemistry", Plenum Press, 1973; Barany *et al.*, "The Peptides: Analysis, Synthesis, Biology" 2, Chapter 1, Academic Press, 1980, and Stewart *et al.*, "Solid Phase Peptide Synthesis", Second Edition, Pierce Chemical Company, 1984. The teachings of these works are hereby incorporated by reference.

The pharmaceutically acceptable salts of the compounds incorporated in the conjugates utilized in the method of treatment of this invention include the conventional non-toxic salts of the compounds of this invention as formed, e.g., from non-toxic inorganic or organic acids. For example, such conventional non-toxic salts include those derived from inorganic acids such as hydrochloric, hydrobromic, sulfuric, sulfamic, phosphoric, nitric and the like: and the salts prepared from organic acids such as acetic, propionic, succinic, glycolic, stearic, lactic, malic, tartaric, citric, ascorbic, pantoic, maleic, hydroxymaleic, phenyl-acetic, glutamic, benzoic, salicylic, sulfanilic, 2-acetoxy-benzoic, fumaric,

- 27 -

toluenesulfonic, methanesulfonic, ethane disulfonic, oxalic, isethionic, trifluoroacetic and the like.

The conjugates utilized in the method of treatment of the instant invention which comprise the oligopeptide containing the PSA cleavage site and a cytotoxic agent may similarly be synthesized by techniques well known in the medicinal chemistry art. For example, a free amine moiety on the cytotoxic agent may be covalently attached to the oligopeptide at the carboxyl terminus such that an amide bond is formed. Similarly, an amide bond may be formed by covalently coupling an amine moiety of the oligopeptide and a carboxyl moiety of the cytotoxic agent. For these purposes a reagent such as 2-(1H-benzotriazol-1-yl)-1,3,3-tetramethyluronium hexafluorophosphate (known as HBTU) and 1-hydroxybenzotriazole hydrate (known as HOBT), dicyclohexyl- carbodiimide (DCC), N-ethyl-N-(3-dimethylaminopropyl)- carbodiimide (EDC), diphenylphosphorylazide (DPPA), benzotriazol-1-yl-oxy-tris-(dimethylamino)phosphonium hexafluorophosphate (BOP) and the like, used in combination or singularly, may be utilized.

Furthermore, the instant conjugate may be formed by a non-peptidyl bond between the PSA cleavage site and a cytotoxic agent. For example, the cytotoxic agent may be covalently attached to the carboxyl terminus of the oligopeptide via a hydroxyl moiety on the cytotoxic agent, thereby forming an ester linkage. For this purpose a reagent such as a combination of HBTU and HOBT, a combination of BOP and imidazole, a combination of DCC and DMAP, and the like may be utilized. The carboxylic acid may also be activated by forming the nitro-phenyl ester or the like and reacted in the presence of DBU (1,8-diazabicyclo[5,4,0]undec-7-ene).

The instant conjugate may also be formed by attachment of the oligopeptide to the cytotoxic agent via a linker unit. Such linker units include, for example, a biscarbonyl alkyl diradical whereby an amine moiety on the cytotoxic agent is connected with the linker unit to form an amide bond and the amino terminus of the oligopeptide is connected with the other end of the linker unit also forming an amide bond. Conversely,

- 28 -

a diaminoalkyl diradical linker unit, whereby a carbonyl moiety on the cytotoxic agent is covalently attached to one of the amines of the linker unit while the other amine of the linker unit is covalently attached to the C terminus of the oligopeptide, may also be useful. Other such linker units which are stable to the physiological environment when not in the presence of free PSA, but are cleavable upon the cleavage of the PSA proteolytic cleavage site, are also envisioned. Furthermore, linker units may be utilized that, upon cleavage of the PSA proteolytic cleavage site, remain attached to the cytotoxic agent but do not significantly decrease the cytotoxic activity of such a post-cleavage cytotoxic agent derivative when compared with an unmodified cytotoxic agent.

One skilled in the art understands that in the synthesis of conjugates utilized in the method of treatment of the invention, one may need to protect or block various reactive functionalities on the starting compounds and intermediates while a desired reaction is carried out on other portions of the molecule. After the desired reactions are complete, or at any desired time, normally such protecting groups will be removed by, for example, hydrolytic or hydrogenolytic means. Such protection and deprotection steps are conventional in organic chemistry. One skilled in the art is referred to Protective Groups in Organic Chemistry, McOmie, ed., Plenum Press, NY, NY (1973); and, Protective Groups in Organic Synthesis, Greene, ed., John Wiley & Sons, NY, NY (1981) for the teaching of protective groups which may be useful in the preparation of compounds of the present invention.

By way of example only, useful amino-protecting groups may include, for example, C₁-C₁₀ alkanoyl groups such as formyl, acetyl, dichloroacetyl, propionyl, hexanoyl, 3,3-diethylhexanoyl, γ -chlorobutyl, and the like; C₁-C₁₀ alkoxycarbonyl and C₅-C₁₅ aryloxycarbonyl groups such as tert-butoxycarbonyl, benzyloxycarbonyl, allyloxycarbonyl, 4-nitrobenzyloxycarbonyl, fluorenylmethyloxycarbonyl and cinnamoyloxycarbonyl; halo-(C₁-C₁₀)-alkoxycarbonyl such as 2,2,2-trichloroethoxycarbonyl; and C₁-C₁₅ arylalkyl and alkenyl group such as benzyl, phenethyl, allyl, trityl, and the like. Other commonly

- 29 -

used amino-protecting groups are those in the form of enamines prepared with β -keto-esters such as methyl or ethyl acetoacetate.


Useful carboxy-protecting groups may include, for example, C₁-C₁₀ alkyl groups such as methyl, tert-butyl, decyl; halo-C₁-C₁₀ alkyl
5 such as 2,2,2-trichloroethyl, and 2-iodoethyl; C₅-C₁₅ arylalkyl such as benzyl, 4-methoxybenzyl, 4-nitrobenzyl, triphenylmethyl, diphenylmethyl; C₁-C₁₀ alkanoyloxymethyl such as acetoxymethyl, propionoxymethyl and the like; and groups such as phenacyl, 4-halophenacyl, allyl, dimethylallyl, tri-(C₁-C₃ alkyl)silyl, such as
10 trimethylsilyl, β -p-toluenesulfonylethyl, β -p-nitrophenyl-thioethyl, 2,4,6-trimethylbenzyl, β -methylthioethyl, phthalimidomethyl, 2,4-dinitrophenylsulphenyl, 2-nitrobenzhydryl and related groups.

Similarly, useful hydroxy protecting groups may include, for example, the formyl group, the chloroacetyl group, the benzyl group, the
15 benzhydryl group, the trityl group, the 4-nitrobenzyl group, the trimethylsilyl group, the phenacyl group, the tert-butyl group, the methoxymethyl group, the tetrahydropyranyl group, and the like.

With respect to the preferred embodiment of the instant method of treatment in which an oligopeptide is combined with the
20 anthracycline antibiotic doxorubicin, the following Reaction Schemes illustrate the synthesis of the conjugates of the instant invention.


- 30 -

REACTION SCHEME I




- 31 -

REACTION SCHEME II




- 32 -

REACTION SCHEME III




- 33 -

REACTION SCHEME IV



- 34 -

REACTION SCHEME V



- 35 -

Reaction Scheme VI illustrates preparation of conjugates utilized in the instant method of treatment wherein the oligopeptides are combined with the vinca alkaloid cytotoxic agent vinblastine.




Attachment of the N-terminus of the oligopeptide to vinblastine is
5 illustrated (S.P. Kandukuri et al. J. Med. Chem. 28:1079-1088 (1985)).

Reaction Scheme VII illustrates preparation of conjugates utilized in the instant method of treatment wherein the oligopeptides are combined with the vinca alkaloid cytotoxic agent vinblastine wherein the attachment of vinblastine is at the C-terminus of the oligopeptide. The
10 use of the 1,3-diaminopropane linker is illustrative only; other spacer units between the carbonyl of vinblastine and the C-terminus of the oligopeptide are also envisioned. Furthermore, Scheme VII illustrates a synthesis of conjugates wherein the C-4-position hydroxy moiety is
15 reacylated following the addition of the linker unit. Applicants have discovered that the desacetyl vinblastine conjugate is also efficacious and may be prepared by eliminating the steps shown in Reaction Scheme VII of protecting the primary amine of the linker and reacting the
20 intermediate with acetic anhydride, followed by deprotection of the amine. Conjugation of the oligopeptide at other positions and functional groups of vinblastine may be readily accomplished by one of ordinary skill in the art and is also expected to provide compounds useful in the treatment of benign prostatic hyperplasia.

It is also understood that conjugates may be prepared wherein the N-terminus of the oligopeptide utilized in the instant method
25 of treatment is combined with one cytotoxic agent, such as vinblastine, while the C-terminus is simultaneously attached to another cytotoxic agent, which is the same or different cytotoxic agent, such as doxorubicin. Reaction Scheme VIII illustrates the synthesis of such a polycytotoxic agent conjugate. Such a polycytotoxic conjugate may offer
30 advantages over a conjugate containing only one cytotoxic agent.


- 36 -

REACTION SCHEME VI



- 37 -


REACTION SCHEME VI (Continued)



wherein R is $-\text{NH}_2$, $-\text{O-alkyl}$ and the like


- 38 -

REACTION SCHEME VII



- 39 -


REACTION SCHEME VII (Continued)



wherein R' is acetyl, alkyl, hydrogen or the like


- 40 -

REACTION SCHEME VIII



- 41 -


REACTION SCHEME VIII (Continued)



- 42 -

The oligopeptide-cytotoxic agent conjugate utilized in the method of treatment of the instant invention wherein the cytotoxic agent is the preferred cytotoxic agent doxorubicin may be described by the general formula I below:

5



wherein:

10

oligopeptide is an oligopeptide which is specifically recognized by the free prostate specific antigen (PSA) and is capable of being proteolytically cleaved by the enzymatic activity of the free prostate specific antigen;

15

X_L is absent or is an amino acid selected from:

- a) phenylalanine,
- b) leucine,
- c) valine,
- 20 d) isoleucine,
- e) (2-naphthyl)alanine,
- f) cyclohexylalanine,
- g) diphenylalanine,
- h) norvaline,
- 25 i) norleucine, and

- 43 -

j) 1,2,3,4-tetrahydroiso quinoline-3-carboxylic acid;

R is hydrogen or $-(C=O)R^1$; and

5 R^1 is C_1 - C_6 -alkyl or aryl,

or the pharmaceutically acceptable salt thereof.

10 In a preferred embodiment of the instant method of treatment of BPH:

oligopeptide is an oligomer that comprises an amino acid sequence selected from:

15 a) AsnLysIleSerTyrGlnIleSer (SEQ.ID.NO.: 13),

b) LysIleSerTyrGlnIleSer (SEQ.ID.NO.: 14),

20 c) GlyGluAsnGlyValGlnLysAspValSerGlnXaaSerIleTyrIleSerGlnThrGlu (SEQ.ID.NO.: 15),

d) GlyLysGlyIleSerSerGlnTyrIleSerAsnThrGluGluArgLeu (SEQ.ID.NO.: 2),

25 e) AsnLysIleSerTyrTyrIleSer (SEQ.ID.NO.: 127),

f) AsnLysAlaSerTyrGlnIleSer (SEQ.ID.NO.: 128),

30 g) SerTyrGlnIleSerSer (SEQ.ID.NO.: 129),

h) LysTyrGlnIleSerSer (SEQ.ID.NO.: 140);

i) hArgTyrGlnIleSerSer (SEQ.ID.NO.: 141);

- 44 -

j) hArgChaGlnSerSer (SEQ.ID.NO.: 185); and

k) TyrGlnSerSer (SEQ.ID.NO.: 186);

5 wherein Xaa is any natural amino acid;

XL is absent or is an amino acid selected from:


- a) leucine,
- b) isoleucine,
- 10 c) norleucine, and
- d) valine; and

R is acetyl, pivaloyl or benzoyl,

15 or the pharmaceutically acceptable salt thereof.

The following compounds are specific examples of the
oligopeptide-cytotoxic agent conjugate utilized in the method of
20 treatment of the instant invention:

- 45 -



wherein X is:

AsnLysIleSerTyrGlnSer — (SEQ.ID.NO.: 13),

AsnLysIleSerTyrGlnSerSer — (SEQ.ID.NO.: 16),

AsnLysIleSerTyrGlnSerSerSer — (SEQ.ID.NO.:17),

AsnLysIleSerTyrGlnSerSerSerThr — (SEQ.ID.NO.:10),

AsnLysIleSerTyrGlnSerSerSerThrGlu — (SEQ.ID.NO.: 3),

AlaAsnLysIleSerTyrGlnSerSerSerThrGlu — (SEQ.ID.NO.: 11),

↗
N-terminus

- 46 -

- Ac — AlaAsnLysIleSerTyrGlnSerSerSerThr — (SEQ.ID.NO.: 117),
- Ac — AlaAsnLysIleSerTyrGlnSerSerSerThrLeu — (SEQ.ID.NO.: 70),
- Ac — AlaAsnLysAlaSerTyrGlnSerAlaSerThrLeu — (SEQ.ID.NO.: 118),
- Ac — AlaAsnLysAlaSerTyrGlnSerAlaSerLeu — (SEQ.ID.NO.: 119),
- Ac — AlaAsnLysAlaSerTyrGlnSerSerSerLeu — (SEQ.ID.NO.: 120),
- Ac — AlaAsnLysAlaSerTyrGlnSerSerLeu — (SEQ.ID.NO.: 121).
- Ac — SerTyrGlnSerSerSerLeu — (SEQ.ID.NO.: 144),
- Ac — hArgTyrGlnSerSerSerLeu — (SEQ.ID.NO.: 145).
- Ac — LysTyrGlnSerSerSerLeu — (SEQ.ID.NO.: 124), or
(Compound 4)
- Ac — LysTyrGlnSerSerNle — (SEQ.ID.NO.: 146).
- ↗
N-terminus

or the pharmaceutically acceptable salt thereof.

- 5 Further examples of conjugates of an oligopeptide and doxorubicin wherein the N-terminus of the oligopeptide is acylated and the C-terminus of the oligopeptide is attached to the doxorubicin at the 3'-amine are as follows:
- 10 Ac-hArgTyrGln-SerSerPro-dox(3') (SEQ.ID.NO.: 151)
 Ac-hArgTyrGln-SerPro-dox(3') (SEQ.ID.NO.: 177)
 Ac-hArgTyrGln-SerSerSerNle-dox(3') (SEQ.ID.NO.: 154)


- 47 -

- Ac-AmfTyrGln-SerSerSerNle-dox(3') (SEQ.ID.NO.: 155)
- H₂NCO-hArgTyrGln-SerSerSerLeu-dox(3') (SEQ.ID.NO.: 156)
- Ac-LysTyrGln-SerSerNle-dox(3') (SEQ.ID.NO.: 146)
- Ac-LysTyrGln-SerLysNle-dox(3') (SEQ.ID.NO.: 178)
- 5 Ac(cis-p-NH₂Cha)TyrGlnSerSerNledox(3') (SEQ.ID.NO.: 161)
- Ac-AlaAspLysAla(hArg)TyrGln-SerSerLeu-dox(3') (SEQ.ID.NO.: 160)
- Ac-hArgTyrGln-SerAsn-dox(3') (SEQ.ID.NO.: 153)
- Ac-hArgTyrGln-SerSerHis-dox(3') (SEQ.ID.NO.: 152)
- Ac-(imidazolyl)LysTyrGln-SerSerLeu-dox(3') (SEQ.ID.NO.: 159)
- 10 Ac-(imidazolyl)LysTyrGlnSerSerSerNle-dox(3') (SEQ.ID.NO.: 162)
- Ac-hArg(Cha)Gln-SerSerSerNle-dox(3') (SEQ.ID.NO.: 163)
- Ac-hArg(Me₂PO₃Tyr)Gln-SerSerSerNle-dox(3') (SEQ.ID.NO.: 167)
- Ac-hArgTyrGln-SerSerSerhArg-dox(3') (SEQ.ID.NO.: 164)
- Ac-hArg(3-Iodo-Tyr)Gln-SerSerSerNle-dox(3') (SEQ.ID.NO.: 166)
- 15 Ac-hArg(O-Me-Tyr)Gln-SerSerSerNle-dox(3') (SEQ.ID.NO.: 169)
- Ac-hArg(p-NH₂-Phe)Gln-SerSerSerNle-dox(3') (SEQ.ID.NO.: 179)
- Ac-hArg(Cha)Gln-SerSerNle-dox(3') (SEQ.ID.NO.: 174)
- Ac-hArg(Cha)Gln-SerProNle-dox(3') (SEQ.ID.NO.: 175)
- Ac(imidazolyl)Lys(Cha)GlnSerSerSerNle-dox(3') (SEQ.ID.NO.: 172)
- 20 Ac-hArg(7-HO-TIC)Gln-SerSerSerNle-dox(3') (SEQ.ID.NO.: 180)
- Ac-hArg(3-Fluoro)TyrGlnSerSerSerNle-dox(3') (SEQ.ID.NO.: 176)
- Ac-(ornithine)TyrGln-SerSerSerNle-dox(3') (SEQ.ID.NO.: 181)
- Ac-LysAlaAlaSerSerSerLeu-dox(3') (SEQ.ID.NO.: 183)
- Ac-hArg(Cha)Gln-SerSerNle-dox(3') (SEQ.ID.NO.: 149)
- 25 Ac-AlaArgLysAlaSerTyrGln-SerLeu-dox(3') (SEQ.ID.NO.: 193) and
- Ac-(Orn)TyrGln-SerSerSerLeu-dox(3') (SEQ.ID.NO.: 194)

or the pharmaceutically acceptable salt thereof.

- 30 The oligopeptide-cytotoxic agent conjugate utilized in the method of treatment of the instant invention wherein the cytotoxic agent is the preferred cytotoxic agent vinblastine or desacetylvinblastine may be described by the general formula I below:

- 48 -



wherein:

5

oligopeptide is an oligopeptide which is specifically recognized by the free prostate specific antigen (PSA) and is capable of being proteolytically cleaved by the enzymatic activity of the free prostate specific antigen;

10

XL is absent or is an amino acid selected from:

15

- a) phenylalanine,
- b) leucine,
- c) valine,
- d) isoleucine,
- e) (2-naphthyl)alanine,
- f) cyclohexylalanine,
- g) diphenylalanine,
- h) norvaline, and
- i) norleucine, and
- j) 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid; or

20

XL is - NH - (CH₂)_n - NH -

- 49 -

R is hydrogen or $-(C=O)R^1$;

R^1 is C_1 - C_6 -alkyl or aryl;

5


R^{19} is hydrogen or acetyl; and

n is 1, 2, 3, 4 or 5,

10 or the pharmaceutically acceptable salt thereof.

The following compounds are specific examples of the oligopeptide-desacetylvinblastine conjugate utilized in the method of treatment of the instant invention:


15



Compound 14

(SEQ.ID.NO.: 183),

- 50 -




Compound 5

(SEQ.ID.NO.: 184),

or the pharmaceutically acceptable salt thereof.

- 5 The following compounds is a specific example of the polycytotoxic agent conjugates utilized in the method of treatment of the instant invention:

- 51 -



or the pharmaceutically acceptable salt thereof.

5

It is well known in the art, and understood in the instant invention, that peptidyl therapeutic agents such as the oligopeptide-cytotoxic agent conjugates preferably have the terminal amino moiety of any oligopeptide substituent protected with a suitable protecting group, such as acetyl, benzoyl, pivaloyl and the like. Such protection of the terminal amino group reduces or eliminates the enzymatic degradation of such peptidyl therapeutic agents by the action of exogenous amino

10

- 52 -

peptidases which are present in the blood plasma of warm blooded animals.

The oligopeptide-cytotoxic agent conjugates utilized in the method of treatment of the instant invention are administered to the patient in the form of a pharmaceutical composition which comprises a conjugate of Formula (I) and a pharmaceutically acceptable carrier, excipient or diluent therefor. As used, "pharmaceutically acceptable" refers to those agents which are useful in the treatment or diagnosis of a warm-blooded animal including, for example, a human, equine, porcine, bovine, murine, canine, feline, or other mammal, as well as an avian or other warm-blooded animal. The preferred mode of administration is parenterally, particularly by the intravenous, intramuscular, subcutaneous, intraperitoneal, or intralymphatic route. Such formulations can be prepared using carriers, diluents or excipients familiar to one skilled in the art. In this regard, See, e.g. Remington's Pharmaceutical Sciences, 16th ed., 1980, Mack Publishing Company, edited by Osol et al. Such compositions may include proteins, such as serum proteins, for example, human serum albumin, buffers or buffering substances such as phosphates, other salts, or electrolytes, and the like. Suitable diluents may include, for example, sterile water, isotonic saline, dilute aqueous dextrose, a polyhydric alcohol or mixtures of such alcohols, for example, glycerin, propylene glycol, polyethylene glycol and the like. The compositions may contain preservatives such as phenethyl alcohol, methyl and propyl parabens, thimerosal, and the like. If desired, the composition can include about 0.05 to about .20 percent by weight of an antioxidant such as sodium metabisulfite or sodium bisulfite.

For intravenous administration, the composition preferably will be prepared so that the amount administered to the patient will be from about .01 to about 1 g of the conjugate. Preferably, the amount administered will be in the range of about .2 g to about 1 g of the conjugate. The conjugates of the invention are effective over a wide dosage range depending on factors such as the disease state to be treated or the biological effect to be modified, the manner in which the conjugate is administered, the age, weight and condition of the patient as well as

- 53 -

other factors to be determined by the treating physician. Thus, the amount administered to any given patient must be determined on an individual basis.

One skilled in the art will appreciate that although specific reagents and reaction conditions are outlined in the following examples, modification can be made which are meant to be encompassed by the spirit and scope of the invention. The following preparations and examples, therefore, are provided to further illustrate the invention, and are not limiting.

10

EXAMPLES

EXAMPLE 1

15- *Identification of the Semenogelin PSA Mediated Cleavage Site:*
Liquefaction of the seminal gel parallels proteolytic fragmentation of semenogelin I [Lilja, H., Laurell, C.B., (1984) Scand. J. Clin. Lab. Inves. 44, 447-452]. It is believed that the proteolytic fragmentation of semenogelin is mainly due to the proteolytic activity of prostate-specific antigen [Lilja, H., (1985) J. Clin. Invest. 76, 1899-1903]. Utilizing the published sequence of semenogelin I [Lilja, H., Abrahamsson, P.A., Lundwall, A., (1989) J. of Biol. Chem. 264, 1894-1900] (Figure 1) we designed polymerase chain reaction primers to clone the semenogelin cDNA from a commercially available prostatic cDNA library (Clontech, Palo Alto, CA.). The purified semenogelin cDNA was placed into the bacterial expression vector pTAC [Linemeyer, D.L., Kelly, L.J., Minke, J.G., Gimenez-Gallego, G., DeSalvo, J. and Thomas, K.A., (1987) Bio/Technology 5, 960-965]. The semenogelin cDNA was designed so that a tubulin epitope was placed at the carboxyl end of semenogelin protein.. The bacterially expressed semenogelin protein was purified on an anti-tubulin antibody column. The purified semenogelin I protein was mixed with commercially prepared prostate-specific antigen (PSA) (York Biologicals International, Stony Brook, NY) in an 100 to 1 molar ratio (semenogelin I/PSA) in 12 mM Tris pH 8.0, 25 mM NaCl,

20

25

30

- 54 -

0.5 mM CaCl₂, and incubated for various times. The digest was fractionated by polyacrylamide gel electrophoresis and transferred by electrophoresis to ProBlott filter paper (Applied Biosystems, Inc., Foster City, CA.) in CAPS buffer [Matsudaira, P., (1987) J. Biol. Chem. 252, 10035-10038]. The ProBlott filter paper was stained with coomassie blue to identify the novel PSA generated semenogelin I protein fragments. The novel fragments were cut out of the filter with a scalpel and submitted for sequence determination. After the proteolytic fragments were identified by variable time digestion, a 10 minute digestion reaction was performed. The affinity of PSA for the 5 potential cleavage sites in semenogelin I was determined to be as follows: site 349/350 > site 375/376 > site 289/290 = site 315/316 > site 159/160. The relative affinities were derived from the coomassie blue staining intensity of each PSA generated peptide fragment. These intensities had approximate ratios of 3:1:0.6:0.3.

EXAMPLE 2

Preparation of Oligopeptides which Comprise the PSA Mediated Cleavage Site:

Oligopeptides were prepared by solid-phase synthesis, using a double coupling protocol for the introduction of amino acids on the Applied Biosystems model 430A automated peptide synthesizer. Deprotection and removal of the oligopeptide from the resin support were achieved by treatment with liquid hydrofluoric acid. The oligopeptides were purified by preparative high pressure liquid chromatography on reverse phase C18 silica columns using an aqueous 0.1% trifluoroacetic acid/acetonitrile gradient. Identity and homogeneity of the oligopeptides were confirmed by amino acid composition analysis, high pressure liquid chromatography, and fast atom bombardment mass spectral analysis. The oligopeptides that were prepared by this method are shown in Figure 2.

- 55 -

EXAMPLE 3

Assessment of the Recognition of Oligopeptides by Free PSA :


The oligopeptides prepared as described in Example 2 were individually
5 dissolved in PSA digestion buffer (12 mM tris(hydroxymethyl)-
aminomethane pH8.0, 25 mM NaCl, 0.5 mM CaCl₂) and the solution
added to PSA at a molar ration of 100 to 1. Alternatively, the PSA
digestion buffer utilized is 50 mM tris(hydroxymethyl)-aminomethane
pH7.4, 140 mM NaCl. The reaction is quenched after various reaction
10 times by the addition of trifluoroacetic acid (TFA) to a final 1%
(volume/volume). Alternatively the reaction is quenched with 10mM
ZnCl₂. The quenched reaction was analyzed by HPLC on a reversed-
phase C18 column using an aqueous 0.1%TFA/acetonitrile gradient. The
results of the assessment are shown in Figure 2. Other oligopeptides
15 prepared as described in Example 2 were tested in the same assay
wherein the reaction was quenched at 4 hours. Those results of the
assessment are shown in Figure 3. The removal of an asparagine residue
from the amino terminus of the oligopeptide results in a significant loss
of PSA mediated peptide hydrolysis, while the presence of a glutamic
20 acid residue at the carboxyl end of the peptide appears not to be essential
to recognition by PSA.

EXAMPLE 4

25 Preparation of Non-cleavable Oligopeptide-Doxorubicin Conjugates:

The derivatives of doxorubicin shown in Table 3 were
prepared using the following general reaction: To a mixture of
doxorubicin (Sigma) and the corresponding peptide (prepared by solid
phase synthesis or commercially available (Sigma)) in DMSO was added
30 HBTU and HOBt along with diisopropylethylamine and the reaction
mixture was stirred overnight. The crude reaction mixture was purified
directly by preparative HPLC on a reversed-phase C-18 column using a
0.1% trifluoroacetic acid (TFA) in acetonitrile/0.1% TFA in water
gradient.

- 56 -

Table 3

5

<u>Compound</u>	<u>R</u>	<u>MS (parent ion)</u>
12a	H-Ala-	615
12b	N-Ac-Ala-	657
12c	N-Ac-Ala-Ala-Ala-	799.5
12d	N-Ac-Ala-Gly-Pro-Thr-Gly-Ala-Ser-Ala-	1199

(SEQ.ID.NO.: 12)

EXAMPLE 5

- 10 *In vitro* Assay of Cytotoxicity of Peptidyl Derivatives of Doxorubicin:
 The cytotoxicities of the non-cleaveable oligopeptide-doxorubicin conjugates, prepared as described in Example 4, against a line of cells which is known to be killed by unmodified doxorubicin were assessed with an Alamar Blue assay. Specifically, cell cultures of LNCaP prostate
- 15 tumor cells, which are a human metastatic prostate adenocarcinoma isolated from a needle biopsy of a lymph node (LNCaP.FGC: American Type Culture Collection, ATCC CRL 1740), or DuPRO cells in 96 well plates were diluted with medium containing various concentrations of a given conjugate (final plate well volume of 200μl). The cells were

- 57 -

incubated for 3 days at 37°C and then 20µl of Alamar Blue was added to the assay well. The cells were further incubated and the assay plates were read on a EL-310 ELISA reader at the dual wavelengths of 570 and 600 nm at 4 and 7 hours after addition of Alamar Blue. Relative
5 percentage viability at the various concentration of conjugate tested was then calculated versus control (no conjugate) cultures. Cytotoxicities of unmodified doxorubicin and unmodified oligopeptide were also assessed. Figure 3 shows the cytotoxicity data for a representative compound (Compound 12d).

10

EXAMPLE 6

Assessment of Enzymatically Active PSA from LNCaP Cells

Enzymatic activity was demonstrated by incubating LNCaP serum free
15 media (concentrated approximately 200 fold) with recombinant Semenogelin I protein. Approximately 0.5 µg of immunologically reactive PSA in concentrated conditioned media [determined by HYBRIDTECH (Tandem E) elisa] was mixed with approximately 3 µg of recombinant Semenogelin I and incubated for 4 hours at 37°C. At the
20 end of the incubation, the digest mixture was analyzed by Western blot procedures. The results show that purified PSA from semen and PSA from LNCaP conditioned media generate identical proteolytic maps of the recombinant Semenogelin I protein. Thus, LNCaP cells produce enzymatically active PSA. LNCaP are tumorigenic in nude mice and
25 produce detectable levels of circulating PSA.


EXAMPLE 7

Preparation of Cleavable Oligopeptide-Doxorubicin Conjugates:

30 The derivatives of doxorubicin wherein an oligopeptide which is proteolytically cleaved by free PSA is covalently attached to the amine of the sugar moiety of the doxorubicin were prepared using the following general reaction: To a mixture of doxorubicin (Sigma) and the corresponding peptide (prepared by solid phase synthesis as described in

- 58 -

Example 2) in DMSO was added HBTU and HOBT along with diisopropylethylamine and the reaction mixture stirred overnight. The crude reaction mixture was purified directly by preparative HPLC on a reversed-phase C-18 column using a 0.1% trifluoroacetic acid (TFA) in acetonitrile/0.1% TFA in water gradient. When reactive amine moieties were present on the peptide, such a functionality was typically protected as the fluorenylmethyloxycarbonyl adduct, which was removed by treatment with a secondary amine, such as piperidine and the like, subsequent to conjugation with doxorubicin. The instant conjugates have a structure of the general formula



and may be represented by the phrase "Ac-peptide-DOX (3')." Conjugates which were prepared by the above general method or by the synthetic route described in Example 8, but utilizing the appropriate starting amino acid residues which are readily available commercially or by synthetic techniques well known in the art, are listed in Tables 5, 5a and 7 in Figures 5, 5A and 7.

EXAMPLE 8

Ac-Lys-Tyr-Gln-Ser-Ser-Ser-Leu-Dox•Acetate

- 59 -

Step A: Ac-Lys(Fmoc)-Gln-Ser(Bzl)-Ser(Bzl)-Ser(Bzl)-Leu-PAM Resin (1).

- Starting with 0.5 mmol (0.67 g) Boc-Leu-PAM resin, the protected peptide was synthesized on a 430A ABI peptide synthesizer. The protocol used a 4 fold excess (2 mmol) of each of the following protected amino acids: Boc-Ser(OBzl), Boc-Gln, Boc-Tyr(BrZ), Boc-Lys(Fmoc). Coupling was achieved using DCC and HOBT activation in methyl-2-pyrrolidinone. Acetic acid was used for the introduction of the N terminal acetyl group. Removal of the Boc group was performed using 50% TFA in methylene chloride and the TFA salt neutralized with diisopropylethylamine. At the completion of the synthesis, the peptide resin was dried to yield 1.3g of (1).

Step B: Ac-Lys(Fmoc)-Tyr-Gln-Ser-Ser-Ser-Leu-OH (2)

- The protected peptide resin (1), 1.3 g, was treated with HF (20 ml) for 2 hrs at 0°C in the presence of anisole (2 ml). After evaporation of the HF, the residue was washed with ether, filtered and extracted with DMF. The DMF filtrate (75 ml) was concentrated to dryness and triturated with H₂O. The insoluble product (2) was filtered and dried (0.46g).

Step C: Ac-Lys(Fmoc)-Tyr-Gln-Ser-Ser-Ser-Leu-Dox (3)

- The above prepared intermediate (2), 0.46g, (0.43 mmol) was dissolved in DMF (15 ml) and doxorubicin hydrochloride, 125 mg (0.215 mmol), added followed by 60 µl of triethylamine (0.430 mmol). The stirred solution was cooled (0°C) and 92 µl of diphenylphosphoryl azide (0.43 mmol) added. After 5 minutes, an additional 92 µl of DPPA was added and the pH adjusted to ~7.5 (pH paper) with TEA. After 1 hour, an additional 92 µl of DPPA was added, pH adjusted to ~7.5, and the reaction stirred at 0°-5°C overnight. After 18 hours, the reaction (found to be complete by analytical HPLC) was concentrated to an oil (3).

Step D: Ac-Lys-Gln-Tyr-Ser-Ser-Ser-Leu-Dox (4).

- 60 -

The above product (3) was dissolved in DMF (20 ml), cooled (0°C) and 10 ml of piperidine added. The solution was concentrated to dryness and purified by preparative HPLC. Buffer A = 15% acetic acid-H₂O; B = 15% acetic acid-methanol. The crude product was dissolved in 300 ml of 10% B/90% A buffer, filtered and purified on a C-18 reverse phase HPLC radial compression column (Waters, Delta-Pak 15µm, 300Å). A step gradient of 10% B to 60% B was used at a flow rate of 75 ml/min (uv = 260 nm). Homogeneous product fractions were pooled, concentrated and freeze-dried from H₂O to yield 125 mg of purified product (4).

EXAMPLE 9

Deacetylvinblastinyl-Leu-Asn-Lys-Ala-Ser-Tyr-Gln-Ser-Ser-Ser-Leu-NH₂•Acetate (5) (SEQ.ID.NO. 184)

Step A: NH₂ - Leu-Asn-Lys(Fmoc)-Ala-Ser-Tyr-Gln-Ser-Ser-Ser-Leu-Amide (6)

Starting with 0.5 mmol of p-methylbenzhydrylamine resin (MBHA), the protected peptide, NH₂-Leu-Asn-Lys(Fmoc)-Ala-Ser(OBzl)-Tyr(BrZ)-Gln-Ser(OBzl)-Ser(OBzl)-Ser(OBzl)-Leu-MBHA, intermediate was synthesized on a 430A ABI peptide synthesizer. The protocol used a 4 fold excess (2 mmol) of each of the following protected amino acids: Boc-Leu, Boc-Asn, Boc-Lys (Fmoc), Boc-Ala, Boc-Ser(OBzl), Boc-Tyr(BrZ), Boc-Gln. Coupling was achieved using DCC and HOBT activation in N-methyl-2-pyrrolidinone (NMP).

Removal of the Boc group was performed using 50% TFA in methylene chloride and the TFA salt neutralized with diisopropylethylamine. The dried protected peptide resin (1.80g) was treated with HF (20 ml) for 2 hrs at 0° C in the presence of anisole (2 ml). After evaporation, the residue was extracted with DMF. The DMF filtrate (75 ml) was concentrated to dryness, dissolved in a 1:1 mixture of acetonitrile-H₂O and freeze-dried to give 750 mg of crude product. A

- 61 -

portion (200 mg) was purified by preparative HPLC on a C-18 reverse phase support (Waters, μ -Bondapak). Buffer A = 15% acetic acid-H₂O; B = 15% acetic acid-methanol. For the purification, the crude product was suspended in 400 ml of 10% B/90% A buffer, filtered and the filtrate
5 loaded onto the column. A step gradient of 10% B to 55% B was used at a flow rate of 75 ml/min. Homogeneous product fractions were pooled, concentrated and freeze-dried from H₂O to yield (6).

Step B: Deacetylvinblastin Monohydrazide (7)

10 1g of vinblastine sulfate was converted to the amine form by extraction in methylene chloride and saturated sodium bicarbonate. The methylene chloride layer was washed with H₂O, dried over anhydrous MgSO₄ and concentrated to dryness. The vinblastine was then dissolved in anhydrous ethanol (20 ml) and anhydrous hydrazine added (20 ml).
15 The solution was heated (60° C) under an N₂ atmosphere for 17 hrs. The reaction was concentrated to an oil, dissolved in methylene chloride, extracted with H₂O and dried over MgSO₄. After evaporation compound (7) was isolated. [Ref: K.S.P. Bhushana Rao *et al.*, J. Med. Chem. (1985), 28:1079.]

20 Step C: Deacetylvinblastine Acid Azide (8).

Deacetylvinblastine monohydrazide (7) (48 mg, 0.0624 mmol) was dissolved in DMF (3 ml), cooled (-15° C) and acidified to ~ 2.5 (pH paper) with HCl/dioxane. Isoamylnitrite (10 μ l) was added
25 followed by an additional 10 μ l after 10 min. HPLC analysis indicated complete conversion of the hydrazide to azide after 5 min. The azide was maintained in solution at -15° C until ready for use.

Step D: Deacetylvinblastinyl-Leu-Asn-Lys-Ala-Ser-Try-Gln-Ser-Ser-Ser-Leu-NH₂•Acetate (5)

30 The oligopeptide product (6) from Step A, 32 mg (0.0225 mmol), was dissolved in DMF (1 ml) and cooled (-15° C). To this solution was added a 1.5 ml DMF solution (0.031 mmol) of desacetylvinblastine acid azide (8). The pH was adjusted to ~ 7.5 (pH

- 62 -

paper) with triethylamine and the reaction stirred at -5° C (2 hr), and 0° C for 18 hr. To the reaction was added H₂O (2 ml) and the solution evaporated to dryness. The intermediate was dissolved in DMF (4 ml), cooled (0° C) and 2 ml of piperidine added. The solution was concentrated to dryness and purified by preparative HPLC as described in Step A. The homogeneous fractions were pooled, concentrated and freeze-dried from H₂O to yield (5).

EXAMPLE 10

10

Deacetylvinblastinyl-Leu-Asn-Lys-Ala-Ser-Try-Gln-Ser-Ser-Ser-Leu--Dox •Acetate (10).

15- Step A: Deacetylvinblastinyl-Leu-Asn-Lys(Fmoc)-Ala-Ser-Try-Gln-Ser-Ser-Ser-Leu-Dox •Acetate (9)

The oligopeptide product (6) prepared as described in Example 9, Step A, (166 mg, 0.125 mmol), was dissolved in DMSO (3 ml) and cooled to -15° C. To this solution was added a DMF solution (0.125 mmol) of desacetylvinblastine acid azide (8) prepared as described in Example 9, Step C. The pH was adjusted to ~ 7.5 (pH paper) with triethylamine and the reaction stirred at -15° C for 90 mins.

25 After stirring 18 hours at 0-5° C, the reaction was concentrated to dryness and the crude residue was dissolved in DMF (10 ml) and filtered. Doxorubicin hydrochloride, 62 mg (0.106 mmol), was added to the filtrate followed by 30 µl of triethylamine. The stirred solution was cooled (0° C) and 27 µl of diphenylphosphoryl azide (DPPA, 0.134 mmol) added. After 5 minutes, an additional 27 µl of DPPA was added and the pH adjusted to ~7.5 (pH paper) with TEA. After 1 hour, 30 an additional 27 µl of DPPA was added, pH adjusted to ~7.5, and the reaction stirred at 0°-5° C overnight. After 18 hours, the reaction (found to be complete by analytical HPLC) was concentrated to an oil (9).

35 Step B: Deacetylvinblastinyl-Leu-Asn-Lys-Ala-Ser-Try-Gln-Ser-Ser-Ser-Leu--Dox •Acetate (10).

- 63 -

- The above intermediate product (9) was dissolved in DMF (20 ml), cooled (0°C) and 10 ml of piperidine added. The solution was concentrated to dryness and purified by preparative HPLC. Buffer A = 15% acetic acid-H₂O; B = 15% acetic acid-methanol. The crude product
- 5 was dissolved in 300 ml of 10% B/90% A buffer, filtered and purified on a C-18 reverse phase HPLC radial compression column (Waters, μ -Bondapak). A step gradient of 10% B to 60% B was used at a flow rate of 75 ml/min (uv = 260 nm). Semi-pure product was further purified on C-18 (Waters, Prep Pak) using Buffer A = 0.13M pH 3.0
- 10 triethylammonium phosphate and Buffer B = acetonitrile. A step gradient of 10% B to 40% B was used at a flow rate of 75 ml/min. (uv = 214 nm). Pure product fractions were pooled, diluted with H₂O and desalted by applying the product onto the same column and eluting the product as the acetate salt with 90% acetonitrile/10% H₂O (1% acetic acid).
- 15 The product fractions were concentrated and freeze dried from H₂O to yield the purified product (10).

EXAMPLE 11

- 20 Ac-Lys-Tyr-Gln-Ser-Ser-Ser-Nle-NH-(CH₂)₃ NH-deacetylvinblastine amide (14)

Step A: Deacetylvinblastine-3-aminopropyl amide (11)

- To a cooled (-15° C) a DMF solution (3 ml, 0.0624 mmol) of
- 25 deacetylvinblastine acid azide (synthesis described in Example 9, Step C) was added 120 μ l of 1,3-diaminopropane in DMF (2 ml). The reaction was stirred at - 10° C for 1 hr, filtered and concentrated to dryness to yield (11).

- 30 Step B: Deacetylvinblastine-3-aminopropylamide-norleucine amide (12)

To a DMF solution (1 ml) of Boc-Nle (22 mg, 0.095 mmol) was added 318 μ l of a 1M solution of HOBt (in NMP) followed by 280 μ l of a 1M solution of DCC (in NMP). After 30 min., intermediate (11)

- 64 -

(0.0624 mmol) was added in a 3.5 ml DMF. The pH of the reaction was adjusted ~ 7.5 with diisopropylethylamine. After stirring for 18 hrs the reaction was concentrated to an oil and the Boc protecting group removed by treating the oil with a 1:1 solution of TFA: CH₂Cl₂ (20 ml). After 5 min. the reaction was concentrated to dryness. Purification was achieved by preparative HPLC on a C-18 reverse phase support (Waters, Delta Pak). Buffer A = 0.1% TFA-H₂O; B= 0.1% TFA-CH₃CN. The crude product was loaded in 100% A buffer (100 ml) and a step gradient of 100% A to 30% A was used at a flow rate of 75 ml/min. Homogeneous product fractions were pooled and freeze-dried to yield (12).

Step C: Ac-Lys(Fmoc)-Tyr-Gln-Ser-Ser-Ser-Nle-OH (13)

The above intermediate was prepared as described in Example 9, Step A for the preparation of Ac-Lys(Fmoc)-Tyr-Gln-Ser-Ser-Ser-Leu-OH.

Step D: Ac-Lys-Tyr-Gln-Ser-Ser-Ser-Nle-NH-(CH₂)₃ NH-deacetylvinblastine amide (14)

The oligopeptide product (13), (70 mg, 0.065 mmol) in DMF (1 ml) was combined with (41 mg, 0.05 mmol) of (12) in DMF (4 ml). The solution was cooled (0° C) and 17 µl of diphenylphosphoryl azide (0.08 mmol) added. After 5 min. an additional 17 µl of DPPA was added and the pH adjusted to ~ 7.5 (pH paper) with triethylamine. After 2 hr. additional (13), 35 mg, was added in DMF (0.5 ml) and 17 µl of DPPA. The pH was maintained at ~ 7.5 with TEA and after 3 hr. an additional 35 mg of (13) was added in DMF (0.5 ml). The reaction was stirred at 0-5° C. After 18 hrs, the reaction was concentrated to dryness, redissolved in DMF (9 ml), cooled (0° C) and 3 ml of piperidine added. The solution was concentrated to dryness and purified by preparative HPLC. Buffer A = 0.1% TFA-H₂O; B= 0.1% TFA-CH₃ CN. The crude product was dissolved in 30% acetic acid - H₂O (100 ml) and purified on a C-18 reverse phase HPLC radial compression column (Waters, Delta Pak). A step gradient of 100% A to 70% A was used at a flow rate of 75 ml/min. Semi-pure product fractions were pooled and freeze-dried. Purification

- 65 -

to homogeneity was achieved by repurification on a C-4 support (Waters, Delta Pak) as described above. Product fractions were pooled and freeze dried to yield pure (14).

5

EXAMPLE 12

Assessment of the Recognition of Oligopeptide-Doxorubicin Conjugates by Free PSA :

The conjugates prepared as described in Examples 7-9 were individually
10 dissolved in PSA digestion buffer (12 mM tris(hydroxymethyl)-aminomethane pH8.0, 25 mM NaCl, 0.5 mM CaCl₂) and the solution added to PSA at a molar ration of 100 to 1. Alternatively, the PSA digestion buffer utilized is 50 mM tris(hydroxymethyl)-aminomethane pH7.4, 140 mM NaCl. The reaction is quenched after various reaction
15 times by the addition of trifluoroacetic acid (TFA) to a final 1% (volume/volume). Alternatively the reaction is quenched with 10mM ZnCl₂. The quenched reaction was analyzed by HPLC on a reversed-phase C18 column using an aqueous 0.1%TFA/acetonitrile gradient. The results of the assessment are shown in Tables 5 and 5a of Figure 5.

20

EXAMPLE 13

Assessment of the Cleavage of Oligopeptide-Doxorubicin Conjugates in Cell Conditioned Media :

25 Cell conditioned serum-free α -MEM media (phenol red minus) was collected 3 days after the addition of the media to either LNCaP or DuPRO (prepared as described in *J. Urology*, 146:915-919 (1991)) cell lines. The media was concentrated 20 fold using an Amicon® Centriprep™ concentrator with a 10,000 molecular weight cutoff. The
30 LNCaP conditioned media contained free PSA protein at, on average, approximately 100 ng/mL concentration as determined by the Tandem®-E PSA immunodetection kit (Hybritech®). There was no detectable free PSA in the DuPRO cell conditioned media.

- 66 -

100 μ L portions of concentrated conditioned media was mixed with 35 μ g of a oligopeptide-doxorubicin conjugate prepared as described in Example 7 and the mixture was incubated at 37°C for 0, 4 and 24 hour time points. The reactions were stopped by the addition of ZnCl₂ (to a
5 0.01M final concentration) and analyzed by HPLC on a reversed-phase C18 column using an aqueous 0.1%TFA/acetonitrile gradient to determine the percentage of peptide-cytotoxic agent conjugate that had been digested. The results of the assessment are shown in Table 6 of Figure 6.

10

EXAMPLE 14

In vitro Assay of Cytotoxicity of Peptidyl Derivatives of Doxorubicin:
The cytotoxicities of the cleaveable oligopeptide-doxorubicin conjugates,
15 prepared as described in Example 7, against a line of cells which is known to be killed by unmodified doxorubicin was assessed with an Alamar Blue assay as described in Example 5. Specifically, cell cultures of LNCaP prostate tumor cells or DuPRO cells in 96 well plates was diluted with medium containing various concentrations of a given
20 conjugate (final plate well volume of 200 μ l). The cells were incubated for 3 days at 37°C, 20 μ l of Alamar Blue is added to the assay well. The cells were further incubated and the assay plates were read on a EL-310 ELISA reader at the dual wavelengths of 570 and 600 nm at 4 and 7 hours after addition of Alamar Blue. Relative percentage viability at the
25 various concentration of conjugate tested was then calculated versus control (no conjugate) cultures. Cytotoxicities of the conjugates were also compared to the cytotoxicity of unmodified doxorubicin and unmodified oligopeptide assessed in the same assay. Results of this assay are shown in Table 7 of Figure 7.

30

- 67 -

EXAMPLE 15*In vivo Efficacy of Peptidyl -Cytotoxic Agent Conjugates*

5 LNCaP.FGC or DuPRO-1 cells are trypsinized, resuspended in the growth medium and centrifuged for 6 mins. at 200xg. The cells are resuspended in serum-free α -MEM and counted. The appropriate volume of this solution containing the desired number of cells is then transferred to a conical centrifuge tube, centrifuged as before and resuspended in the appropriate volume of a cold 1:1 mixture of α -MEM-
10 Matrigel. The suspension is kept on ice until the animals are inoculated.

Male nude mice (10-12 weeks old) are restrained without anesthesia and are inoculated with 0.5 mL of cell suspension on the left flank by subcutaneous injection using a 22G needle. Mice are either given
15 approximately 5×10^5 DuPRO cells or 1.5×10^7 LNCaP.FGC cells.

Following inoculation with the tumor cells the mice are treated under one of two protocols:

Protocol A:

20 One day after cell inoculation the animals are dosed with a 0.1-0.5 mL volume of test conjugate, doxorubicin or vehicle control (sterile water). Dosages of the conjugate and doxorubicin are initially the maximum non-lethal amount, but may be subsequently titrated lower. Identical doses are administered at 24 hour intervals for 5 days. After 10 days, blood
25 samples are removed from the mice and the serum level of PSA is determined. Similar serum PSA levels are determined at 5-10 day intervals. At the end of 5.5 weeks the mice are sacrificed and weights of any tumors present are measured and serum PSA again determined. The
30 animals' weights are determined at the beginning and end of the assay.

Protocol B:

Ten days after cell inoculation, blood samples are removed from the animals and serum levels of PSA are determined. Animals are then grouped according to their PSA serum levels. At 14-15 days after cell

- 68 -

5 inoculation, the animals are dosed with a 0.1-0.5 mL volume of test conjugate, doxorubicin or vehicle control (sterile water). Dosages of the conjugate and doxorubicin are initially the maximum non-lethal amount, but may be subsequently titrated lower. Identical doses are administered at 24 hour intervals for 5 days. Serum PSA levels are determined at 5-10 day intervals. At the end of 5.5 weeks the mice are sacrificed, weights of any tumors present are measured and serum PSA again determined. The animals' weights are determined at the beginning and end of the assay.

- 69 -

SEQUENCE LISTING

(1) GENERAL INFORMATION:

- (i) APPLICANT: DeFeo-Jones, Deborah
Garsky, Victor M.
Jones, Raymond E.
Oliff, Allen I.
Scolnick, Edward M.
- (ii) TITLE OF INVENTION: CONJUGATES USEFUL IN THE TREATMENT OF BENIGN PROSTATIC HYPERPLASIA
- (iii) NUMBER OF SEQUENCES: 194
- (iv) CORRESPONDENCE ADDRESS:
 - (A) ADDRESSEE: DAVID A. MUTHARD
 - (B) STREET: 126 E. Lincoln Avenue, P.O. BOX 2000
 - (C) CITY: RAHWAY
 - (D) STATE: NEW JERSEY
 - (E) COUNTRY: U.S.A.
 - (F) ZIP: 07065
- (v) COMPUTER READABLE FORM:
 - (A) MEDIUM TYPE: Floppy disk
 - (B) COMPUTER: IBM PC compatible
 - (C) OPERATING SYSTEM: PC-DOS/MS-DOS
 - (D) SOFTWARE: PatentIn Release #1.0, Version #1.30
- (vi) CURRENT APPLICATION DATA:
 - (A) APPLICATION NUMBER:
 - (B) FILING DATE:
 - (C) CLASSIFICATION:
- (viii) ATTORNEY/AGENT INFORMATION:
 - (A) NAME: Muthard, David A.
 - (B) REGISTRATION NUMBER: 35,297
 - (C) REFERENCE/DOCKET NUMBER: 19560
- (ix) TELECOMMUNICATION INFORMATION:
 - (A) TELEPHONE: (908)594-3903
 - (B) TELEFAX: (908)594-4720

(2) INFORMATION FOR SEQ ID NO:1:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 462 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: peptide
- (iii) HYPOTHETICAL: NO

- 70 -

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

Met	Lys	Pro	Asn	Ile	Ile	Phe	Val	Leu	Ser	Leu	Leu	Leu	Ile	Leu	Glu	1	5	10	15
Lys	Gln	Ala	Ala	Val	Met	Gly	Gln	Lys	Gly	Gly	Ser	Lys	Gly	Arg	Leu	20	25	30	
Pro	Ser	Glu	Phe	Ser	Gln	Phe	Pro	His	Gly	Gln	Lys	Gly	Gln	His	Tyr	35	40	45	
Ser	Gly	Gln	Lys	Gly	Lys	Gln	Gln	Thr	Glu	Ser	Lys	Gly	Ser	Phe	Ser	50	55	60	
Ile	Gln	Tyr	Thr	Tyr	His	Val	Asp	Ala	Asn	Asp	His	Asp	Gln	Ser	Arg	65	70	75	80
Lys	Ser	Gln	Gln	Tyr	Asp	Leu	Asn	Ala	Leu	His	Lys	Thr	Thr	Lys	Ser	85	90	95	
Gln	Arg	His	Leu	Gly	Gly	Ser	Gln	Gln	Leu	Leu	His	Asn	Lys	Gln	Glu	100	105	110	
Gly	Arg	Asp	His	Asp	Lys	Ser	Lys	Gly	His	Phe	His	Arg	Val	Val	Ile	115	120	125	
His	His	Lys	Gly	Gly	Lys	Ala	His	Arg	Gly	Thr	Gln	Asn	Pro	Ser	Gln	130	135	140	
Asp	Gln	Gly	Asn	Ser	Pro	Ser	Gly	Lys	Gly	Ile	Ser	Ser	Gln	Tyr	Ser	145	150	155	160
Asn	Thr	Glu	Glu	Arg	Leu	Trp	Val	His	Gly	Leu	Ser	Lys	Glu	Gln	Thr	165	170	175	
Ser	Val	Ser	Gly	Ala	Gln	Lys	Gly	Arg	Lys	Gln	Gly	Gly	Ser	Gln	Ser	180	185	190	
Ser	Tyr	Val	Leu	Gln	Thr	Glu	Glu	Leu	Val	Ala	Asn	Lys	Gln	Gln	Arg	195	200	205	
Glu	Thr	Lys	Asn	Ser	His	Gln	Asn	Lys	Gly	His	Tyr	Gln	Asn	Val	Val	210	215	220	
Glu	Val	Arg	Glu	Glu	His	Ser	Ser	Lys	Val	Gln	Thr	Ser	Leu	Cys	Pro	225	230	235	240
Ala	His	Gln	Asp	Lys	Leu	Gln	His	Gly	Ser	Lys	Asp	Ile	Phe	Ser	Thr	245	250	255	

- 71 -

Gln Asp Glu Leu Leu Val Tyr Asn Lys Asn Gln His Gln Thr Lys Asn
 260 265 270
 Leu Asn Gln Asp Gln Gln His Gly Arg Lys Ala Asn Lys Ile Ser Tyr
 275 280 285
 Gln Ser Ser Ser Thr Glu Glu Arg Arg Leu His Tyr Gly Glu Asn Gly
 290 295 300
 Val Gln Lys Asp Val Ser Gln Ser Ser Ile Tyr Ser Gln Thr Glu Glu
 305 310 315 320
 Lys Ala Gln Gly Lys Ser Gln Lys Gln Ile Thr Ile Pro Ser Gln Glu
 325 330 335
 Gln Glu His Ser Gln Lys Ala Asn Lys Ile Ser Tyr Gln Ser Ser Ser
 340 345 350
 Thr Glu Glu Arg Arg Leu His Tyr Gly Glu Asn Gly Val Gln Lys Asp
 355 360 365
 Val Ser Gln Arg Ser Ile Tyr Ser Gln Thr Glu Lys Leu Val Ala Gly
 370 375 380
 Lys Ser Gln Ile Gln Ala Pro Asn Pro Lys Gln Glu Pro Trp His Gly
 385 390 395 400
 Glu Asn Ala Lys Gly Glu Ser Gly Gln Ser Thr Asn Arg Glu Gln Asp
 405 410 415
 Leu Leu Ser His Glu Gln Lys Gly Arg His Gln His Gly Ser His Gly
 420 425 430
 Gly Leu Asp Ile Val Ile Ile Glu Gln Glu Asp Asp Ser Asp Arg His
 435 440 445
 Leu Ala Gln His Leu Asn Asn Asp Arg Asn Pro Leu Phe Thr
 450 455 460

(2) INFORMATION FOR SEQ ID NO:2:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 15 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: peptide
- (iii) HYPOTHETICAL: NO
- (iv) ANTI-SENSE: NO
- (v) FRAGMENT TYPE: internal

- 72 -

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

Gly	Lys	Gly	Ile	Ser	Ser	Gln	Tyr	Ser	Asn	Thr	Glu	Glu	Arg	Leu
1				5					10					15

(2) INFORMATION FOR SEQ ID NO:3:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 11 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:

Asn	Lys	Ile	Ser	Tyr	Gln	Ser	Ser	Ser	Thr	Glu
1				5					10	

(2) INFORMATION FOR SEQ ID NO:4:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 19 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:

Gly	Glu	Asn	Gly	Val	Gln	Lys	Asp	Val	Ser	Gln	Arg	Ser	Ile	Tyr	Ser
1				5					10					15	

Gln Thr Glu

- 73 -

(2) INFORMATION FOR SEQ ID NO:5:

- (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 19 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:

Gly Glu Asn Gly Val Gln Lys Asp Val Ser Gln Ser Ser Ile Tyr Ser
1 5 10 15

Gln Thr Glu

(2) INFORMATION FOR SEQ ID NO:6:

- (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 25 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:6:

Gly Arg Lys Ala Asn Lys Ile Ser Tyr Gln Ser Ser Ser Thr Glu Glu
1 5 10 15

Arg Arg Leu His Tyr Gly Glu Asn Gly
20 25

(2) INFORMATION FOR SEQ ID NO:7:

- 74 -

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 8 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
 - (ii) MOLECULE TYPE: peptide
 - (iii) HYPOTHETICAL: NO
 - (iv) ANTI-SENSE: NO
 - (v) FRAGMENT TYPE: internal
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:7:
- | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|
| Ser | Tyr | Gln | Ser | Ser | Ser | Thr | Glu |
| 1 | | | | 5 | | | |
- (2) INFORMATION FOR SEQ ID NO:8:
- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 9 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
 - (ii) MOLECULE TYPE: peptide
 - (iii) HYPOTHETICAL: NO
 - (iv) ANTI-SENSE: NO
 - (v) FRAGMENT TYPE: internal
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:8:
- | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Ile | Ser | Tyr | Gln | Ser | Ser | Ser | Thr | Glu |
| 1 | | | | 5 | | | | |
- (2) INFORMATION FOR SEQ ID NO:9:
- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 10 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
 - (ii) MOLECULE TYPE: peptide

- 75 -

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:9:

Lys	Ile	Ser	Tyr	Gln	Ser	Ser	Ser	Thr	Glu
1				5					10

(2) INFORMATION FOR SEQ ID NO:10:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 10 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:10:

Asn	Lys	Ile	Ser	Tyr	Gln	Ser	Ser	Ser	Thr
1				5					10

(2) INFORMATION FOR SEQ ID NO:11:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 12 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(v) FRAGMENT TYPE: internal

- 76 -

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:11:

Ala	Asn	Lys	Ile	Ser	Tyr	Gln	Ser	Ser	Ser	Thr	Glu
1				5					10		

(2) INFORMATION FOR SEQ ID NO:12:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 8 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:12:

Ala	Gly	Pro	Thr	Gly	Ala	Ser	Ala
1				5			

(2) INFORMATION FOR SEQ ID NO:13:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 7 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:13:

Asn	Lys	Ile	Ser	Tyr	Gln	Ser
1				5		

(2) INFORMATION FOR SEQ ID NO:14:

- 77 -

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 6 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

- (ii) MOLECULE TYPE: peptide

- (iii) HYPOTHETICAL: NO

- (iv) ANTI-SENSE: NO

- (v) FRAGMENT TYPE: internal

- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:14:

Lys Ile Ser Tyr Gln Ser
1 5

- (2) INFORMATION FOR SEQ ID NO:15:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 19 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

- (ii) MOLECULE TYPE: peptide

- (iii) HYPOTHETICAL: NO

- (iv) ANTI-SENSE: NO

- (v) FRAGMENT TYPE: internal

- (ix) FEATURE:

- (A) NAME/KEY: Peptide
- (B) LOCATION: 12
- (D) OTHER INFORMATION: /note= "any natural amino acid"

- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:15:

Gly Glu Asn Gly Val Gln Lys Asp Val Ser Gln Xaa Ser Ile Tyr Ser
1 5 10 15

Gln Thr Glu

- (2) INFORMATION FOR SEQ ID NO:16:

- (i) SEQUENCE CHARACTERISTICS:

- 78 -

- (A) LENGTH: 8 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:16:

Asn Lys Ile Ser Tyr Gln Ser Ser
1 5

(2) INFORMATION FOR SEQ ID NO:17:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 9 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:17:

Asn Lys Ile Ser Tyr Gln Ser Ser Ser
1 5

(2) INFORMATION FOR SEQ ID NO:18:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 10 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

- 79 -

(iv) ANTI-SENSE: NO

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:18:

Ala Asn Lys Ile Ser Tyr Gln Ser Ser Ser
1 5 10

(2) INFORMATION FOR SEQ ID NO:19:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 10 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:19:

Lys Ile Ser Tyr Gln Ser Ser Ser Thr Glu
1 5 10

(2) INFORMATION FOR SEQ ID NO:20:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 17 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(v) FRAGMENT TYPE: internal

- 80 -

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:20:

Gln	Leu	Asp	Asn	Lys	Ile	Ser	Tyr	Gln	Ser	Ser	Thr	His	Gln	Ser
1				5				10					15	

Ser

(2) INFORMATION FOR SEQ ID NO:21:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 7 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:21:

Asn	Arg	Ile	Ser	Tyr	Gln	Ser
1				5		

(2) INFORMATION FOR SEQ ID NO:22:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 7 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:22:

Asn	Lys	Val	Ser	Tyr	Gln	Ser
1				5		

- 81 -

(2) INFORMATION FOR SEQ ID NO:23:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 8 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:23:

Asn Lys Met Ser Tyr Gln Ser Ser
1 5

(2) INFORMATION FOR SEQ ID NO:24:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 8 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:24:

Asn Lys Leu Ser Tyr Gln Ser Ser
1 5

(2) INFORMATION FOR SEQ ID NO:25:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 9 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

- 82 -

- (ii) MOLECULE TYPE: peptide
- (iii) HYPOTHETICAL: NO
- (iv) ANTI-SENSE: NO
- (v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:25:

Asn Lys Ile Thr Tyr Gln Ser Ser Ser
1 5

(2) INFORMATION FOR SEQ ID NO:26:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 9 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: peptide
- (iii) HYPOTHETICAL: NO
- (iv) ANTI-SENSE: NO
- (v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:26:

Asn Lys Ile Ser Phe Gln Ser Ser Ser
1 5

(2) INFORMATION FOR SEQ ID NO:27:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 10 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: peptide
- (iii) HYPOTHETICAL: NO
- (iv) ANTI-SENSE: NO
- (v) FRAGMENT TYPE: internal

- 83 -

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:27:

Asn	Lys	Ile	Ser	Trp	Gln	Ser	Ser	Ser	Thr
1				5					10

(2) INFORMATION FOR SEQ ID NO:28:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 10 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:28:

Asn	Lys	Ile	Ser	Tyr	Asn	Ser	Ser	Ser	Thr
1				5					10

(2) INFORMATION FOR SEQ ID NO:29:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 10 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:29:

Asn	Lys	Ile	Ser	Tyr	Gln	Thr	Ser	Ser	Thr
1				5					10

(2) INFORMATION FOR SEQ ID NO:30:

- (i) SEQUENCE CHARACTERISTICS:

- 84 -

- (A) LENGTH: 7 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:30:

Asn Lys Ile Ser Tyr Gln Ser
1 5

(2) INFORMATION FOR SEQ ID NO:31:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 8 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:31:

Gln Lys Ile Ser Tyr Gln Ser Ser
1 5

(2) INFORMATION FOR SEQ ID NO:32:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 9 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

- 85 -

(iv) ANTI-SENSE: NO

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:32:

Asn Arg Ile Thr Tyr Gln Ser Ser Ser
1 5

(2) INFORMATION FOR SEQ ID NO:33:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 10 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:33:

Asn Arg Ile Ser Phe Gln Ser Ser Ser Thr
1 5 10

(2) INFORMATION FOR SEQ ID NO:34:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 10 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(v) FRAGMENT TYPE: internal

- 86 -

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:34:

Gln	Lys	Ile	Ser	Tyr	Gln	Thr	Ser	Ser	Thr
1			5						10

(2) INFORMATION FOR SEQ ID NO:35:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 10 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:35:

Asn	Arg	Ile	Ser	Trp	Gln	Ser	Ser	Ser	Thr
1			5						10

(2) INFORMATION FOR SEQ ID NO:36:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 10 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:36:

Asn	Arg	Ile	Ser	Tyr	Gln	Thr	Ser	Ser	Thr
1			5						10

(2) INFORMATION FOR SEQ ID NO:37:

- (i) SEQUENCE CHARACTERISTICS:

- 87 -

- (A) LENGTH: 10 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:37:

Asn	Lys	Ile	Thr	Tyr	Gln	Thr	Ser	Ser	Thr
1				5					10

(2) INFORMATION FOR SEQ ID NO:38:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 10 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:38:

Asn	Lys	Leu	Ser	Tyr	Gln	Thr	Ser	Ser	Thr
1				5					10

(2) INFORMATION FOR SEQ ID NO:39:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 10 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

- 88 -

(iv) ANTI-SENSE: NO

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:39:

Gln	Lys	Leu	Ser	Tyr	Gln	Ser	Ser	Ser	Thr
1				5					10

(2) INFORMATION FOR SEQ ID NO:40:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 10 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:40:

Asn	Arg	Leu	Ser	Tyr	Gln	Thr	Ser	Ser	Thr
1				5					10

(2) INFORMATION FOR SEQ ID NO:41:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 10 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(v) FRAGMENT TYPE: internal

- 89 -

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:41:

Asn	Lys	Val	Ser	Phe	Gln	Ser	Ser	Ser	Thr
1				5					10

(2) INFORMATION FOR SEQ ID NO:42:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 10 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:42:

Asn	Arg	Val	Ser	Trp	Gln	Ser	Ser	Ser	Thr
1				5					10

(2) INFORMATION FOR SEQ ID NO:43:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 10 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:43:

Gln	Lys	Val	Ser	Tyr	Gln	Ser	Ser	Ser	Thr
1				5					10

(2) INFORMATION FOR SEQ ID NO:44:

- (i) SEQUENCE CHARACTERISTICS:

- 90 -

- (A) LENGTH: 10 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:44:

Asn	Lys	Ile	Ser	Tyr	Gln	Ser	Ser	Ser	Thr
1					5				10

(2) INFORMATION FOR SEQ ID NO:45:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 19 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:45:

Gly	Glu	Gln	Gly	Val	Gln	Lys	Asp	Val	Ser	Gln	Ser	Ser	Ile	Tyr	Ser
1				5					10					15	

Gln Thr Glu

(2) INFORMATION FOR SEQ ID NO:46:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 15 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

- 91 -

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:46:

Gly	Lys	Gly	Ile	Ser	Ser	Gln	Tyr	Ser	Asn	Thr	Asp	Glu	Arg	Leu
1				5					10					15

(2) INFORMATION FOR SEQ ID NO:47:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 19 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:47:

Gly	Glu	Asn	Gly	Leu	Gln	Lys	Asp	Val	Ser	Gln	Ser	Ser	Ile	Tyr	Ser
1				5					10					15	

Gln Thr Glu

(2) INFORMATION FOR SEQ ID NO:48:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 19 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

- 92 -

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:48:

Gly	Glu	Asn	Gly	Val	Asn	Lys	Asp	Val	Ser	Gln	Ser	Ser	Ile	Tyr	Ser
1				5					10					15	

Gln Thr Glu

(2) INFORMATION FOR SEQ ID NO:49:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 19 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:49:

Gly	Glu	Asn	Gly	Val	Gln	Arg	Asp	Val	Ser	Gln	Arg	Ser	Ile	Tyr	Ser
1				5					10					15	

Gln Thr Glu

(2) INFORMATION FOR SEQ ID NO:50:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 19 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(v) FRAGMENT TYPE: internal

- 93 -

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:50:

Gly Glu Asn Gly Val Gln Lys Asp Val Ser Gln Lys Ser Ile Tyr Ser
1 5 10 15

Gln Thr Glu

(2) INFORMATION FOR SEQ ID NO:51:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 19 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:51:

Gly Glu Asn Gly Val Gln Lys Asp Leu Ser Gln Thr Ser Ile Tyr Ser
1 5 10 15

Gln Thr Glu

(2) INFORMATION FOR SEQ ID NO:52:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 19 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(v) FRAGMENT TYPE: internal

- 94 -

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:52:

Gly	Glu	Asn	Gly	Val	Gln	Lys	Asp	Val	Ser	Gln	Ser	Ser	Ile	Phe	Ser
1				5					10					15	

Gln Thr Glu

(2) INFORMATION FOR SEQ ID NO:53:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 19 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:53:

Gly	Glu	Asn	Gly	Val	Gln	Lys	Asp	Met	Ser	Gln	Ser	Ser	Ile	Tyr	Thr
1				5					10					15	

Gln Thr Glu

(2) INFORMATION FOR SEQ ID NO:54:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 19 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:54:

Gly	Glu	Asn	Gly	Val	Gln	Lys	Asp	Val	Ser	Gln	Arg	Ser	Ile	Tyr	Thr
1				5					10					15	

Gln Thr Glu

- 95 -

(2) INFORMATION FOR SEQ ID NO:55:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 19 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

- (ii) MOLECULE TYPE: peptide

- (iii) HYPOTHETICAL: NO

- (iv) ANTI-SENSE: NO

- (v) FRAGMENT TYPE: internal

- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:55:

Gly Glu Asn Gly Val Gln Lys Asp Val Ser Gln Ser Ser Ile Tyr Ser
1 5 10 15

Gln Ser Glu

(2) INFORMATION FOR SEQ ID NO:56:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 19 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

- (ii) MOLECULE TYPE: peptide

- (iii) HYPOTHETICAL: NO

- (iv) ANTI-SENSE: NO

- (v) FRAGMENT TYPE: internal

- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:56:

Gly Glu Asn Gly Val Gln Lys Asp Val Ser Gln Arg Ser Ile Tyr Ser
1 5 10 15

Asn Thr Glu

(2) INFORMATION FOR SEQ ID NO:57:

- 96 -

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 15 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: peptide
- (iii) HYPOTHETICAL: NO
- (iv) ANTI-SENSE: NO
- (v) FRAGMENT TYPE: internal
-
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:57:
- | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Gly | Lys | Ala | Ile | Ser | Ser | Gln | Tyr | Ser | Asn | Thr | Glu | Glu | Arg | Leu |
| 1 | | | | 5 | | | | | 10 | | | | | 15 |
- (2) INFORMATION FOR SEQ ID NO:58:
- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 15 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: peptide
- (iii) HYPOTHETICAL: NO
- (iv) ANTI-SENSE: NO
- (v) FRAGMENT TYPE: internal
-
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:58:
- | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Gly | Lys | Gly | Ile | Ser | Ser | Gln | Tyr | Ser | Asn | Ser | Glu | Glu | Arg | Leu |
| 1 | | | | 5 | | | | | 10 | | | | | 15 |
- (2) INFORMATION FOR SEQ ID NO:59:
- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 15 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: peptide

- 97 -

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:59:

Gly	Arg	Gly	Ile	Ser	Ser	Gln	Tyr	Ser	Asn	Thr	Glu	Glu	Arg	Leu
1				5					10					15

(2) INFORMATION FOR SEQ ID NO:60:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 15 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:60:

Gly	Lys	Gly	Ile	Thr	Ser	Gln	Tyr	Ser	Asn	Thr	Glu	Glu	Arg	Leu
1				5					10					15

(2) INFORMATION FOR SEQ ID NO:61:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 15 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:61:

Gly Lys Gly Ile Ser Thr Gln Tyr Ser Asn Thr Glu Glu Arg Leu
1 5 10 15

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 15 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(iii) HYPOTHETICAL: NO

(v) FRAGMENT TYPE: internal

Gly Lys Gly Ile Ser Ser Asn Tyr Ser Asn Thr Glu Glu Arg Leu
1 5 10 15

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 15 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(iii) HYPOTHETICAL: NO

(v) FRAGMENT TYPE: internal

Ala Lys Gly Ile Ser Ser Gln Tyr Ser Asn Thr Glu Glu Arg Leu
1 5 10 15

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 15 amino acids

- 99 -

- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:64:

Gly	Lys	Gly	Ile	Ser	Ser	Gln	Phe	Ser	Asn	Thr	Glu	Glu	Arg	Leu
1				5					10					15

(2) INFORMATION FOR SEQ ID NO:65:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 15 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:65:

Gly	Lys	Gly	Ile	Ser	Ser	Gln	Tyr	Thr	Asn	Ser	Glu	Glu	Arg	Leu
1				5					10					15

(2) INFORMATION FOR SEQ ID NO:66:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 15 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

- 100 -

(iv) ANTI-SENSE: NO

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:66:

Gly	Lys	Gly	Ile	Ser	Ser	Gln	Tyr	Ser	Asn	Ser	Glu	Glu	Arg	Leu
1				5					10					15

(2) INFORMATION FOR SEQ ID NO:67:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 25 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:67:

Ser	Gln	Lys	Ala	Asn	Lys	Ile	Ser	Tyr	Gln	Ser	Ser	Ser	Thr	Glu	Glu
1				5					10					15	

Arg	Arg	Leu	His	Tyr	Gly	Glu	Asn	Gly
			20					25

(2) INFORMATION FOR SEQ ID NO:68:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 8 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(v) FRAGMENT TYPE: internal

- 101 -

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:68:

Ile Ser Tyr Gln Ser Ser Ser Thr
1 5

(2) INFORMATION FOR SEQ ID NO:69:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 9 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:69:

Ala Asn Lys Ile Ser Tyr Gln Ser Ser
1 5

(2) INFORMATION FOR SEQ ID NO:70:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 12 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:70:

Ala Asn Lys Ile Ser Tyr Gln Ser Ser Ser Thr Leu
1 5 10

(2) INFORMATION FOR SEQ ID NO:71:

- 102 -

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 12 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

- (ii) MOLECULE TYPE: peptide

- (iii) HYPOTHETICAL: NO

- (iv) ANTI-SENSE: NO

- (v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:71:

Ala	Asn	Gly	Ile	Ser	Tyr	Gln	Ser	Ser	Ser	Thr	Glu
1				5					10		

(2)- INFORMATION FOR SEQ ID NO:72:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 12 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

- (ii) MOLECULE TYPE: peptide

- (iii) HYPOTHETICAL: NO

- (iv) ANTI-SENSE: NO

- (v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:72:

Ala	Asn	Pro	Ile	Ser	Tyr	Gln	Ser	Ser	Ser	Thr	Glu
1				5					10		

(2) INFORMATION FOR SEQ ID NO:73:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 12 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

- (ii) MOLECULE TYPE: peptide

- 103 -

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:73:

Ala	Asn	Lys	Ile	Ser	Tyr	Gln	Ser	Ala	Ser	Thr	Glu
1				5						10	

(2) INFORMATION FOR SEQ ID NO:74:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 12 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:74:

Ala	Asn	Lys	Ile	Ser	Tyr	Gln	Ser	Ser	Lys	Thr	Glu
1				5					10		

(2) INFORMATION FOR SEQ ID NO:75:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 11 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(v) FRAGMENT TYPE: internal

- 104 -

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:75:

Ala	Asn	Lys	Ile	Ser	Tyr	Gln	Ser	Ser	Thr	Glu
1				5					10	

(2) INFORMATION FOR SEQ ID NO:76:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 12 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(v) FRAGMENT TYPE: internal

(ix) FEATURE:

- (A) NAME/KEY: Peptide
 - (B) LOCATION: 5
 - (D) OTHER INFORMATION: /label= d-serine
- /note= "unnatural configuration of the amino acid"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:76:

Ala	Asn	Lys	Ile	Ser	Tyr	Gln	Ser	Ser	Ser	Thr	Glu
1				5					10		

(2) INFORMATION FOR SEQ ID NO:77:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 12 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(v) FRAGMENT TYPE: internal

(ix) FEATURE:

- (A) NAME/KEY: Peptide

- 105 -

(B) LOCATION: 4

(D) OTHER INFORMATION: /label= d-isoleucine

/note= "unnatural amino acid stereochemical configuration"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:77:

Ala	Asn	Lys	Ile	Ser	Tyr	Gln	Ser	Ser	Ser	Thr	Glu
1				5						10	

(2) INFORMATION FOR SEQ ID NO:78:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 12 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:78:

Ala	Asn	Lys	Ile	Ser	Tyr	Gln	Ser	Ser	Gln	Thr	Glu
1				5						10	

(2) INFORMATION FOR SEQ ID NO:79:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 12 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:79:

Ala	Asn	Lys	Ile	Ser	Tyr	Gln	Ser	Ala	Lys	Thr	Glu
1				5						10	

- 106 -

(2) INFORMATION FOR SEQ ID NO:80:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 12 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
 - (ii) MOLECULE TYPE: peptide
 - (iii) HYPOTHETICAL: NO
 - (iv) ANTI-SENSE: NO
 - (v) FRAGMENT TYPE: internal
 - (ix) FEATURE:
 - (A) NAME/KEY: Peptide
 - (B) LOCATION: 3
 - (D) OTHER INFORMATION: /label= d-lysine
- /note= "unnatural amino acid stereochemical configuration"
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:80:

Ala	Asn	Lys	Ile	Ser	Tyr	Gln	Ser	Ser	Ser	Thr	Glu
1				5					10		

(2) INFORMATION FOR SEQ ID NO:81:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 10 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: peptide
- (iii) HYPOTHETICAL: NO
- (iv) ANTI-SENSE: NO
- (v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:81:

Ala	Asn	Lys	Ile	Ser	Tyr	Gln	Ser	Thr	Glu
1				5					10

(2) INFORMATION FOR SEQ ID NO:82:

- 107 -

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 10 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

- (ii) MOLECULE TYPE: peptide

- (iii) HYPOTHETICAL: NO

- (iv) ANTI-SENSE: NO

- (v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:82:

Ala	Asn	Lys	Ser	Tyr	Gln	Ser	Ser	Thr	Glu
1			5						10

(2) INFORMATION FOR SEQ ID NO:83:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 10 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

- (ii) MOLECULE TYPE: peptide

- (iii) HYPOTHETICAL: NO

- (iv) ANTI-SENSE: NO

- (v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:83:

Ala	Asn	Lys	Ile	Tyr	Gln	Ser	Ser	Thr	Glu
1			5						10

(2) INFORMATION FOR SEQ ID NO:84:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 12 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

- (ii) MOLECULE TYPE: peptide

- 108 -

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:84:

Ala	Asn	Lys	Ala	Ser	Tyr	Gln	Ser	Ala	Ser	Thr	Glu
1				5					10		

(2) INFORMATION FOR SEQ ID NO:85:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 12 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:85:

Ala	Asn	Glu	Ile	Ser	Tyr	Gln	Ser	Ala	Ser	Thr	Glu
1				5					10		

(2) INFORMATION FOR SEQ ID NO:86:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 7 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(v) FRAGMENT TYPE: internal

- 109 -

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:86:

Lys Ile Ser Tyr Gln Ser Ser
1 5

(2) INFORMATION FOR SEQ ID NO:87:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 7 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:87:

Ser Tyr Gln Ser Ser Thr Glu
1 5

(2) INFORMATION FOR SEQ ID NO:88:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 7 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:88:

Ser Tyr Gln Ser Ser Thr Leu
1 5

(2) INFORMATION FOR SEQ ID NO:89:

- 110 -

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 8 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:89:

Ala	Ser	Tyr	Gln	Ser	Ser	Thr	Glu
1				5			

(2) INFORMATION FOR SEQ ID NO:90:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 10 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:90:

Glu	Ile	Ser	Tyr	Gln	Ser	Ser	Ser	Thr	Glu
1				5					10

(2) INFORMATION FOR SEQ ID NO:91:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 12 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

- 111 -

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:91:

Ala	Asn	Glu	Ile	Ser	Tyr	Gln	Ser	Ser	Ser	Thr	Glu
1				5					10		

(2) INFORMATION FOR SEQ ID NO:92:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 12 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:92:

Ala	Asn	Lys	Ile	Ser	Tyr	Tyr	Ser	Ser	Ser	Thr	Glu
1				5					10		

(2) INFORMATION FOR SEQ ID NO:93:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 12 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(v) FRAGMENT TYPE: internal

- 112 -

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:93:

Ala	Asn	Lys	Ile	Ser	Tyr	Tyr	Ser	Ala	Ser	Thr	Glu
1				5					10		

(2) INFORMATION FOR SEQ ID NO:94:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 7 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:94:

Ala	Ser	Tyr	Gln	Ser	Ser	Leu
1				5		

(2) INFORMATION FOR SEQ ID NO:95:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:95:

Ala	Asn	Ser	Tyr	Gln	Ser	Ser	Ser	Thr	Glu
1				5					10

(2) INFORMATION FOR SEQ ID NO:96:

- 113 -

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 9 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

- (ii) MOLECULE TYPE: peptide

- (iii) HYPOTHETICAL: NO

- (iv) ANTI-SENSE: NO

- (v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:96:

Ala Ser Tyr Gln Ser Ser Ser Thr Glu
1 5

(2) INFORMATION FOR SEQ ID NO:97:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 8 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

- (ii) MOLECULE TYPE: peptide

- (iii) HYPOTHETICAL: NO

- (iv) ANTI-SENSE: NO

- (v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:97:

Ser Tyr Gln Ser Ser Ser Thr Glu
1 5

(2) INFORMATION FOR SEQ ID NO:98:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 12 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

- (ii) MOLECULE TYPE: peptide

- 114 -

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:98:

Ala	Asn	Lys	Ala	Ser	Tyr	Gln	Ser	Ala	Ser	Thr	Cys
1				5					10		

(2) INFORMATION FOR SEQ ID NO:99:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 5 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:99:

Gln	Ser	Ser	Thr	Glu
1			5	

(2) INFORMATION FOR SEQ ID NO:100:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 6 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(v) FRAGMENT TYPE: internal

- 115 -

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:100:

Tyr Gln Ser Ser Thr Glu
1 5

(2) INFORMATION FOR SEQ ID NO:101:

- (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 6 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:101:

Ser Gln Ser Ser Thr Glu
1 5

(2) INFORMATION FOR SEQ ID NO:102:

- (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:102:

Ala Asn Lys Ile Ser Gln Ser Ser Thr Glu
1 5 10

(2) INFORMATION FOR SEQ ID NO:103:

- 116 -

(i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 11 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(v) FRAGMENT TYPE: internal

(ix) FEATURE:
 (A) NAME/KEY: Peptide
 (B) LOCATION: 3
 (D) OTHER INFORMATION: /label= unnatural
/note= "ornithine"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:103:

Ala	Asn	Xaa	Ile	Ser	Tyr	Gln	Ser	Ser	Thr	Glu
1				5					10	

(2) INFORMATION FOR SEQ ID NO:104:

(i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 7 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(v) FRAGMENT TYPE: internal

(ix) FEATURE:
 (A) NAME/KEY: Peptide
 (B) LOCATION: 2
 (D) OTHER INFORMATION: /label= unnatural
/note= "3,4-dichlorophenalanine"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:104:

Ser	Xaa	Gln	Ser	Ser	Thr	Glu
1				5		

- 117 -

(2) INFORMATION FOR SEQ ID NO:105:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 7 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: peptide
- (iii) HYPOTHETICAL: NO
- (iv) ANTI-SENSE: NO
- (v) FRAGMENT TYPE: internal
- (ix) FEATURE:
 - (A) NAME/KEY: Peptide
 - (B) LOCATION: 2
 - (D) OTHER INFORMATION: /label= unnatural/note= "(3-pyridinyl)alanine"
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:105:

Ser	Xaa	Gln	Ser	Ser	Thr	Glu
1				5		

(2) INFORMATION FOR SEQ ID NO:106:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 7 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: peptide
- (iii) HYPOTHETICAL: NO
- (iv) ANTI-SENSE: NO
- (v) FRAGMENT TYPE: internal
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:106:

Ser	Lys	Gln	Ser	Ser	Thr	Glu
1				5		

(2) INFORMATION FOR SEQ ID NO:107:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 7 amino acids
 - (B) TYPE: amino acid

- 118 -

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:107:

Ser Tyr Gln Ser Ser Ser Leu
1 5

(2) INFORMATION FOR SEQ ID NO:108:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 7 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(v) FRAGMENT TYPE: internal

(ix) FEATURE:

(A) NAME/KEY: Peptide

(B) LOCATION: 1

(D) OTHER INFORMATION: /label= unnatural
/note= "epsilon aminocaproic acid"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:108:

Xaa Tyr Gln Ser Ser Ser Leu
1 5

(2) INFORMATION FOR SEQ ID NO:109:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 11 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

- 119 -

- (ii) MOLECULE TYPE: peptide
- (iii) HYPOTHETICAL: NO
- (iv) ANTI-SENSE: NO
- (v) FRAGMENT TYPE: internal
- (ix) FEATURE:
 - (A) NAME/KEY: Peptide
 - (B) LOCATION: 4
 - (D) OTHER INFORMATION: /label= unnatural
/note= "N-methylisoleucine"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:109:

Ala	Asn	Lys	Xaa	Ser	Tyr	Gln	Ser	Ser	Thr	Glu
1				5					10	

(2) INFORMATION FOR SEQ ID NO:110:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 7 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

- (ii) MOLECULE TYPE: peptide
- (iii) HYPOTHETICAL: NO
- (iv) ANTI-SENSE: NO
- (v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:110:

Ser	Tyr	Gln	Ser	Ser	Thr	Glu
1			5			

(2) INFORMATION FOR SEQ ID NO:111:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 6 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

- (ii) MOLECULE TYPE: peptide
- (iii) HYPOTHETICAL: NO

- 120 -

(iv) ANTI-SENSE: NO

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:111:

Tyr Gln Ser Ser Thr Glu
1 5

(2) INFORMATION FOR SEQ ID NO:112:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 7 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:112:

Ser Tyr Lys Ser Ser Thr Glu
1 5

(2) INFORMATION FOR SEQ ID NO:113:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 7 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:113:

- 121 -

Ser Tyr Tyr Ser Ser Thr Glu
1 5

(2) INFORMATION FOR SEQ ID NO:114:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 6 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

- (ii) MOLECULE TYPE: peptide

- (iii) HYPOTHETICAL: NO

- (iv) ANTI-SENSE: NO

- (v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:114:

Ser Tyr Gln Ser Ser Leu
1 5

(2) INFORMATION FOR SEQ ID NO:115:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 6 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

- (ii) MOLECULE TYPE: peptide

- (iii) HYPOTHETICAL: NO

- (iv) ANTI-SENSE: NO

- (v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:115:

Ser Tyr Gln Ser Ser Leu
1 5

(2) INFORMATION FOR SEQ ID NO:116:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 7 amino acids
 - (B) TYPE: amino acid

- 122 -

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(v) FRAGMENT TYPE: internal

(ix) FEATURE:

(A) NAME/KEY: Peptide

(B) LOCATION: 1

(D) OTHER INFORMATION: /label= unnatural

/note= "2,3-diaminopropionic acid"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:116:

Xaa	Tyr	Gln	Ser	Ser	Ser	Leu
1				5		

(2) INFORMATION FOR SEQ ID NO:117:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 11 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:117:

Ala	Asn	Lys	Ile	Ser	Tyr	Gln	Ser	Ser	Ser	Thr
1				5					10	

(2) INFORMATION FOR SEQ ID NO:118:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 12 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

- 123 -

- (ii) MOLECULE TYPE: peptide
- (iii) HYPOTHETICAL: NO
- (iv) ANTI-SENSE: NO
- (v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:118:

Ala Asn Lys Ala Ser Tyr Gln Ser Ala Ser Thr Leu
1 5 10

(2) INFORMATION FOR SEQ ID NO:119:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 11 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: peptide
- (iii) HYPOTHETICAL: NO
- (iv) ANTI-SENSE: NO
- (v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:119:

Ala Asn Lys Ala Ser Tyr Gln Ser Ala Ser Leu
1 5 10

(2) INFORMATION FOR SEQ ID NO:120:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 11 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: peptide
- (iii) HYPOTHETICAL: NO
- (iv) ANTI-SENSE: NO
- (v) FRAGMENT TYPE: internal

- 124 -

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:120:

Ala	Asn	Lys	Ala	Ser	Tyr	Gln	Ser	Ser	Ser	Leu
1				5						10

(2) INFORMATION FOR SEQ ID NO:121:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 10 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:121:

Ala	Asn	Lys	Ala	Ser	Tyr	Gln	Ser	Ser	Leu
1				5					10

(2) INFORMATION FOR SEQ ID NO:122:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 7 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(v) FRAGMENT TYPE: internal

(ix) FEATURE:

(A) NAME/KEY: Peptide

(B) LOCATION: 7

(D) OTHER INFORMATION: /label= d-leucine

/note= "unnatural amino acid stereochemical configuration"

- 125 -

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:122:

Ser Tyr Gln Ser Ser Thr Leu
1 5

(2) INFORMATION FOR SEQ ID NO:123:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 11 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:123:

Ala Asn Lys Ala Ser Tyr Ala Ser Ser Ser Leu
1 5 10

(2) INFORMATION FOR SEQ ID NO:124:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 7 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:124:

Lys Tyr Gln Ser Ser Ser Leu
1 5

(2) INFORMATION FOR SEQ ID NO:125:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 7 amino acids
(B) TYPE: amino acid

- 126 -

(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide
(iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:125:

Ser Tyr Gln Ser Ser Lys Leu
1 5

(2) INFORMATION FOR SEQ ID NO:126:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 7 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide
(iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(v) FRAGMENT TYPE: internal

(ix) FEATURE:
(A) NAME/KEY: Peptide
(B) LOCATION: 7
(D) OTHER INFORMATION: /label= d-leucine
/note= "unnatural amino acid stereochemical configuration"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:126:

Ser Tyr Gln Ser Ser Lys Leu
1 5

(2) INFORMATION FOR SEQ ID NO:127:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 7 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

- 127 -

- (ii) MOLECULE TYPE: peptide
- (iii) HYPOTHETICAL: NO
- (iv) ANTI-SENSE: NO
- (v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:127:

Asn Lys Ile Ser Tyr Tyr Ser
1 5

(2) INFORMATION FOR SEQ ID NO:128:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 7 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: peptide
- (iii) HYPOTHETICAL: NO
- (iv) ANTI-SENSE: NO
- (v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:128:

Asn Lys Ala Ser Tyr Gln Ser
1 5

(2) INFORMATION FOR SEQ ID NO:129:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 5 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: peptide
- (iii) HYPOTHETICAL: NO
- (iv) ANTI-SENSE: NO
- (v) FRAGMENT TYPE: internal

- 128 -

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:129:

Ser Tyr Gln Ser Ser
1 5

(2) INFORMATION FOR SEQ ID NO:130:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 8 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:130:

Asn Lys Ile Ser Tyr Gln Ser Ala
1 5

(2) INFORMATION FOR SEQ ID NO:131:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 8 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:131:

Ala Asn Lys Ile Ser Tyr Tyr Ser
1 5

- 129 -

(2) INFORMATION FOR SEQ ID NO:132:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 8 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: peptide
- (iii) HYPOTHETICAL: NO
- (iv) ANTI-SENSE: NO
- (v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:132:

Ala Asn Lys Ala Ser Tyr Gln Ser
1 5

(2) INFORMATION FOR SEQ ID NO:133:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 6 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: peptide
- (iii) HYPOTHETICAL: NO
- (iv) ANTI-SENSE: NO
- (v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:133:

Ser Tyr Gln Ser Ser Thr
1 5

(2) INFORMATION FOR SEQ ID NO:134:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 6 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

- 130 -

- (ii) MOLECULE TYPE: peptide
- (iii) HYPOTHETICAL: NO
- (iv) ANTI-SENSE: NO
- (v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:134:

Ser Tyr Gln Ser Ser Ser
1 5

(2) INFORMATION FOR SEQ ID NO:135:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 6 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: peptide
- (iii) HYPOTHETICAL: NO
- (iv) ANTI-SENSE: NO
- (v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:135:

Ser Tyr Gln Ser Ser Leu
1 5

(2) INFORMATION FOR SEQ ID NO:136:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 9 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: peptide
- (iii) HYPOTHETICAL: NO
- (iv) ANTI-SENSE: NO
- (v) FRAGMENT TYPE: internal

- 131 -

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:136:

Ala Asn Lys Ile Ser Tyr Gln Ser Ala
1 5

(2) INFORMATION FOR SEQ ID NO:137:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 9 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:137:

Ala Asn Lys Ile Ser Tyr Tyr Ser Ser
1 5

(2) INFORMATION FOR SEQ ID NO:138:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 9 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:138:

Ala Asn Lys Ile Ser Tyr Tyr Ser Ala
1 5

- 132 -

(2) INFORMATION FOR SEQ ID NO:139:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 9 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
 - (ii) MOLECULE TYPE: peptide
 - (iii) HYPOTHETICAL: NO
 - (iv) ANTI-SENSE: NO
 - (v) FRAGMENT TYPE: internal
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:139:
- | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Ala | Asn | Lys | Ala | Ser | Tyr | Gln | Ser | Ala |
| 1 | | | | 5 | | | | |

(2) INFORMATION FOR SEQ ID NO:140:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 5 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
 - (ii) MOLECULE TYPE: peptide
 - (iii) HYPOTHETICAL: NO
 - (iv) ANTI-SENSE: NO
 - (v) FRAGMENT TYPE: internal
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:140:
- | | | | | |
|-----|-----|-----|-----|-----|
| Lys | Tyr | Gln | Ser | Ser |
| 1 | | | 5 | |

(2) INFORMATION FOR SEQ ID NO:141:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 5 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

- 133 -

- (ii) MOLECULE TYPE: peptide
- (iii) HYPOTHETICAL: NO
- (iv) ANTI-SENSE: NO
- (v) FRAGMENT TYPE: internal

- (ix) FEATURE:
 - (A) NAME/KEY: Peptide
 - (B) LOCATION: 1
 - (D) OTHER INFORMATION: /label= homoarginine

- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:141:

Xaa Tyr Gln Ser Ser
1 5

- (2) INFORMATION FOR SEQ ID NO:142:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 6 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

- (ii) MOLECULE TYPE: peptide
- (iii) HYPOTHETICAL: NO
- (iv) ANTI-SENSE: NO
- (v) FRAGMENT TYPE: internal

- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:142:

Lys Tyr Gln Ser Ser Ser
1 5

- (2) INFORMATION FOR SEQ ID NO:143:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 6 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

- (ii) MOLECULE TYPE: peptide
- (iii) HYPOTHETICAL: NO

- 134 -

(iv) ANTI-SENSE: NO

(v) FRAGMENT TYPE: internal

(ix) FEATURE:

(A) NAME/KEY: Peptide

(B) LOCATION: 1

(D) OTHER INFORMATION: /label= homoarginine

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:143:

Xaa Tyr Gln Ser Ser Ser
1 5

(2) INFORMATION FOR SEQ ID NO:144:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 7 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:144:

Ser Tyr Gln Ser Ser Ser Leu
1 5

(2) INFORMATION FOR SEQ ID NO:145:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 7 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(v) FRAGMENT TYPE: internal

- 135 -

(ix) FEATURE:

- (A) NAME/KEY: Peptide
- (B) LOCATION: 1
- (D) OTHER INFORMATION: /label= homoarginine

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:145:

Xaa Tyr Gln Ser Ser Ser Leu
1 5

(2) INFORMATION FOR SEQ ID NO:146:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 7 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(v) FRAGMENT TYPE: internal

(ix) FEATURE:

- (A) NAME/KEY: Peptide
- (B) LOCATION: 7
- (D) OTHER INFORMATION: /label= norleucine

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:146:

Lys Tyr Gln Ser Ser Ser Leu
1 5

(2) INFORMATION FOR SEQ ID NO:147:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 5 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(ix) FEATURE:

- (A) NAME/KEY: Peptide
- (B) LOCATION: 2
- (D) OTHER INFORMATION: /product= "cyclohexylalanine"

- 136 -

(ix) FEATURE:

- (A) NAME/KEY: Peptide
- (B) LOCATION: 1
- (D) OTHER INFORMATION: /product= "homoarginine"

(ix) FEATURE:

- (A) NAME/KEY: Peptide
- (B) LOCATION: 5
- (D) OTHER INFORMATION: /product= "norleucine"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:147:

Xaa Xaa Gln Ser Leu
1 5

(2) INFORMATION FOR SEQ ID NO:148:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 6 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(ix) FEATURE:

- (A) NAME/KEY: Peptide
- (B) LOCATION: 1
- (D) OTHER INFORMATION: /product= "homoarginine"

(ix) FEATURE:

- (A) NAME/KEY: Peptide
- (B) LOCATION: 2
- (D) OTHER INFORMATION: /product= "homotyrosine"

(ix) FEATURE:

- (A) NAME/KEY: Peptide
- (B) LOCATION: 6
- (D) OTHER INFORMATION: /product= "norleucine"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:148:

Xaa Xaa Gln Ser Ser Leu
1 5

(2) INFORMATION FOR SEQ ID NO:149:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 6 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

- 137 -

(ii) MOLECULE TYPE: peptide

(ix) FEATURE:

(A) NAME/KEY: Peptide

(B) LOCATION: 1

(D) OTHER INFORMATION: /product= "homoarginine"

(ix) FEATURE:

(A) NAME/KEY: Peptide

(B) LOCATION: 2

(D) OTHER INFORMATION: /product= "cyclohexylhomoalanine"

(ix) FEATURE:

(A) NAME/KEY: Peptide

(B) LOCATION: 6

(D) OTHER INFORMATION: /product= "norleucine"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:149:

Xaa Xaa Gln Ser Ser Leu
1 5

(2) INFORMATION FOR SEQ ID NO:150:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 10 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(ix) FEATURE:

(A) NAME/KEY: Peptide

(B) LOCATION: 10

(D) OTHER INFORMATION: /product= "cyclohexylalanine"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:150:

Ala Asn Lys Ala Ser Tyr Gln Ser Ser Xaa
1 5 10

(2) INFORMATION FOR SEQ ID NO:151:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 6 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

- 138 -

(ix) FEATURE:

- (A) NAME/KEY: Peptide
- (B) LOCATION: 1
- (D) OTHER INFORMATION: /product= "homoarginine"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:151:

Xaa Tyr Gln Ser Ser Pro
1 5

(2) INFORMATION FOR SEQ ID NO:152:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 6 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(ix) FEATURE:

- (A) NAME/KEY: Peptide
- (B) LOCATION: 1
- (D) OTHER INFORMATION: /product= "homoarginine"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:152:

Xaa Tyr Gln Ser Ser His
1 5

(2) INFORMATION FOR SEQ ID NO:153:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 5 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(ix) FEATURE:

- (A) NAME/KEY: Peptide
- (B) LOCATION: 1
- (D) OTHER INFORMATION: /product= "homoarginine"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:153:

Xaa Tyr Gln Ser Asn
1 5

- 139 -

(2) INFORMATION FOR SEQ ID NO:154:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 7 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(ix) FEATURE:

- (A) NAME/KEY: Peptide
- (B) LOCATION: 1
- (D) OTHER INFORMATION: /product= "homoarginine"

(ix) FEATURE:

- (A) NAME/KEY: Peptide
- (B) LOCATION: 7
- (D) OTHER INFORMATION: /product= "norleucine"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:154:

Xaa Tyr Gln Ser Ser Ser Leu
1 5

(2) INFORMATION FOR SEQ ID NO:155:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 7 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(ix) FEATURE:

- (A) NAME/KEY: Peptide
- (B) LOCATION: 1
- (D) OTHER INFORMATION: /product= "4-aminomethylphenylalanine"

(ix) FEATURE:

- (A) NAME/KEY: Peptide
- (B) LOCATION: 7
- (D) OTHER INFORMATION: /product= "norleucine"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:155:

Xaa Tyr Gln Ser Ser Ser Leu
1 5

(2) INFORMATION FOR SEQ ID NO:156:

- 140 -

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 7 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

- (ix) FEATURE:
 (A) NAME/KEY: Peptide
 (B) LOCATION: 1
 (D) OTHER INFORMATION: /product= "homoarginine"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:156:

Xaa Tyr Gln Ser Ser Leu
1 5

(2) INFORMATION FOR SEQ ID NO:157:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 10 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

- (ix) FEATURE:
 (A) NAME/KEY: Peptide
 (B) LOCATION: 10
 (D) OTHER INFORMATION: /product= "cyclohexylalanine"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:157:

Ala Asn Lys Ala Lys Tyr Gln Ser Ser Xaa
1 5 10

(2) INFORMATION FOR SEQ ID NO:158:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 7 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(ix) FEATURE:

- 141 -

(A) NAME/KEY: Peptide
(B) LOCATION: 1
(D) OTHER INFORMATION: /product=
"2(4,6-dimethylpyrimidine)lysine"

(ix) FEATURE:
(A) NAME/KEY: Peptide
(B) LOCATION: 7
(D) OTHER INFORMATION: /product= "norleucine"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:158:

Xaa Tyr Gln Ser Ser Ser Leu
1 5

(2) INFORMATION FOR SEQ ID NO:159:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 6 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(ix) FEATURE:
(A) NAME/KEY: Peptide
(B) LOCATION: 1
(D) OTHER INFORMATION: /product= "N'-(2-imidazolyl)lysine"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:159:

Xaa Tyr Gln Ser Ser Leu
1 5

(2) INFORMATION FOR SEQ ID NO:160:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(ix) FEATURE:
(A) NAME/KEY: Peptide
(B) LOCATION: 5
(D) OTHER INFORMATION: /product= "homoarginine"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:160:

- 142 -

Ala Asn Lys Ala Xaa Tyr Gln Ser Ser Leu
1 5 10

(2) INFORMATION FOR SEQ ID NO:161:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 7 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

- (ix) FEATURE:
 (A) NAME/KEY: Peptide
 (B) LOCATION: 1
 (D) OTHER INFORMATION: /product=
"(4-aminocyclohexyl)alanine"

- (ix) FEATURE:
 (A) NAME/KEY: Peptide
 (B) LOCATION: 7
 (D) OTHER INFORMATION: /product= "norleucine"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:161:

Xaa Tyr Gln Ser Ser Ser Leu
1 5

(2) INFORMATION FOR SEQ ID NO:162:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 7 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

- (ix) FEATURE:
 (A) NAME/KEY: Peptide
 (B) LOCATION: 1
 (D) OTHER INFORMATION: /product= "N'-(2-imidazolyl)lysine"

- (ix) FEATURE:
 (A) NAME/KEY: Peptide
 (B) LOCATION: 7
 (D) OTHER INFORMATION: /product= "norleucine"

(xi) SEQUENCE DESCRIPTION: SEQ NO:162:

- 143 -

Xaa Tyr Gln Ser Ser Ser Leu
1 5

(2) INFORMATION FOR SEQ ID NO:163:

- (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 7 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(ix) FEATURE:

- (A) NAME/KEY: Peptide
(B) LOCATION: 1
(D) OTHER INFORMATION: /product= "homoarginine"

(ix) FEATURE:

- (A) NAME/KEY: Peptide
(B) LOCATION: 2
(D) OTHER INFORMATION: /product= "cyclohexylalanine"

(ix) FEATURE:

- (A) NAME/KEY: Peptide
(B) LOCATION: 7
(D) OTHER INFORMATION: /product= "norleucine"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:163:

Xaa Xaa Gln Ser Ser Ser Leu
1 5

(2) INFORMATION FOR SEQ ID NO:164:

- (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 7 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(ix) FEATURE:

- (A) NAME/KEY: Peptide
(B) LOCATION: 1
(D) OTHER INFORMATION: /product= "homoarginine"

(ix) FEATURE:

- (A) NAME/KEY: Peptide
(B) LOCATION: 7
(D) OTHER INFORMATION: /product= "homoarginine"

- 144 -

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:164:

Xaa Tyr Gln Ser Ser Xaa
1 5

(2) INFORMATION FOR SEQ ID NO:165:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(ix) FEATURE:
(A) NAME/KEY: Peptide
(B) LOCATION: 5
(D) OTHER INFORMATION: /product= "N'-(2-imidazolyl)lysine"

(ix) FEATURE:
(A) NAME/KEY: Peptide
(B) LOCATION: 10
(D) OTHER INFORMATION: /product= "norleucine"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:165:

Ala Asn Lys Ala Xaa Tyr Gln Ser Ser Leu
1 5 10

(2) INFORMATION FOR SEQ ID NO:166:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 7 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(ix) FEATURE:
(A) NAME/KEY: Peptide
(B) LOCATION: 1
(D) OTHER INFORMATION: /product= "homoarginine"

(ix) FEATURE:
(A) NAME/KEY: Peptide
(B) LOCATION: 2
(D) OTHER INFORMATION: /product= "3-iodotyrosine"

(ix) FEATURE:
(A) NAME/KEY: Peptide

- 145 -

(B) LOCATION: 7

(D) OTHER INFORMATION: /product= "norleucine"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:166:

Xaa Xaa Gln Ser Ser Ser Leu
1 5

(2) INFORMATION FOR SEQ ID NO:167:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 7 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(ix) FEATURE:

(A) NAME/KEY: Peptide

(B) LOCATION: 1

(D) OTHER INFORMATION: /product= "homoarginine"

(ix) FEATURE:

(A) NAME/KEY: Peptide

(B) LOCATION: 2

(D) OTHER INFORMATION: /product= "O-dimethylphosphotyrosine"

(ix) FEATURE:

(A) NAME/KEY: Peptide

(B) LOCATION: 7

(D) OTHER INFORMATION: /product= "norleucine"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:167:

Xaa Xaa Gln Ser Ser Ser Leu
1 5

(2) INFORMATION FOR SEQ ID NO:168:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 6 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(ix) FEATURE:

(A) NAME/KEY: Peptide

(B) LOCATION: 1

- 146 -

(D) OTHER INFORMATION: /product= "homoarginine"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:168:

Xaa Tyr Gln Ser Ser Asp
1 5

(2) INFORMATION FOR SEQ ID NO:169:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 7 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(ix) FEATURE:

- (A) NAME/KEY: Peptide
- (B) LOCATION: 1
- (D) OTHER INFORMATION: /product= "homoarginine"

(ix) FEATURE:

- (A) NAME/KEY: Peptide
- (B) LOCATION: 2
- (D) OTHER INFORMATION: /product= "O-methyltyrosine"

(ix) FEATURE:

- (A) NAME/KEY: Peptide
- (B) LOCATION: 7
- (D) OTHER INFORMATION: /product= "norleucine"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:169:

Xaa Xaa Gln Ser Ser Ser Leu
1 5

(2) INFORMATION FOR SEQ ID NO:170:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 10 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(ix) FEATURE:

- (A) NAME/KEY: Peptide
- (B) LOCATION: 10
- (D) OTHER INFORMATION: /product= "norleucine"

- 147 -

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:170:

Ala Asn Lys Ala Lys Tyr Gln Ser Ser Leu
1 5 10

(2) INFORMATION FOR SEQ ID NO:171:

- (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 7 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(ix) FEATURE:

- (A) NAME/KEY: Peptide
(B) LOCATION: 1
(D) OTHER INFORMATION: /product= "homoarginine"

(ix) FEATURE:

- (A) NAME/KEY: Peptide
(B) LOCATION: 2
(D) OTHER INFORMATION: /product= "cyclohexylalanine"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:171:

Xaa Xaa Gln Ser Ser Ser Leu
1 5

(2) INFORMATION FOR SEQ ID NO:172:

- (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 7 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(ix) FEATURE:

- (A) NAME/KEY: Peptide
(B) LOCATION: 1
(D) OTHER INFORMATION: /product= "N'-(2-imidazolyl)lysine"

(ix) FEATURE:

- (A) NAME/KEY: Peptide
(B) LOCATION: 2
(D) OTHER INFORMATION: /product= "cyclohexylalanine"

(ix) FEATURE:

- (A) NAME/KEY: Peptide

- 148 -

(B) LOCATION: 7

(D) OTHER INFORMATION: /product= "norleucine"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:172:

Xaa Xaa Gln Ser Ser Ser Leu
1 5

(2) INFORMATION FOR SEQ ID NO:173:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 6 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(ix) FEATURE:

(A) NAME/KEY: Peptide

(B) LOCATION: 1

(D) OTHER INFORMATION: /product= "homoarginine"

(ix) FEATURE:

(A) NAME/KEY: Peptide

(B) LOCATION: 2

(D) OTHER INFORMATION: /product= "cyclohexylalanine"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:173:

Xaa Xaa Gln Ser Ser Ser
1 5

(2) INFORMATION FOR SEQ ID NO:174:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 6 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(ix) FEATURE:

(A) NAME/KEY: Peptide

(B) LOCATION: 1

(D) OTHER INFORMATION: /product= "homoarginine"

(ix) FEATURE:

(A) NAME/KEY: Peptide

(B) LOCATION: 2

(D) OTHER INFORMATION: /product= "cyclohexylalanine"

- 149 -

(ix) FEATURE:

- (A) NAME/KEY: Peptide
- (B) LOCATION: 6
- (D) OTHER INFORMATION: /product= "norleucine"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:174:

Xaa Xaa Gln Ser Ser Leu
1 5

(2) INFORMATION FOR SEQ ID NO:175:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 6 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(ix) FEATURE:

- (A) NAME/KEY: Peptide
- (B) LOCATION: 1
- (D) OTHER INFORMATION: /product= "homoarginine"

(ix) FEATURE:

- (A) NAME/KEY: Peptide
- (B) LOCATION: 2
- (D) OTHER INFORMATION: /product= "cyclohexylalanine"

(ix) FEATURE:

- (A) NAME/KEY: Peptide
- (B) LOCATION: 6
- (D) OTHER INFORMATION: /product= "norleucine"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:175:

Xaa Xaa Gln Ser Pro Leu
1 5

(2) INFORMATION FOR SEQ ID NO:176:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 7 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(ix) FEATURE:

- 150 -

- (A) NAME/KEY: Peptide
- (B) LOCATION: 1
- (D) OTHER INFORMATION: /product= "homoarginine"

(ix) FEATURE:

- (A) NAME/KEY: Peptide
- (B) LOCATION: 2
- (D) OTHER INFORMATION: /product= "3-fluorotyrosine"

(ix) FEATURE:

- (A) NAME/KEY: Peptide
- (B) LOCATION: 7
- (D) OTHER INFORMATION: /product= "norleucine"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:176:

Xaa Xaa Gln Ser Ser Ser Leu
1 5

(2) INFORMATION FOR SEQ ID NO:177:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 5 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(ix) FEATURE:

- (A) NAME/KEY: Peptide
- (B) LOCATION: 1
- (D) OTHER INFORMATION: /product= "homoarginine"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:177:

Xaa Tyr Gln Ser Pro
1 5

(2) INFORMATION FOR SEQ ID NO:178:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 6 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(ix) FEATURE:

- (A) NAME/KEY: Peptide
- (B) LOCATION: 6

- 151 -

(D) OTHER INFORMATION: /product= "norleucine"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:178:

Lys Tyr Gln Ser Lys Leu
1 5

(2) INFORMATION FOR SEQ ID NO:179:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 7 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(ix) FEATURE:
(A) NAME/KEY: Peptide
(B) LOCATION: 1
(D) OTHER INFORMATION: /product= "homoarginine"

(ix) FEATURE:
(A) NAME/KEY: Peptide
(B) LOCATION: 2
(D) OTHER INFORMATION: /product= "4-aminophenylalanine"

(ix) FEATURE:
(A) NAME/KEY: Peptide
(B) LOCATION: 7
(D) OTHER INFORMATION: /product= "norleucine"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:179:

Xaa Xaa Gln Ser Ser Ser Leu
1 5

(2) INFORMATION FOR SEQ ID NO:180:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 7 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(ix) FEATURE:
(A) NAME/KEY: Peptide
(B) LOCATION: 1
(D) OTHER INFORMATION: /product= "homoarginine"

- 152 -

(ix) FEATURE:

- (A) NAME/KEY: Peptide
- (B) LOCATION: 2
- (D) OTHER INFORMATION: /product= "7-HO-tetrahydroisoquinoline CO2H"

(ix) FEATURE:

- (A) NAME/KEY: Peptide
- (B) LOCATION: 7
- (D) OTHER INFORMATION: /product= "norleucine"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:180:

Xaa Xaa Gln Ser Ser Ser Leu
1 5

(2) INFORMATION FOR SEQ ID NO:181:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 7 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(ix) FEATURE:

- (A) NAME/KEY: Peptide
- (B) LOCATION: 1
- (D) OTHER INFORMATION: /product= "ornithine"

(ix) FEATURE:

- (A) NAME/KEY: Peptide
- (B) LOCATION: 7
- (D) OTHER INFORMATION: /product= "norleucine"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:181:

Xaa Tyr Gln Ser Ser Ser Leu
1 5

(2) INFORMATION FOR SEQ ID NO:182:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 7 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

- 153 -

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:182:

Lys Ala Ala Ser Ser Ser Leu
1 5

(2) INFORMATION FOR SEQ ID NO:183:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 7 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(ix) FEATURE:

- (A) NAME/KEY: Peptide
- (B) LOCATION: 7
- (D) OTHER INFORMATION: /product= "norleucine"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:183:

Lys Tyr Gln Ser Ser Ser Leu
1 5

(2) INFORMATION FOR SEQ ID NO:184:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 11 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:184:

Leu Asn Lys Ala Ser Tyr Gln Ser Ser Ser Leu
1 5 10

(2) INFORMATION FOR SEQ ID NO:185:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 5 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

- 154 -

(ix) FEATURE:

- (A) NAME/KEY: Peptide
- (B) LOCATION: 1
- (D) OTHER INFORMATION: /product= "homoarginine"

(ix) FEATURE:

- (A) NAME/KEY: Peptide
- (B) LOCATION: 2
- (D) OTHER INFORMATION: /product= "cyclohexylalanine"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:185:

Xaa Xaa Gln Ser Ser
1 5

(2) INFORMATION FOR SEQ ID NO:186:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 4 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:186:

Tyr Gln Ser Ser
1

(2) INFORMATION FOR SEQ ID NO:187:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 4 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(ix) FEATURE:

- (A) NAME/KEY: Peptide
- (B) LOCATION: 1
- (D) OTHER INFORMATION: /product= "homoarginine"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:187:

Xaa Tyr Gln Ser
1

- 155 -

(2) INFORMATION FOR SEQ ID NO:188:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 6 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(ix) FEATURE:

- (A) NAME/KEY: Peptide
 (B) LOCATION: 1
 (D) OTHER INFORMATION: /product= "homoarginine"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:188:

Xaa Tyr Gln Ser Ser Ser
1 5

(2) INFORMATION FOR SEQ ID NO:189:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 5 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(ix) FEATURE:

- (A) NAME/KEY: Peptide
 (B) LOCATION: 5
 (D) OTHER INFORMATION: /product= "norleucine"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:189:

Gln Ser Ser Ser Leu
1 5

(2) INFORMATION FOR SEQ ID NO:190:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 6 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

- 156 -

(ix) FEATURE:

- (A) NAME/KEY: Peptide
- (B) LOCATION: 1
- (D) OTHER INFORMATION: /product=
"7-HO-tetrahydro-3-isoquinoline CO2H"

(ix) FEATURE:

- (A) NAME/KEY: Peptide
- (B) LOCATION: 6
- (D) OTHER INFORMATION: /product= "norleucine"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:190:

Xaa Gln Ser Ser Ser Leu
1 5

(2) INFORMATION FOR SEQ ID NO:191:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 11 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:191:

Ala Asn Lys Ala Ser Tyr Ala Ser Ser Ser Leu
1 5 10

(2) INFORMATION FOR SEQ ID NO:192:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 7 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:192:

Ser Tyr Gln Ser Ser Lys Leu
1 5

(2) INFORMATION FOR SEQ ID NO:193:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 9 amino acids
- (B) TYPE: amino acid

- 157 -

- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:193:

Ala Asn Lys Ala Ser Tyr Gln Ser Leu
1 5

(2) INFORMATION FOR SEQ ID NO:194:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 7 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(ix) FEATURE:

- (A) NAME/KEY: Peptide
- (B) LOCATION: 1
- (D) OTHER INFORMATION: /product= "ornithine"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:194:

Xaa Tyr Gln Ser Ser Ser Leu
1 5

- 158 -

WHAT IS CLAIMED IS:

1. A method of treating an adverse condition of the prostate which comprises administering to a mammal in need of said treatment a conjugate, said conjugate which comprises a pharmaceutical agent, effective in the treatment of said condition, attached to an oligopeptide, wherein the oligopeptide comprises a sequence of amino acids that is recognized and selectively proteolytically cleaved by free prostate specific antigen, wherein the means of attachment is directly through a covalent bond or via a linker unit,

or the pharmaceutically acceptable salt thereof.

2. A method of treating benign prostatic hyperplasia which comprises administering to a mammal in need of said treatment a conjugate, said conjugate which comprises a cytotoxic agent attached to a oligopeptide, wherein the oligopeptide comprises a sequence of amino acids that is recognized and selectively proteolytically cleaved by free prostate specific antigen, wherein the means of attachment is directly through a covalent bond or via a linker unit,

or the pharmaceutically acceptable salt thereof.

3. The method of treatment according to Claim 2 wherein the cytotoxic agent is a member of a class of cytotoxic agents selected from the following classes:

- a) anthracycline family of drugs,
- b) the vinca alkaloid drugs,
- c) the mitomycins,
- d) the bleomycins,
- e) the cytotoxic nucleosides,
- f) the pteridine family of drugs,
- g) diynenes,
- h) estramustine,

- 159 -

- i) cyclophosphamide,
- j) the podophyllotoxins, and
- k) the taxanes;

5 or the pharmaceutically acceptable salt thereof.

4. The method of treatment according to Claim 2 wherein the cytotoxic agent is selected from the following cytotoxic agents:

- 10 a) doxorubicin,
- b) carminomycin,
- c) daunorubicin,
- d) aminopterin,
- e) methotrexate,
- 15 f) methopterin,
- g) dichloro-methotrexate,
- h) mitomycin C,
- i) porfiromycin,
- j) 5-fluorouracil,
- 20 k) 6-mercaptopurine,
- l) cytosine arabinoside,
- m) podophyllotoxin,
- n) etoposide,
- o) etoposide phosphate,
- 25 p) melphalan,
- q) vinblastine,
- r) vincristine,
- s) leurosidine,
- t) vindesine,
- 30 u) estramustine,
- v) cisplatin,
- w) cyclophosphamide,
- x) leurosine, and
- y) taxol;

- 160 -


or the pharmaceutically acceptable salt thereof.

5 5. The method of treatment according to Claim 2
 wherein the cytotoxic agent is selected from doxorubicin, vinblastine and
 desacetylvinblastine or a cytotoxic derivative thereof.

10 6. The method of treatment according to Claim 2
 wherein the cytotoxic agent is selected from vinblastine and
 desacetylvinblastine or a cytotoxic derivative thereof.

7. The method of treatment according to Claim 5
 wherein the conjugate is of the formula I:

15



wherein:

20 oligopeptide is an oligopeptide which is specifically recognized by the
 free prostate specific antigen (PSA) and is capable of being
 proteolytically cleaved by the enzymatic activity of the free prostate
 specific antigen;

- 161 -

X_L is absent or is an amino acid selected from:

- a) phenylalanine,
- b) leucine,
- c) valine,
- 5 d) isoleucine,
- e) (2-naphthyl)alanine,
- f) cyclohexylalanine,
- g) diphenylalanine,
- h) norvaline, and
- 10 i) norleucine, and
- j) 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid;

R is hydrogen or $-(C=O)R^1$; and

- 15 R^1 is C_1 - C_6 -alkyl or aryl,

or the pharmaceutically acceptable salt thereof.

- 20 8. The method of treatment according to Claim 7 wherein:

oligopeptide is an oligomer that comprises an amino acid sequence selected from:


- 25 a) AsnLysIleSerTyrGlnSer (SEQ.ID.NO.: 13),
- b) LysIleSerTyrGlnSer (SEQ.ID.NO.: 14),
- c) GlyGluAsnGlyValGlnLysAspValSerGlnXaaSerIleTyrIleSerGlnThrGlu
30 (SEQ.ID.NO.: 15),
- d) GlyLysGlyIleSerSerGlnTyrIleSerAsnThrGluGluArgLeu
(SEQ.ID.NO.: 2),

- 162 -

- e) AsnLysIleSerTyrTyrSer (SEQ.ID.NO.: 127),
f) AsnLysAlaSerTyrGlnSer (SEQ.ID.NO.: 128),
5 g) SerTyrGlnSerSer (SEQ.ID.NO.: 129),
h) LysTyrGlnSerSer (SEQ.ID.NO.: 140);
i) hArgTyrGlnSerSer (SEQ.ID.NO.: 141);
10 j) hArgChaGlnSerSer (SEQ.ID.NO.: 185); and
k) TyrGlnSerSer (SEQ.ID.NO.: 186);
15 wherein hArg is homoarginine and Xaa is any natural amino acid;
XL is absent or is an amino acid selected from:
a) leucine,
b) isoleucine,
20 c) norleucine and
d) valine; and
R is acetyl, pivaloyl or benzoyl,
25 or the pharmaceutically acceptable salt thereof.

9. The method of treatment according to Claim 7
wherein the conjugate is selected from:

- 163 -



wherein X is:

AsnLysIleSerTyrGlnSer—	(SEQ.ID.NO.: 13),
AsnLysIleSerTyrGlnSerSer—	(SEQ.ID.NO.: 16),
AsnLysIleSerTyrGlnSerSerSer —	(SEQ.ID.NO.: 17),
AsnLysIleSerTyrGlnSerSerSerThr —	(SEQ.ID.NO.:10),
AsnLysIleSerTyrGlnSerSerSerThrGlu —	(SEQ.ID.NO.: 3),
AlaAsnLysIleSerTyrGlnSerSerSerThrGlu —	(SEQ.ID.NO.: 11),
N-terminus	

- 164 -

- Ac — AlaAsnLysIleSerTyrGlnSerSerSerThr — (SEQ.ID.NO.: 117),
- Ac — AlaAsnLysIleSerTyrGlnSerSerSerThrLeu — (SEQ.ID.NO.: 70),
- Ac — AlaAsnLysAlaSerTyrGlnSerAlaSerThrLeu — (SEQ.ID.NO.: 118),
- Ac — AlaAsnLysAlaSerTyrGlnSerAlaSerLeu — (SEQ.ID.NO.: 119),
- Ac — AlaAsnLysAlaSerTyrGlnSerSerSerLeu — (SEQ.ID.NO.: 120),
- Ac — AlaAsnLysAlaSerTyrGlnSerSerLeu — (SEQ.ID.NO.: 121),
- Ac — SerTyrGlnSerSerSerLeu — (SEQ.ID.NO.: 144),
- Ac — hArgTyrGlnSerSerSerLeu — (SEQ.ID.NO.: 145),
- Ac — LysTyrGlnSerSerSerLeu — (SEQ.ID.NO.: 124), or
- Ac — LysTyrGlnSerSerNle — (SEQ.ID.NO.: 146),
- ↙
- N-terminus

or the pharmaceutically acceptable salt thereof.

- 5 10. The method of treatment according to Claim 7
wherein the conjugate is selected from:

- Ac-hArgTyrGln-SerSerPro-dox(3') (SEQ.ID.NO.: 151)
- Ac-hArgTyrGln-SerPro-dox(3') (SEQ.ID.NO.: 177)
- 10 Ac-hArgTyrGln-SerSerSerNle-dox(3') (SEQ.ID.NO.: 154)
- Ac-AmfTyrGln-SerSerSerNle-dox(3') (SEQ.ID.NO.: 155)
- H₂NCO-hArgTyrGln-SerSerSerLeu-dox(3') (SEQ.ID.NO.: 156)

- 165 -

- Ac-LysTyrGln-SerSerNle-dox(3') (SEQ.ID.NO.: 146)
- Ac-LysTyrGln-SerLysNle-dox(3') (SEQ.ID.NO.: 178)
- Ac(cis-p-NH₂Cha)TyrGlnSerSerNledox(3') (SEQ.ID.NO.: 161)
- Ac-AlaAspLysAla(hArg)TyrGln-SerSerLeu-dox(3') (SEQ.ID.NO.: 160)
- 5 Ac-hArgTyrGln-SerAsn-dox(3') (SEQ.ID.NO.: 153)
- Ac-hArgTyrGln-SerSerHis-dox(3') (SEQ.ID.NO.: 152)
- Ac-(imidazolyl)LysTyrGln-SerSerLeu-dox(3') (SEQ.ID.NO.: 159)
- Ac-(imidazolyl)LysTyrGlnSerSerSerNle-dox(3') (SEQ.ID.NO.: 162)
- Ac-hArg(Cha)Gln-SerSerSerNle-dox(3') (SEQ.ID.NO.: 163)
- 10 Ac-hArg(Me₂PO₃Tyr)Gln-SerSerSerNle-dox(3') (SEQ.ID.NO.: 167)
- Ac-hArgTyrGln-SerSerSerhArg-dox(3') (SEQ.ID.NO.: 164)
- Ac-hArg(3-Iodo-Tyr)Gln-SerSerSerNle-dox(3') (SEQ.ID.NO.: 166)
- Ac-hArg(O-Me-Tyr)Gln-SerSerSerNle-dox(3') (SEQ.ID.NO.: 169)
- Ac-hArg(p-NH₂-Phe)Gln-SerSerSerNle-dox(3') (SEQ.ID.NO.: 179)
- 15 Ac-hArg(Cha)Gln-SerSerNle-dox(3') (SEQ.ID.NO.: 174)
- Ac-hArg(Cha)Gln-SerProNle-dox(3') (SEQ.ID.NO.: 175)
- Ac(imidazolyl)Lys(Cha)GlnSerSerSerNle-dox(3') (SEQ.ID.NO.: 172)
- Ac-hArg(7-HO-TIC)Gln-SerSerSerNle-dox(3') (SEQ.ID.NO.: 180)
- Ac-hArg(3-Fluoro)TyrGlnSerSerSerNle-dox(3') (SEQ.ID.NO.: 176)
- 20 Ac-(ornithine)TyrGln-SerSerSerNle-dox(3') (SEQ.ID.NO.: 181)
- Ac-LysAlaAlaSerSerSerLeu-dox(3') (SEQ.ID.NO.: 183)
- Ac-hArgh(Cha)Gln-SerSerNle-dox(3') (SEQ.ID.NO.: 149)
- Ac-AlaArgLysAlaSerTyrGln-SerLeu-dox(3') (SEQ.ID.NO.: 193) and
- Ac-(Om)TyrGln-SerSerSerLeu-dox(3') (SEQ.ID.NO.: 194)


25

or the pharmaceutically acceptable salt thereof.

11. The method of treatment according to Claim 6
wherein the conjugate is of the formula II:

30

- 166 -



wherein:

- 5 oligopeptide is an oligopeptide which is specifically recognized by the free prostate specific antigen (PSA) and is capable of being proteolytically cleaved by the enzymatic activity of the free prostate specific antigen;
- 10 X_L is absent or is an amino acid selected from:
 - a) phenylalanine,
 - b) leucine,
 - c) valine,
 - d) isoleucine,
 - 15 e) (2-naphthyl)alanine,
 - f) cyclohexylalanine,
 - g) diphenylalanine,
 - h) norvaline,
 - i) norleucine, and
 - 20 j) 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid; or

X_L is - NH - (CH₂)_n - NH -

- 167 -

R is hydrogen or $-(C=O)R^1$;

R^1 is C_1 - C_6 -alkyl or aryl;


5 R^{19} is hydrogen or acetyl; and

n is 1, 2, 3, 4 or 5,

or the pharmaceutically acceptable salt thereof.

10

12. The method of treatment according to Claim 11 wherein the conjugate is of the formula II:



15

wherein:


oligopeptide is an oligopeptide which is specifically recognized by the free prostate specific antigen (PSA) and is capable of being
 20 proteolytically cleaved by the enzymatic activity of the free prostate specific antigen,

- 168 -

or the pharmaceutically acceptable salt thereof.


13. The method of treatment according to Claim 11 wherein the conjugate is selected from:

5



and

- 169 -



Compound 5 (SEQ.ID.NO.: 184),

or the pharmaceutically acceptable salt thereof.

14. A method of treating an adverse condition of the prostate which comprises administering to a mammal in need of said treatment a conjugate, said conjugate which comprises two pharmaceutical agents, wherein at least one pharmaceutical agent is effective against said condition, attached to an oligopeptide, wherein the oligopeptide comprises a sequence of amino acids that is recognized and selectively proteolytically cleaved by free prostate specific antigen, wherein the means of attachment is directly through a covalent bond or via a linker unit,

or the pharmaceutically acceptable salt thereof.


15. A method of treating benign prostatic hyperplasia which comprises administering to a mammal in need of said treatment a conjugate, said conjugate which comprises two cytotoxic agents attached to an oligopeptide, wherein the oligopeptide comprises a sequence of

- 170 -

amino acids that is recognized and selectively proteolytically cleaved by free prostate specific antigen, wherein the means of attachment is directly through a covalent bond or via a linker unit,

5 or the pharmaceutically acceptable salt thereof.

16. The method of treatment according to Claim 15 wherein the conjugate is



10

or the pharmaceutically acceptable salt thereof.

- 171 -

17. A pharmaceutical composition useful for treating an adverse condition of the prostate comprising a pharmaceutical carrier, and dispersed therein, a therapeutically effective amount of a conjugate, said conjugate which comprises a pharmaceutical agent, effective in the
5 treatment of said condition, attached to a oligopeptide, wherein the oligopeptide comprises a sequence of amino acids that is recognized and selectively proteolytically cleaved by free prostate specific antigen, wherein the means of attachment is directly through a covalent bond or
10 via a linker unit,


or the pharmaceutically acceptable salt thereof.

18. A pharmaceutical composition useful for treating benign prostatic hyperplasia comprising a pharmaceutical carrier, and
15 dispersed therein, a therapeutically effective amount of a conjugate, said conjugate which comprises a cytotoxic agent attached to a oligopeptide, wherein the oligopeptide comprises a sequence of amino acids that is recognized and selectively proteolytically cleaved by free prostate specific antigen, wherein the means of attachment is directly through a
20 covalent bond or via a linker unit,

or the pharmaceutically acceptable salt thereof.

19. The composition according to Claim 18 wherein the
25 conjugate is of the formula I:

- 172 -



i

wherein:

- 5 oligopeptide is an oligopeptide which is specifically recognized by the free prostate specific antigen (PSA) and is capable of being proteolytically cleaved by the enzymatic activity of the free prostate specific antigen;
- 10 XL is absent or is an amino acid selected from:
- a) phenylalanine,
 - b) leucine,
 - c) valine,
 - d) isoleucine,
 - 15 e) (2-naphthyl)alanine,
 - f) cyclohexylalanine,
 - g) diphenylalanine,
 - h) norvaline,
 - i) norleucine, and
 - 20 j) 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid;


R is hydrogen or $-(C=O)R^1$; and

- 173 -

R^1 is C_1 - C_6 -alkyl or aryl,

or the pharmaceutically acceptable salt thereof.

- 5 20. The composition according to Claim 18 wherein the conjugate is selected from:



wherein X is:

AsnLysIleSerTyrGlnSer —	(SEQ.ID.NO.: 13),
AsnLysIleSerTyrGlnSerSer —	(SEQ.ID.NO.: 16),
AsnLysIleSerTyrGlnSerSerSer —	(SEQ.ID.NO.: 17),
AsnLysIleSerTyrGlnSerSerSerThr —	(SEQ.ID.NO.: 10),
AsnLysIleSerTyrGlnSerSerSerThrGlu —	(SEQ.ID.NO.: 3),
AlaAsnLysIleSerTyrGlnSerSerSerThrGlu —	(SEQ.ID.NO.: 11),
↑ N-terminus	

- 174 -

Ac — AlaAsnLysIleSerTyrGlnSerSerSerThr — (SEQ.ID.NO.: 117),

Ac — AlaAsnLysIleSerTyrGlnSerSerSerThrLeu — (SEQ.ID.NO.: 70),

Ac — AlaAsnLysAlaSerTyrGlnSerAlaSerThrLeu — (SEQ.ID.NO.: 118),

Ac — AlaAsnLysAlaSerTyrGlnSerAlaSerLeu — (SEQ.ID.NO.: 119),

Ac — AlaAsnLysAlaSerTyrGlnSerSerSerLeu — (SEQ.ID.NO.: 120),

Ac — AlaAsnLysAlaSerTyrGlnSerSerLeu — (SEQ.ID.NO.: 121),

Ac — SerTyrGlnSerSerSerLeu — (SEQ.ID.NO.: 144),

Ac — hArgTyrGlnSerSerSerLeu — (SEQ.ID.NO.: 145),

Ac — LysTyrGlnSerSerSerLeu — (SEQ.ID.NO.: 124), or

Ac — LysTyrGlnSerSerNle — (SEQ.ID.NO.: 146),

↑
N-terminus

or the pharmaceutically acceptable salt thereof.

21. The composition according to Claim 18 wherein the
5 conjugate is selected from:


- Ac-hArgTyrGln-SerSerPro-dox(3') (SEQ.ID.NO.: 151)
Ac-hArgTyrGln-SerPro-dox(3') (SEQ.ID.NO.: 177)
Ac-hArgTyrGln-SerSerSerNle-dox(3') (SEQ.ID.NO.: 154)
10 Ac-AmfTyrGln-SerSerSerNle-dox(3') (SEQ.ID.NO.: 155)
H₂NCO-hArgTyrGln-SerSerSerLeu-dox(3') (SEQ.ID.NO.: 156)
Ac-LysTyrGln-SerSerNle-dox(3') (SEQ.ID.NO.: 146)

- 175 -

- Ac-LysTyrGln-SerLysNle-dox(3') (SEQ.ID.NO.: 178)
Ac(cis-p-NH₂Cha)TyrGlnSerSerNledox(3') (SEQ.ID.NO.: 161)
Ac-AlaAspLysAla(hArg)TyrGln-SerSerLeu-dox(3') (SEQ.ID.NO.: 160)
Ac-hArgTyrGln-SerAsn-dox(3') (SEQ.ID.NO.: 153)
5 Ac-hArgTyrGln-SerSerHis-dox(3') (SEQ.ID.NO.: 152)
Ac-(imidazolyl)LysTyrGln-SerSerLeu-dox(3') (SEQ.ID.NO.: 159)
Ac-(imidazolyl)LysTyrGlnSerSerSerNle-dox(3') (SEQ.ID.NO.: 162)
Ac-hArg(Cha)Gln-SerSerSerNle-dox(3') (SEQ.ID.NO.: 163)
Ac-hArg(Me₂PO₃Tyr)Gln-SerSerSerNle-dox(3') (SEQ.ID.NO.: 167)
10 Ac-hArgTyrGln-SerSerSerhArg-dox(3') (SEQ.ID.NO.: 164)
Ac-hArg(3-Iodo-Tyr)Gln-SerSerSerNle-dox(3') (SEQ.ID.NO.: 166)
Ac-hArg(O-Me-Tyr)Gln-SerSerSerNle-dox(3') (SEQ.ID.NO.: 169)
Ac-hArg(p-NH₂-Phe)Gln-SerSerSerNle-dox(3') (SEQ.ID.NO.: 179)
Ac-hArg(Cha)Gln-SerSerNle-dox(3') (SEQ.ID.NO.: 174)
15 Ac-hArg(Cha)Gln-SerProNle-dox(3') (SEQ.ID.NO.: 175)
Ac(imidazolyl)Lys(Cha)GlnSerSerSerNle-dox(3') (SEQ.ID.NO.: 172)
Ac-hArg(7-HO-TIC)Gln-SerSerSerNle-dox(3') (SEQ.ID.NO.: 180)
Ac-hArg(3-Fluoro)TyrGlnSerSerSerNle-dox(3') (SEQ.ID.NO.: 176)
Ac-(ornithine)TyrGln-SerSerSerNle-dox(3') (SEQ.ID.NO.: 181)
20 Ac-LysAlaAlaSerSerSerLeu-dox(3') (SEQ.ID.NO.: 183)
Ac-hArg(Cha)Gln-SerSerNle-dox(3') (SEQ.ID.NO.: 149)
Ac-AlaArgLysAlaSerTyrGln-SerLeu-dox(3') (SEQ.ID.NO.: 193) and
Ac-(Orn)TyrGln-SerSerSerLeu-dox(3') (SEQ.ID.NO.: 194)
25 or the pharmaceutically acceptable salt thereof.

22. The composition according to Claim 18 wherein the conjugate is of the formula II:

- 176 -



wherein:

- 5 oligopeptide is an oligopeptide which is specifically recognized by the free prostate specific antigen (PSA) and is capable of being proteolytically cleaved by the enzymatic activity of the free prostate specific antigen;
- 10 X_L is absent or is an amino acid selected from:
 - a) phenylalanine,
 - b) leucine,
 - c) valine,
 - d) isoleucine,
 - 15 e) (2-naphthyl)alanine,
 - f) cyclohexylalanine,
 - g) diphenylalanine,
 - h) norvaline,
 - i) norleucine, and
 - 20 j) 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid; or

X_L is - NH - (CH₂)_n - NH -

- 177 -

R is hydrogen or $-(C=O)R^1$;

R^1 is C_1 - C_6 -alkyl or aryl;


5 R^{19} is hydrogen or acetyl; and

n is 1, 2, 3, 4 or 5,

or the pharmaceutically acceptable salt thereof.

10

23. The composition according to Claim 22 wherein the conjugate is:



N-terminus

Ac—LysTyrGlnSerSerSerNle—NH


Compound 14

(SEQ.ID.NO.: 183),

15 or the pharmaceutically acceptable salt thereof.

24. The composition according to Claim 18 wherein the conjugate is of the formula II:

- 178 -




wherein:

- 5 oligopeptide is an oligopeptide which is specifically recognized by the free prostate specific antigen (PSA) and is capable of being proteolytically cleaved by the enzymatic activity of the free prostate specific antigen,
- 10 or the pharmaceutically acceptable salt thereof.
25. The composition according to Claim 24 wherein the conjugate is:

15

- 179 -



Compound 5 (SEQ.ID.NO.: 184),

or the pharmaceutically acceptable salt thereof.

26. A pharmaceutical composition useful for treating an adverse condition of the prostate which comprises administering to a mammal in need of said treatment a conjugate, said conjugate which comprises two pharmaceutical agents, wherein at least one pharmaceutical agent is effective against said condition, attached to a oligopeptide, wherein the oligopeptide comprises a sequence of amino acids that is recognized and selectively proteolytically cleaved by free prostate specific antigen, wherein the means of attachment is directly through a covalent bond or via a linker unit,

or the pharmaceutically acceptable salt thereof.

27. A pharmaceutical composition useful for treating benign prostatic hyperplasia comprising a pharmaceutical carrier, and dispersed therein, a therapeutically effective amount of a conjugate, said conjugate which comprises two cytotoxic agents attached to a


- 180 -

oligopeptide, wherein the oligopeptide comprises a sequence of amino acids that is recognized and selectively proteolytically cleaved by free prostate specific antigen, wherein the means of attachment is a covalent bond or a chemical linker,

5

or the pharmaceutically acceptable salt thereof.

28. The composition according to Claim 27 wherein the conjugate is



10

or the pharmaceutically acceptable salt thereof.

1: MetLysProAsnIleIlePheValLeuSerLeuLeuLeuIleLeuGluLysGlnAlaAla -
 21: ValMetGlyGlnLysGlyGlySerLysGlyArgLeuProSerGluPheSerGlnPhePro -
 41: HisGlyGlnLysGlyGlnHisTyrSerGlyGlnLysGlyLysGlnGlnThrGluSerLys -
 61: GlySerPheSerIleGlnTyrThrTyrHisValAspAlaAsnAspHisAspGlnSerArg -
 81: LysSerGlnGlnTyrAspLeuAsnAlaLeuHisLysThrThrLysSerGlnArgHisLeu -
 101: GlyGlySerGlnGlnLeuLeuHisAsnLysGlnGluGlyArgAspHisAspLysSerLys -
 121: GlyHisPheHisArgValValIleHisHisLysGlyGlyLysAlaHisArgGlyThrGln -
 141: AsnProSerGlnAspGlnGlyAsnSerProSerGlyLysGlyIleSerSerGlnTyrSer ^{CS#5} -
 161: AsnThrGluGluArgLeuTrpValHisGlyLeuSerLysGlnGlnThrSerValSerGly -
 181: AlaGlnLysGlyArgLysGlnGlyGlySerGlnSerSerTyrValLeuGlnThrGluGlu -
 201: LeuValAlaAsnLysGlnGlnArgGluThrLysAsnSerHisGlnAsnLysGlyHisTyr -
 221: GlnAsnValValGluValArgGluGluHisSerSerLysValGlnThrSerLeuCysPro -
 241: AlaHisGlnAspLysLeuGlnHisGlySerLysAspIlePheSerThrGlnAspGluLeu -
 261: LeuValTyrAsnLysAsnGlnHisGlnThrLysAsnLeuAsnGlnAspGlnGlnHisGly -
 281: ArgLysAlaAsnLysIleSerTyrGlnSerSerSerThrGluGluArgArgLeuHisTyr ^{CS#3} -
 301: GlyGluAsnGlyValGlnLysAspValSerGlnSerSerIleTyrSerGlnThrGluGlu ^{CS#4} -
 321: LysAlaGlnGlyLysSerGlnLysGlnIleThrIleProSerGlnGluGlnGluHisSer -
 341: GlnLysAlaAsnLysIleSerTyrGlnSerSerSerThrGluGluArgArgLeuHisTyr ^{CS#1} -
 361: GlyGluAsnGlyValGlnLysAspValSerGlnArgSerIleTyrSerGlnThrGluLys ^{CS#2} -
 381: LeuValAlaGlyLysSerGlnIleGlnAlaProAsnProLysGlnGluProTrpHisGly -
 401: GluAsnAlaLysGlyGluSerGlyGlnSerThrAsnArgGluGlnAspLeuLeuSerHis -
 421: GluGlnLysGlyArgHisGlnHisGlySerHisGlyGlyLeuAspIleValIleIleGlu -
 441: GlnGluAspAspSerAspArgHisLeuAlaGlnHisLeuAsnAsnAspArgAsnProLeu -
 461: PheThr -

FIG.1

2/11

		PERCENT PEPTIDE HYDROLYSIS TIME OF INCUBATION (HOURS)					
PEPTIDE		0.5	1	2	3	4	20
1.	SYQSSSTE	ND	0	ND	0	ND	0
2.	ISYQSSSTE	ND	0	ND	0	ND	0
3.	KISYQSSSTE	ND	10	ND	30	ND	90
4.	NKISYQSSSTE	ND	30	ND	70	ND	100
5.	NKISYQSSST	ND	20	30	ND	ND	100
6.	ANKISYQSSSTE	15	25	ND	ND	80	100
7.	ANKISYQSSS	4	6	16	30	45	ND
8.	NKISYQSSS	2	6	22	44	55	ND
9.	ANKISYQSS	1	ND	12	ND	39	ND
10.	GRKANKISYQS- SSTEERRLLHYGENG	20	50	ND	ND	90	100

ND = NOT DETERMINED

FIG. 2

3/11

PEPTIDE	SALT	SEQ. ID. NO	% PEPTIDE CLEAVED AT 4 HRS BY YORK PSA
SEMENOGELIN (463 aa)			100 (30 MIN)
GRKANKISYQ-SSSTEERRLHYGENG	TFA	6	100 (2 HRS)
SQKANKISYQ-SSSTEERRLHYGENG	TFA	67	100 (3 HRS)
ANKISYQ-SSSTE	TFA	11	98
ISYQ-SSST	TFA	68	0
NKISYQ-SSST	TFA	10	62
NKISYQ-SSSTE	TFA	3	90
KISYQ-SSSTE	TFA	9	49
SYQ-SSSTE	TFA	7	0 (3 HRS)
ISYQ-SSSTE	TFA	8	0
NKISYQ-SSS	TFA	17	55
ANKISYQ-SSS	TFA	18	45
ANKISYQ-SS	TFA	69	39
ANKISYQ-SSSSTE- <i>amide</i>	TFA	11	43
Ac-ANKISYQ-SSSTL	TFA	70	57
Ac-ANKISYQ-SSSTE- <i>amide</i>	TFA	11	40
Ac-ANKISYQ-SSSTL- <i>amide</i>	TFA	70	46
Ac-ANGISYQ-SSSTE- <i>amide</i>		71	0
Ac-ANPISYQ-SSSTE- <i>amide</i>		72	0
Ac-ANKISYQ-SASTE- <i>amide</i>	TFA	73	66
Ac-ANKISYQ-SSKTE- <i>amide</i>	TFA	74	80
Ac-ANKISYQ-SSTE- <i>amide</i>	TFA	75	44
Ac-ANKI(dS)YQ-SSSTE- <i>amide</i>	TFA	76	9
Ac-ANK(dI)SYQ-SSSTE- <i>amide</i>	TFA	77	0
Ac-ANKISYQ-SSQTE- <i>amide</i>	TFA	78	55
Ac-ANKISYQ-SAKTE- <i>amide</i>	TFA	79	80
Ac-AN(dK)ISYQ-SSSTE- <i>amide</i>	TFA	80	3
Ac-ANKISYQ-STE- <i>amide</i>	TFA	81	28
Ac-ANKIYQ-SSTE- <i>amide</i>	TFA	82	0
Ac-ANKSYQ-SSTE- <i>amide</i>	TFA	83	10
Ac-ANKASYQ-SASTE- <i>amide</i>	TFA	84	98
Ac-ANEISYQ-SASTE- <i>amide</i>		85	10
Ac-NKISYQ-SS- <i>amide</i>	TFA	16	30
Ac-KISYQ-SS- <i>amide</i>	TFA	86	15
Ac-SYQ-SSTE- <i>amide</i>		87	65
Ac-SYQ-SSSTL- <i>acid</i>		88	83
Ac-ASYQ-SSTE- <i>amide</i>		89	68
Ac-EISYQ-SSSTE- <i>amide</i>		90	0
Ac-ANEISYQ-SSSTE- <i>amide</i>		91	0

FIG.3

4/11

PEPTIDE	SALT	SEQ. ID. NO	% PEPTIDE CLEAVED AT 4 HRS BY YORK PSA
Ac-ANKISYY-SSSTE-amide	TFA	92	73
Ac-ANKISYY-SASTE-amide	TFA	93	91
Ac-ASYQ-SSL-acid		94	71
Ac-ANSYQ-SSSTE-amide		95	28
Ac-ASYQ-SSSTE-amide		96	64
Ac-SYQ-SSSTE-amide		97	50
Ac-ANKASYQ-SASTC-amide	TFA	98	78
Ac-Q-SSTE-amide		99	0
Ac-YQ-SSTE-amide		100	0
Ac-SQ-SSTE-amide		101	0
Ac-ANKISQ-SSTE-amide	TFA	102	0
Ac-AN(ORN)ISYQ-SSTE-amide	TFA	103	34
Ac-S(3 PAL)Q-SSTE-amide		104	4
Ac-S(3,4-C12F)Q-SSTE-amide		105	6
Ac-SKQ-SSTE-amide	TFA	106	0
Ac-SYQ-SSTL-acid		88	81
Ac-SYQ-SSSL-acid		107	98
(e-ACA)-YQ-SSSL-amide	AA	108	0
ANK(N-Me-I)SYQ-SSTE-amide	TFA	109	0
SYQ-SSTE-amide		110	0
HO(CH ₂) ₂ CO-YQ-SSTE-amide		111	0
Ac-SYK-SSTE-amide	TFA	112	5
Ac-SYY-SSTE-amide		113	93
Ac-SYQ-SSL-NH ₂		114	32
Ac-SYQ-SSL-acid		115	72
DAP-YQ-SSSL-amide	AA	116	0

FIG.3A

5/11

PEPTIDE	SALT	SEQ. ID. NO.	TIME TO CLEAVE 50% OF SUBSTRATE BY YORK PSA
SEMONOGELIN (463 aa)			100% AT 30 MIN
Ac-hR(Cho)Q-SNNle-acid	TFA	149	4 HR = 0% (PS)
Ac-hR(Cho)Q-SNle-acid	TFA	147	200 (PS)
Ac-hRhYQ-SSNle-acid	TFA	148	95 (PS)
Ac-ANKASYQ-SS-Cho-NH ₂	TFA	150	>240 (4 HR = 31%)
Ac-hRYQ-SSP-acid	TFA	151	30
hRYQ-SSH-acid	TFA	152	>240 (4 HR = 0%)
Ac-hRYQ-SSH-acid	TFA	152	60
hRYQ-SP-acid	TFA	177	>240 (4 HR = 0%)
Ac-hRYQ-SP-acid	TFA	177	>240 (4 HR = 0%)
Ac-hRYQ-SN-acid	TFA	153	90
Ac-hRYQ-S-acid	TFA	187	>240 (4 HR = 0%)
Ac-hRYQ-SSSNle-acid		154	40
Ac-(Amf)YQ-SSSNle-acid		155	50
NH ₂ CO-hRYQ-SSSL-acid	TFA	156	60
Ac-ANKAKYQ-SS(Cho)-NH ₂	TFA	157	240
Ac-(DPL)YQ-SSSNle-acid	TFA	158	120
Ac-(imidazolyl)KYQ-SSL-acid	TFA	159	25
Ac-ANKA(hR)YQ-SSL-acid	TFA	160	105
Ac-(p-NH ₂ -Cho)YQ-SSSNle-acid	TFA	161	140
Ac-(imidazolyl)KYQSSSNle-acid	TFA	162	25
Ac-hR(Cho)Q-SSSNle-acid	TFA	163	120
Ac-hRYQ-SSShR-acid	TFA	164	70
Ac-hRYQ-SSS(Mel)	TFA	188	90
Ac-hRYQ-SSS(Ethylester-L)		156	85
Ac-ANKA(imidazolyl)KYQ-SSNle-acid	TFA	165	95
Ac-hR(3-Iodo-Y)Q-SSSNle-acid	TFA	166	55
Ac-hR(Me ₂ PO ₃ -Y)Q-SSSNle-acid	TFA	167	4 HR = 0%
Ac-hRYQ-SSD-acid	TFA	168	25
Ac-hR(O-Me-Y)Q-SSSNle-acid	TFA	169	4 HR = 0%
Ac-ANKAKYQ-SSNle-acid	TFA	170	80
Ac-hR(Cho)Q-SSS(ethylester-L)		171	4 HR = 36%
Ac-(imidazolyl)K(Cho)Q-SSSNle-acid	TFA	172	180 (PS)
Ac-hR(TIC)Q-SSSNle-acid	TFA	179	4 HR = 0%
Ac-Q-SSSNle-acid	TFA	189	4 HR = 0%
Ac-hR(Cho)Q-SSS-acid	TFA	173	120
Ac-hR(Cho)Q-SSNle-acid	TFA	174	60 (PS)
Ac-hR(Cho)Q-SPNle-acid	TFA	175	4 HR = 12%
Ac-hR(m-fluoro-Y)Q-SSSNle-acid	TFA	176	100
Ac-(7-HO-TIC)Q-SSSNle-acid	TFA	190	4 HR = 0%

FIG.3B

6/11




FIG.4

7/11

DOXORUBICIN-COGENER	SALT	SEQ. ID. NO.	% PEPTIDE CLEAVED
			AT 4 HOURS BY YORK PSA
Ac-ANKISYQ-SSST-DOX (3')	TFA	117	20 (1 HR) NO SAMPLE LEFT
Ac-ANKISYQ-SSSTL-DOX (3')	TFA	70	87
Ac-ANKASYQ-SASTL-DOX (3')	AA	118	NA
Ac-ANKASYQ-SASL-DOX (3')	AA	119	100 (3 HR)
Ac-ANKASYQ-SSSL-DOX (3')	AA	120	100 (3 HR)
Ac-ANKASYQ-SSL-DOX (3')	AA	121	91
Ac-SYQ-SST(dL)-DOX (3')		122	17
Ac-SYQ-SSSL-DOX (3')		107	95 (PS)
Ac-ANKASYA-SSSL-DOX (3')	AA	123	0
Ac-KYQ-SSSL-DOX (3')	AA	124	98 (PS)
Ac-SYQ-SSKL-DOX (3')	AA	125	88
Ac-SYQ-SSK(dL)-DOX (3')	AA	126	87

FIG.5

8/11

DOXORUBICIN-COGENER	SALT	SEQ. ID. NO.	TIME TO CLEAVE 50% OF SUBSTRATE BY YORK PSA
Ac-(ORN)YQ-SSSNle-DOX (3')	AA	181	4 HR = 20%
Ac-KAASSSL-DOX (3')	AA	182	10X [ENZ] 20 HR = 11%
Ac-hRh(Cho)Q-SSNle-DOX (3')	AA	149	4 HR = 30%
Ac-hRYQ-SSP-DOX (3')		151	45
Ac-hRYQ-SP-DOX (3')		177	>240 (4 HR = 0%)
Ac-hRYQ-SSSNle-DOX (3')		154	190 (PS)
Ac-AmfYQ-SSSNle-DOX (3')		155	110 (PS)
NH ₂ CO-hRYQ-SSSL-DOX (3')		156	105
Ac-KYQ-SSNle-DOX (3')	AA	146	>240 (4 HR = 36%) (PS)
Ac-KYQ-SKNle-DOX (3')	AA	178	>240 (4 HR = 20%) (NO PROD)
Ac-(cis-p-NH ₂ Cho)YQSSNleDOX(3')		161	240 (PS)
Ac-ANKA(hR)YQ-SSL-DOX (3')		160	60
Ac-hRYQ-SN-DOX (3')	AA	153	90 (PS)
Ac-hRYQ-SSH-DOX (3')	AA	152	110
Ac-(imidazolyl)KYQ-SSL-DOX (3')		159	150
Ac-(imidazolyl)KYQSSSNle-DOX (3')		162	60
Ac-hR(Cho)Q-SSSNle-DOX (3')		163	130
Ac-hR(Me ₂ PO ₃ Y)Q-SSSNle-DOX (3')		167	4 HR = 0%
Ac-hRYQ-SSShR-DOX (3')		164	50
Ac-hR(3-Iodo-Y)Q-SSSNle-DOX (3')		166	4 HR = 0% (PS)
Ac-hR(O-Me-Y)Q-SSSNle-DOX (3')		169	4 HR = 20% (PS)
Ac-hR(p-NH ₂ -F)Q-SSSNle-DOX (3')		179	90 (PS)
Ac-hR(Cho)Q-SSNle-DOX (3')		174	120
Ac-hR(Cho)Q-SPNle-DOX (3')		175	4 HR = 0%
Ac(imidazolyl)K(Cho)QSSSNleDOX(3')		172	180
Ac-hR(TIC)Q-SSSNle-DOX (3')		180	4 HR = 14%
Ac-hR(3-Fluoro)YQSSSNleDOX (3')		176	4 HR = 26%
desAc-vinblastine-LNKASYQ-SSL-DOX	AA	184	70 (PS)
Ac-ANKASYQ-SL-DOX (3')	TFA	193	90
Ac-(ORN)YQ-SSSNle-DOX (3')	TFA	194	120

FIG.5A

9/11

<u>DOXORUBICIN-CONGENER</u>	<u>SALT</u>	<u>SEQ. ID. NO.</u>	<u>% PEPTIDE CLEAVED/ LNCaP MEDIA 4 HR</u>	<u>% PEPTIDE CLEAVED/ DuPRO MEDIA 4 HR</u>
Ac-ANKASYQ-SASL-DOX (3')	AA	119	92	13
Ac-ANKASYQ-SSSL-DOX (3')	AA	121	98	13
Ac-ANKASYQ-SSL-DOX (3')		122	95	27
Ac-SYQ-SSSL-DOX (3')		107	63	0

FIG. 6

10/11

CYTOTOXIC AGENT-COGENER	SALT	SEQ. ID. NO.	INCoP CELL KILL EC50 (μ M)
Ac-ANKISYQ-SSST-DOX(3')	TFA	117	>100
Ac-ANKISYQ-SSSTL-DOX(3')	TFA	70	8.4
Ac-ANKASYQ-SASTL-DOX(3')	AA	118	31
Ac-ANKASYQ-SASL-DOX(3')	AA	119	16 (DuPRO > 100)
Ac-ANKASYQ-SSSL-DOX(3')	AA	120	15
Ac-ANKASYQ-SSL-DOX(3')	AA	121	6.5 (DuPRO = 117)
Ac-SYQ-SSSL-DOX(3')		144	20 (DuPRO > 100) (PS)
Ac-ANKASYA-SSSL-DOX(3')	AA	191	>100
Ac-KYQ-SSSL-DOX(3')	AA	124	6.5 (DuPRO>100) (PS)
Ac-SYQ-SSKL-DOX(3')	AA	192	11.8 (DuPRO>100)
Ac-SYQ-SSK(dL)-DOX(3')	AA		>100 (DuPRO>100)
Ac-hRYQ-SSSL-DOX(3')	AA	145	6.4 (DuPRO>100)
Ac-KYQ-SSSNle-DOX(3')	AA	183	4.4 (DuPRO>100)
Ac-(ORN)YQ-SSSNle-DOX(3')	AA	181	3.3 (DuPRO = 65)
Ac-hRh(Cho)Q-SSNle-DOX(3')	AA	149	
o-Me-A-DX(3')	AA		7.0 (DuPRO = 20.8)
M-DOX(3')	AA		6.0 (DuPRO = 13.8)
			{4.9 (DuPRO = 33.3)}
G-DOX(3')	AA		>100 (DuPRO>100)
N-methyl-G-DOX(3')	AA		39.0 (DuPRO = 58.8)
NH ₂ (CH ₂) ₅ -CO-DOX(3')	AA		59.2 (DuPRO > 100)
Ac-hRYQ-SSP-DOX(3')		151	{33.3 (DuPR=100)}
Ac-hRYQ-SP-DOX(3')		177	25.2 (DuPRO = 44.5)
Ac-hRYQ-SSSNle-DOX(3')		154	4.4 (DuPRO = 41.0) (PS)
Ac-AmfYQ-SSSNle-DOX(3')		155	7.6 (DuPRO>100) (PS)
NH ₂ CO-hRYQ-SSSL-DOX(3')		156	35.7 (DuPRO>100)
Ac-KYQ-SSNle-DOX(3')	AA	146	4.6 (DuPRO = 76.9) (PS)
Ac-KYQ-SKNle-DOX(3')	AA	178	5.7 (DuPRO>>100) {3.6}
Ac-(cis-p-NH ₂ Cho)YQSSNleDOX(3')		161	9.8 (DuPRO = 47.1) (PS)
Ac-ANKA(hR)YQ-SSL-DOX(3')		160	7.3 (DuPRO>>100)
AchRYQ-SN-DOX(3')	AA	153	70.4 (DuPRO = 75.0)
Ac-hRYQ-SSH-DOX(3')	AA	152	25.4 (DuPRO = 35.7)
Ac-(imidazolyl)KYQ-SSL-DOX(3')	AA	159	6.3 (DuPRO = 12.8) (PS)
Ac-(imidazolyl)KYQSSSNle-DOX(3')		162	3.2 (DuPRO = 23) (PS AT 50 mM)
Ac-hR(Cho)Q-SSSNle-DOX(3')		163	2.3 (DuPRO >>100)
Ac-hR(Me ₂ PO ₃ Y)Q-SSSNle-DOX(3')		167	8.0 (DuPRO>100)
Ac-hRYQ-SSShR-DOX(3')		164	32 (DuPRO>100)
Ac-hR(3-Iodo-Y)Q-SSSNle-DOX(3')		166	12.8 (DuPRO = 60.8)
Ac-hR(O-Me-Y)Q-SSSNle-DOX(3')		169	7.4 (DuPRO = 13.5)

FIG.7

11/11

CYTOTOXIC AGENT-COGENER	SALT	SEQ. ID. NO.	LNCaP CELL KILL EC50 (μ M)
Ac-hR(p-NH ₂ -F)Q-SSSNie-DOX(3')		179	7.5 (DuPRO>100)
Ac-hR(Cho)Q-SSNie-DOX(3')		174	3.4 (DuPRO>100)
Ac-hR(Cho)Q-SPNie-DOX(3')		175	12.3 (DuPRO>100)
Ac-ANKASYQ-SL-DOX(3')	TFA	193	10 (DuPRO>100)
Ac-(ORN)YQ-SSSNie-DOX(3')	TFA	194	7.0 (DuPRO>100)
Ac-(imidazolyl)K(Cho)QSSSNieDOX(3')		172	4.0 (DuPRO>100)(PS)
Ac-hR(TIC)Q-SSSNie-DOX(3')		180	3.2 (DuPRO = 50.9)
Ac-hR(3-Fluoro)YQSSSNieDOX(3')		176	3.2 (DuPRO = 58.8)
vinblastine			0.5 (DuPRO = 85)
DAP-desAc-vinblastine	TFA		150 (DuPRO>>100)
Ac-KYQ-SSSNie-DAP-desAc-vinblastine	TFA	183	14.7 (DuPRO>>100) {4.8}
Nie-DAP-desAc-vinblastine	TFA		5.9 (DuPRO>100)
desAc-vinblastine-LNKASYQ-SSSL-amide	AA	184	1.6 (DuPRO>>100)

FIG.7A

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US96/16490

A. CLASSIFICATION OF SUBJECT MATTER

IPC(6) :A61K 31/40, 31/44, 31/70, 38/02, 38/07, 38/08, 38/10, 38/14

US CL :514/2, 8, 14, 15, 16, 17, 18, 34, 283

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 514/2, 8, 14, 15, 16, 17, 18, 34, 283; 530/300, 322, 327, 328, 329, 330

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

APS, DIALOG

search terms: prostate, psa, protease, cleavage, proteolysis, substrate, hyperplasia, conjugate, linker

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A,P	US 5,501,983 A (LILJA ET AL) 26 March 1996 (26.03.96), see column 1, lines 13-37.	1-28
A,P	US 5,502,037 A (A. KONDRATYEV) 26 March 1996 (26.03.96), see column 5, lines 36-48, column 6, lines 44-62.	1-28
X,P	WO 96/00503 A1 (MERCK & CO., INC.) 11 January 1996 (11.01.96), see entire document, especially page 20, line 20 - page 21, line 9, claims 12-20.	1-12, 17-22, 24
A	US 5,349,066 A (KANEKO ET AL) 20 September 1994 (20.09.94).	1-28
A	US 5,391,723 A (J. PRIEST) 21 February 1995 (21.02.95).	1-28



Further documents are listed in the continuation of Box C.



See patent family annex.

•

Special categories of cited documents:

A

document defining the general state of the art which is not considered to be of particular relevance

E

earlier document published on or after the international filing date

L

document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

O

document referring to an oral disclosure, use, exhibition or other means

P

document published prior to the international filing date but later than the priority date claimed

T

later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X

document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y

document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

A

document member of the same patent family

Date of the actual completion of the international search

03 DECEMBER 1996

Date of mailing of the international search report

31 JAN 1997

Name and mailing address of the ISA/US
Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

JEFFREY E. RUSSEL

Telephone No. (703) 308-0196